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Computational Tools for the Untargeted Assignment of FT-MS Metabolomics 
Datasets 
 
 Metabolomics is the study of metabolomes, the sets of metabolites 
observed in living systems. Metabolism interconverts these metabolites to 
provide the molecules and energy necessary for life processes. Many disease 
processes, including cancer, have a significant metabolic component that 
manifests as differences in what metabolites are present and in what quantities 
they are produced and utilized. Thus, using metabolomics, differences between 
metabolomes in disease and non-disease states can be detected and these 
differences improve our understanding of disease processes at the molecular 
level. Despite the potential benefits of metabolomics, the comprehensive 
investigation of metabolomes remains difficult.  
A popular analytical technique for metabolomics is mass spectrometry. 
Advances in Fourier transform mass spectrometry (FT-MS) instrumentation have 
yielded simultaneous improvements in mass resolution, mass accuracy, and 
detection sensitivity. In the metabolomics field, these advantages permit more 
complicated, but more informative experimental designs such as the use of 
multiple isotope-labeled precursors in stable isotope-resolved metabolomics 
(SIRM) experiments. 
However, despite these potential applications, several outstanding 
problems hamper the use of FT-MS for metabolomics studies. First, artifacts and 
data quality problems in FT-MS spectra can confound downstream data 
analyses, confuse machine learning models, and complicate the robust detection 
and assignment of metabolite features. Second, the assignment of observed 
spectral features to metabolites remains difficult. Existing targeted approaches 
for assignment often employ databases of known metabolites; however, 
metabolite databases are incomplete, thus limiting or biasing assignment results. 
Additionally, FT-MS provides limited structural information for observed 
metabolites, which complicates the determination of metabolite class (e.g. lipid, 
sugar, etc. ) for observed metabolite spectral features, a necessary step for many 
metabolomics experiments.  
To address these problems, a set of tools were developed. The first tool 
identifies artifacts with high peak density observed in many FT-MS spectra and 
removes them safely. Using this tool, two previously unreported types of high 
peak density artifact were identified in FT-MS spectra: fuzzy sites and partial 
ringing. Fuzzy sites were particularly problematic as they confused and reduced 
the accuracy of machine learning models trained on datasets containing these 
artifacts. Second, a tool called SMIRFE was developed to assign isotope-
     
 
resolved molecular formulas to observed spectral features in an untargeted 
manner without a database of expected metabolites. This new untargeted 
method was validated on a gold-standard dataset containing both unlabeled and 
15N-labeled compounds and was able to identify 18 of 18 expected spectral 
features. Third, a collection of machine learning models was constructed to 
predict if a molecular formula corresponds to one or more lipid categories. These 
models accurately predict the correct one of eight lipid categories on our training 
dataset of known lipid and non-lipid molecular formulas with precisions and 
accuracies over 90% for most categories.   
These models were used to predict lipid categories for untargeted 
SMIRFE-derived assignments in a non-small cell lung cancer dataset. 
Subsequent differential abundance analysis revealed a sub-population of non-
small cell lung cancer samples with a significantly increased abundance in sterol 
lipids. This finding implies a possible therapeutic role of statins in the treatment 
and/or prevention of non-small cell lung cancer. Collectively these tools represent 
a pipeline for FT-MS metabolomics datasets that is compatible with isotope 
labeling experiments. With these tools, more robust and untargeted metabolic 
analyses of disease will be possible. 
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CHAPTER 1. BACKGROUND 
1.1 Metabolism, Metabolites and Metabolomics 
Living systems require a large set of chemically diverse molecules to 
enable the processes of life. These molecules span a large range of chemical 
heterogeneity consisting of many different elements (including CHONPS (an 
acronym for carbon, hydrogen, oxygen, nitrogen, phosphorus and sulfur), 
halogens (Bergmann and Bergmann, 1991) (Schomburg and Köhrle, 2008), 
silicon (Jugdaohsingh, 2007), selenium (Schomburg and Köhrle, 2008), cobalt 
(Rickes et al., 1948), calcium (Berridge et al., 1999), magnesium (Lukaski et al., 
1996) and various other trace elements (Mertz, 2012)), masses that range from a 
few Daltons (e.g. H2 (Tamagnini et al., 2002)) to millions of Daltons (e.g. the 
protein Titin (Fulton and Isaacs, 1991)) and a wide range of chemical structures 
and properties (Berdy, 2005) (Bode et al., 2002) (Bourgaud et al., 2001). A 
subset of these molecules is acquired from the environment, while others are 
produced through the interconversion of other molecules. All molecules that are 
acted upon by these chemical processes in living systems can be considered 
metabolites including large macromolecular entities such as chromosomes and 
proteins as well as “small” molecules such as glucose, amino acids and lipids. 
Small is often defined according to an arbitrary mass cutoff (e.g. <1600 Daltons) 
and some definitions of metabolite are restricted to only these compounds (Moco 
et al., 2007). While this latter definition is more restrictive, this definition of 




Building upon this definition, the set of chemical processes that interconvert 
these metabolites constitutes metabolism (Niedenführ et al., 2015). Many of 
these chemical processes are catalyzed by enzymes that are gene products. 
These enzymes not only enable chemical processes to occur at rates that are 
biologically relevant (Lewis and Wolfenden, 2008) (Radzicka and Wolfenden, 
1995) , but also serve as important points of regulation (Metallo and 
Vander Heiden, 2013) that can be affected by changes in signaling or the cellular 
environment (Saltiel and Kahn, 2001). This regulation affects which metabolites 
are produced (Mor et al., 2011), when they are produced (Bass and Takahashi, 
2010), where they are produced (Ryu et al., 2018) (Alam et al., 2017) and in what 
quantities. Most metabolites in a living system are produced from other 
metabolites through these metabolic processes. This chain of derivation starts 
with one or more exogenously supplied metabolites, which can be referred to as 
‘feed metabolites’ (Menküc et al., 2008). In many cases, these feed metabolites 
are themselves metabolic products from other living systems. Therefore, 
metabolism can refer to the set of chemical reactions that occur in a single 
organism and to the web of reactions that span multiple organisms or even an 
entire ecosystem (Penuelas and Sardans, 2009) (Goodacre, 2007).  
 Describing metabolism at these higher levels of biological organization 
requires introducing two new terms: the metabolome and metabolomics. The 
metabolome is the entirety of metabolites interconverted by the metabolism of 
one or more living systems in the biosphere (Fiehn, 2002). Thus, metabolomes 
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are to metabolites what genomes, transcriptomes, and proteomes are to genes, 
transcripts, and protein, respectively. Metabolomics is the comprehensive study 
of metabolomes. In this definition, ‘comprehensive’ seeks to discriminate 
between metabolite ‘stamp collecting’ and true metabolomics that seeks to 
integrate patterns of observed metabolites and their respective concentrations 
(absolute or relative) within the larger system (Wishart, 2008). This definition also 
discriminates traditional biochemical research from metabolomics research. For 
example, a biochemist studying a single enzyme or a small subset of metabolites 
in a pathway is not necessarily performing metabolomics research, just as 
research regarding a single protein or a small set of related proteins is not 
proteomics.  
 Although metabolomics constitutes more than simply identifying 
metabolites from a living system, the robust identification of metabolites in living 
systems is an unsolved problem in metabolomics that must be addressed 
(Wishart, 2011). A major component to this problem is the immense 
computational complexity of developing algorithms for identifying detected 
metabolites in metabolomics experiments (Alonso et al., 2015). The algorithms 
presented in Chapter 3 partially address this problem by enabling the assignment 
of elemental formulas without databases of known metabolites to observed 
features from high-resolution mass spectra.  
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1.2 Why Study the Metabolome? 
Interest in metabolomics has grown significantly over the past several 
decades (Goodacre et al., 2004).  This surge can be attributed to many factors, 
including improved analytical methods for the detection and characterization of 
metabolites (Hu et al., 2005) (Eliuk and Makarov, 2015) (Roessner and Beckles, 
2009) , but also an improved understanding of how better knowledge of the 
metabolome provides insights into living systems in both healthy and pathological 
states. Metabolism is the process by which living systems generate many of the 
small molecules necessary for the synthesis of larger macromolecular entities. 
Additionally, metabolism provides the energy necessary for their synthesis. Thus, 
metabolites represent the currency of life and understanding which metabolites 
are present in a system, in what concentrations, and how they differ between 
disease and non-disease is extremely helpful in understanding life processes.  
Metabolomics provides a window into cellular metabolism. Excluding the 
very small subset of reactions that occur without catalysis, metabolism, and 
therefore the metabolome, is a functional output of an organism’s genome, 
transcriptome, and proteome (Gieger et al., 2008). Thus, to understand the 
relationship between phenotypes of interest and the molecular state of a system, 
it is imperative to consider not only changes at the genomic, transcriptomic, and 
proteomic level, but also changes at the metabolic level.  
To illustrate this point, consider the following example: the presence of a 
gene in an organism’s genome does not directly indicate when an active gene 
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product is present, due to various types of regulation. When the metabolome is 
not considered, an entire layer of possible relevant regulation can be overlooked. 
The activities of enzymes, for instance, are often regulated by the concentration 
of one or more other metabolites. One mechanism by which this regulation is 
achieved is through the binding of metabolites to sites on enzymes to decrease 
or increase their activity. When these sites are not the active site, this is called 
allosteric inhibition or activation (Stadtman, 1970). Often the immediate or 
downstream products of many enzymes bind to inhibit enzyme activity in a 
process called feedback inhibition (Goyal et al., 2010). Thus, even when there is 
a large concentration of a particular enzyme, the metabolic state of the system 
may result in all those enzyme molecules being inactive. Likewise, if a large 
amount of that inactive enzyme were to be expressed (say due to a constituently 
active transcription factor), the increase in mRNA and protein levels would result 
in measurable transcriptomic and proteomic changes without substantial 
metabolic changes. Without metabolomic information, the transcriptomic and 
proteomic signature of that regulatory event cannot be functionally interpreted in 
terms of changes in small molecule phenotype.  
 Metabolomics also enables insight into the short-term effects of stimuli on 
a system of interest in ways that observations of higher levels of biological 
information do not easily allow (Wilson and Nicholson, 2003). Changes at the 
metabolic level can be sudden and dramatic (Fernie and Stitt, 2012) (Arrivault et 
al., 2009) . For example, when metabolite concentrations are near the inflection 
point of the allosteric binding curve for an enzyme or other protein, small relative 
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changes in a metabolite’s concentration can result in dramatic changes in protein 
activity, especially for heterotrophic effects (van Vugt-Lussenburg et al., 2006). 
Additionally, it has been observed that allosteric regulation can operate on a 
faster time scale compared to transcriptional regulation (Link et al., 2013) and 
that metabolic alteration precedes transcriptional responses to some stimuli 
(Ralser et al., 2009). While rapid changes in transcription (on the scale of 
minutes) have been observed in situations such as heat shock (O'Brien and Lis, 
1993) (and these transcripts would still need to be translated), in general, 
metabolic regulation occurs more quickly than transcriptional regulation.  
Furthermore, the substantial metabolic changes that can arise from 
enzyme regulation, either inhibition or activation, can result in dramatic changes 
in phenotype. For example, Soman, a chemical warfare agent that inhibits 
acetylcholinesterase can distribute throughout a human and cause neurotoxicity 
and death via respiratory paralysis in less than five minutes. Inhibition of 
acetylcholinesterase will have immediate impacts at the metabolic level including 
the accumulation of acetylcholine, a reduction in acetic acid and choline at the 
synaptic cleft and an accumulation of pinacolylmethylphosphoric acid (a 
metabolite of Soman) (Adeyinka and Kondamudi, 2018) (Schulze et al., 2016) . 
These metabolic changes occur almost immediately upon exposure and although 
transcriptomic changes are observed in the hours following exposure, the 
transcriptomic profile continues to change out to 168 hours post exposure. 
(Dillman III et al., 2009) .The ability for metabolic changes to rapidly impact 
phenotype are also observed with pharmaceuticals. Glucocorticoids 
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mechanistically alter gene expression and take hours or days to have a direct 
impact on an undesirable phenotype (Jin et al., 2003). On the other hand, a 
pharmaceutical such as Sildenafil inhibits a pre-existing protein to result in the 
accumulation of cGMP for a relatively rapid phenotypic response (Eardley et al., 
2002). As many pharmaceuticals have direct and noticeable impacts on the 
metabolome, metabolomics provides valuable insights into the mechanisms by 
which these drugs function as well as ways to quantify their effects at the 
mechanistic level (Kell and Goodacre, 2014) (James, 2013).  
Additionally metabolomics provides great insights into a living system’s 
interaction with the environment (Athersuch, 2012). Small molecules from the 
environment, either from the diet or other forms of exposure (including 
pharmaceuticals) are subject to metabolic transformation. Some of these inputs 
are metabolized to produce the energy needed for cellular function or the 
precursor molecules needed for macromolecule synthesis. The set of possible 
fates for an input molecule depends on which metabolic activities are present 
and the state of the system (Creek et al., 2012). By observing the fates of one or 
more input compounds to a system, a subset of metabolic activities present in 
the system can be inferred. For example, if glucose is observed to be converted 
to glucose-6-phosphate, this implies the activity of a hexokinase and provides 
insight into the regulatory state of the system (e.g. some hexokinases are sterol 
sensitive (Foretz et al., 1999), some are insulin sensitive (Kruszynska et al., 
1998), the glucokinase isoform is regulated by the glucokinase regulatory protein 
(Farrelly et al., 1999)). One way in which the fates of metabolites can be 
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determined is via stable isotope tracing, which will be discussed later.  
Differences in the fates of the same (or related) molecules under different 
conditions (disease versus no disease) can provide mechanistic explanations for 
how different phenotypes differ at the level of metabolism in specific mechanistic 
ways (e.g. a patient with glucokinase deficiency would have absent or diminished 
glucose -> glucose-6-phosphate activity).  
 Finally, although metabolism is the summation of all chemical processes 
that occur in a living system, metabolism is both an output of a biological system 
and also an input to the system. As stated previously, metabolism provides living 
systems with the molecules needed for energy, signaling, and the synthesis of 
large chemical entities. Thus, metabolites are the currency of life and are both 
inputs to living systems as well as intermediates and outputs. Therefore, 
differences in which metabolites are present and in what quantities between 
disease and non-disease states can be purely diagnostic or can directly drive the 
formation of disease or be a mixture of both. For example, the change in 
concentration or presence of a metabolite can imply the presence of a 
pathological event, but are not directly be involved in the formation of the 
pathological phenotype. For example, pinacolylmethylphosphoric acid is a 
biomarker of Soman exposure but is not involved in the mechanism of Soman 
toxicity. (Schulze et al., 2016). On the other hand, oncometabolites such as 2-
Hydroxyglutarate drive the formation of cancer by resulting in upstream 
epigenetic changes altering gene expression are examples of metabolites that 
are directly involved in the formation of a pathological phenotype. In many cases, 
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most disease related metabolites reside somewhere in-between on this 
spectrum. For example, benzo-[a]-pyrene, a carcinogenic compound found in 
cigarette smoke requires metabolic modification to become carcinogenic (Sims et 
al., 1974).  
 These examples demonstrate the potential benefits and the necessity of 
studying the metabolome to understand how the small molecules in a system 
relate to its phenotypes of interest. Through metabolomics, the metabolome can 
be characterized and more accurate and predictive models of life processes at 
the systems-level can be constructed. In turn, these models provide researchers 
the ability to better predict the outcomes of molecular phenotypes and inform 
possible interventions to interfere or correct pathological phenotypes. However, 
the construction of accurate models requires high quality metabolomics data. 
Tools that improve the data quality of metabolomics datasets acquired using 
Fourier-transform mass spectrometry are presented in Chapter 2. These higher 
quality datasets enable more robust assignment methods described in Chapter 3 
which can then be classified into lipids using tools from Chapter 4.   
1.3 Metabolic Reprogramming in Cancer 
For cancer cells to proliferate, grow, and survive, cancer cells produce 
many metabolites in different amounts than their non-transformed counterparts. 
For example, the production of new cancer cells requires large amounts of lipids, 
amino acids, and nucleic acids as precursors to produce larger molecular entities 
such as lipid membranes, proteins, chromosomes etc. in the daughter cell. 
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Additionally, the production of these large molecular entities and their precursors 
is energetically demanding, requiring large amounts of reducing equivalents and 
ATP.  
Under normal conditions, the production of these precursors and the 
production of energy molecules are tightly regulated. However, acquiring these 
metabolic capabilities is an essential step in the development of cancer. The 
process by which cancer cells alter their metabolism to acquire these metabolic 
capabilities is called metabolic reprogramming and represents one of the ten 
cancer hallmarks (Hanahan and Weinberg, 2011).  
The observation that cellular metabolism can differ significantly between 
cancer and non-cancer cells has been known since Dr. Warburg’s studies in 
1924 (Warburg et al., 1924). These studies revealed that under normoxic 
conditions, some cancer cells will preferentially metabolize glucose to lactate 
(sometimes referred to as “aerobic glycolysis”), a phenomenon typically observed 
in normal cells only under hypoxic conditions.  This property of some cancer cells 
is now known as the “Warburg Effect” and is just one example of metabolic 
reprogramming observed in cancer. 
 The exact roles that metabolic reprogramming serve in the development of 
cancer remains unclear. For example, Dr. Warburg in 1956 hypothesized that 
aerobic glycolysis was a byproduct of mitochondrial damage that prevented 
efficient mitochondrial respiration and that this process was essential in the 
development of cancer (Warburg, 1956). While his hypothesis was incorrect, 
metabolic alterations between cancer and non-cancer are common (Ward and 
11 
 
Thompson, 2012). Although some metabolic alterations may simply be a 
byproduct of disease processes, numerous studies (see examples below) have 
also demonstrated that the reprogramming of cellular metabolism may confer 
beneficial properties to cancer cells that enable their malignant proliferation. 
For example, several studies have observed that the pyruvate generated 
by glycolysis in cancer cells is converted to lactate due to the upregulation of 
lactate dehydrogenase (Rong et al., 2013) (Xiao et al., 2016). Lactate 
dehydrogenase regenerates NAD+ from NADH which is needed to drive 
oxidative glycolysis and has been shown to promote tumor growth (Fan et al., 
2011). Additionally, hypoxic cells in tumors have been observed to secrete 
lactate into the tumor microenvironment through monocarboxylate transporters 
and this lactate is then taken up by oxygenated tumor cells to fuel their oxidative 
metabolism (Semenza, 2008) (Sonveaux et al., 2008). These same studies 
demonstrated that abolition of this lactate uptake slows tumor growth and 
preferentially kills hypoxic cancer cells (Sonveaux et al., 2008). This process is 
also believed to be important for the maintenance of intracellular pH and the 
creation of an acidic tumor microenvironment (Pinheiro et al., 2010), which has 
been shown to inhibit immune function (Huber et al., 2017) and promote cancer 
metastasis (Riemann et al., 2016).  
Furthermore, a shift towards aerobic glycolysis may reduce reactive 
oxygen species formation (Brand and Hermfisse, 1997); however, other studies 
indicate that higher levels of reactive oxygen species may be beneficial in cancer 
development (Mittler, 2017). Finally, previous studies have shown that the 
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upregulation of lactate production can promote cancer resistance to commonly 
used chemotherapeutic drugs (Li et al., 2015).  
While lactate metabolism may contribute to cancer development in a 
variety of ways, it is not the only metabolite of glucose that can be produced by 
glycolysis. Additionally, several of the intermediates of the glycolysis pathway 
can be shunted to produce other necessary biomolecules, e.g. glucose-6-
phosphate is needed for the oxidative branch (NADPH-producing) of the pentose 
phosphate pathway (PPP) and in glycogen synthesis, fructose-6-phosphate is 
needed for PPP, and pyruvate is needed for alanine biosynthesis. Therefore, 
aerobic glycolysis not only produces the energy needed for cancer cells, albeit at 
2 ATP at a time, it may also provide a source of necessary precursors for other 
anabolic processes.  
Although these examples demonstrate the potential beneficial role of 
glycolysis in cancer cells, enhanced glycolysis is also a normal response to 
hypoxia. So while enhanced glucose uptake via the upregulation of glucose 
transport has been observed in cancer (Schwartzenberg-Bar-Yoseph et al., 
2004) (Kaira et al., 2014) (Pinheiro et al., 2011) and could be a compensatory 
mechanism for reduced energy production from glycolysis, it is also an expected 
response to hypoxia (Ouiddir et al., 1999). The relationship between hypoxia 
related proteins such as HIF-1alpha and cancer implicated growth factors and 
signaling pathways (such as epithelial growth factor receptor (EGFR) (Lee et al., 
2009)) suggest the relationship between hypoxia and cancer development is 
complex. Regardless, the observation that glucose uptake into cancer cells is 
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typically much higher than glucose intake into non-cancer cells is the principle 
underlying positron emission tomography (PET) imaging (Gambhir, 2002). 
However, a significant number of malignant tumors have been found to be PET-
negative (Lieberman et al., 2011) and the glucose uptake measured by PET is 
not always a useful estimate of cell proliferation or cancer grade (Avril et al., 
2001).  
Metabolic reprogramming has been observed to occur in other pathways 
beside glycolysis. Similar reprogramming has also been observed in the TCA 
cycle. Although a shift towards glycolysis may seem to imply a lower demand for 
mitochondrially derived ATP, which largely depends on TCA cycle generated 
reducing equivalents and their reoxidation via ATP-coupled respiration, this may 
not be the case in all situations. For example, enhanced fatty acid oxidation has 
been observed in a variety of cancers (Liu, 2006) and is a major source of ATP 
via the TCA cycle and oxidative phosphorylation. Furthermore, even if TCA-
derived ATP is not in demand, the TCA cycle is the source for both reducing 
equivalents and TCA cycle intermediates needed for biogenesis (Jin et al., 2016). 
For example, oxaloacetate can be converted to aspartate which is needed for 
pyrimidine biosynthesis, succinyl-CoA is needed for porphyrin biosynthesis, and 
citrate from the TCA cycle is the major source of cytosolic acetyl-CoA needed for 
lipid production. However, removing these intermediates from the TCA cycle 
cannot occur indefinitely and additional carbon must be added to maintain the 
cycle. Several studies have observed the upregulation of anapleurotic reactions 
that produce TCA cycle intermediates (either directly or indirectly) including 
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glutaminolysis (Lu et al., 2010) and pyruvate carboxylase (Sellers et al., 2015a), 
which both produce oxaloacetate. Combined with a source of acetyl-CoA (such 
as beta oxidation or pyruvate dehydrogenase), these reactions enable the TCA 
cycle to continue even if intermediates are removed for biosynthetic roles.  
Additionally, glutamine appears to play a key role in other aspects of 
cancer development. High extracellular glutamine for example may drive cell 
transformation (McKeehan, 1982) and intracellular glutamine serves a carbon 
source for pyrimidine biosynthesis and nitrogen for both purine and pyrimidine 
biosynthesis (Lacey and Wilmore, 1990). Also the reductive carboxylation of 
alpha-ketoglutarate (a metabolite of glutamine) has been observed to be 
necessary for lipid production in hypoxic conditions such as a poorly vascularized 
tumor or in cells with mitochondrial defects (Mullen et al., 2014). The ability of 
altered glutamine metabolism to sustain key portions of metabolism under harsh 
conditions could contribute to the resiliency of cancer cells but also can result in 
“glutamine addiction”, which could be exploited for therapeutic purposes (Wise 
and Thompson, 2010) (Bolzoni et al., 2016).  
 Metabolic reprogramming is not limited to glycolysis or the TCA cycle. 
Both the PPP and lipid biosynthesis pathways are often upregulated as well. The 
PPP produces the majority of the pentoses needed for nucleotides (Raı̈s et al., 
1999), and the oxidative branch is a major source of NADPH, which is needed for 
lipid and cholesterol biosynthesis, the regeneration of glutathione, and thus the 
neutralization of reactive oxygen species (Rush et al., 1985). The first step in the 
oxidative branch of the PPP, glucose-6-phosphate dehydrogenase (G6PD) has 
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been shown to be a regulator of oxidative stress (Nóbrega-Pereira et al., 2016) 
and G6PD mutants that reduce NADPH production are possibly protective 
against cancer (Dore et al., 2016), while upregulation of G6PD has been 
observed in cancer (Jonas et al., 1992). Altered lipid metabolism is also observed 
in cancer. Lipids serve as the building blocks of cellular membranes and 
signaling molecules and thus are necessary for malignant proliferation. De novo 
lipid synthesis provides many of these lipids for some cancer cells (Hilvo et al., 
2011) and the production of these lipids requires acetyl-CoA, NADPH and ATP. 
Additionally, sterol production is enhanced in cancer as well and has been 
correlated with increased invasiveness (Bao et al., 2016) and drug resistance 
(Janvilisri et al., 2003).  
 The observation that metabolic reprogramming occurs ubiquitously in 
cancer has led some researchers to claim that cancer is as much a metabolic 
disease as it is a genetic disease (Seyfried et al., 2013). While there is truth to 
this claim, since cancer metabolism is the functional output of a cancer cell’s 
genome (or a tumor’s genome given the amount of heterogeneity observed in 
tumors (Paz-Yaacov et al., 2015)), the relationship between cancer metabolism 
and genetic alterations observed in cancer are complex and clearly not 
independent. For example, well known cancer related genes have less well-
known roles in regulating cellular metabolism. For instance, the tumor suppressor 
gene TP53 not only slows cancer growth through cell-cycle arrest and the 
activation of apoptosis (Livingstone et al., 1992), but also through the regulation 
of many metabolic pathways both directly and indirectly. Activated p53 has been 
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shown to bind and inhibit G6PD to limit flux through the pentose phosphate 
pathway (Jiang et al., 2011). Additionally, p53 promotes the expression of TIGAR 
which lowers fructose-2,6-bisphosphate levels to inhibit glycolysis (Bensaad et 
al., 2006), and has been shown to regulate many effectors of lipid metabolism 
including SREBP-1 (Yahagi et al., 2003), SIRT-1 (Nemoto et al., 2004), 
aromatase (Wang et al., 2012), Acad11 (Jiang et al., 2015), Lipin1 (Assaily et al., 
2011) and caveolin 1 (Bist et al., 2000). Thus, loss of TP53 not only inhibits cell 
cycle arrest and apoptosis (Livingstone et al., 1992), it also enables the 
dysregulation of metabolism in a manner that promotes cancer growth. 
Additionally, many oncogenes also have important roles in cancer 
metabolic reprogramming. C-Myc overexpression is correlated with a coordinated 
change in many aspects of cellular metabolism. C-Myc signaling has been shown 
to stimulate glycolysis through the upregulation of GLUT1 HK2, PFKM (Osthus et 
al., 2000) and to promote glutaminolysis (Wise et al., 2008). Similar coordinated 
alterations in metabolism are observed with Ras (Kimmelman, 2015), EGFR (Kim 
et al., 2018), and ALK mutations (McDonnell et al., 2013). Furthermore, several 
metabolic enzymes have been shown to have potential roles in tumor 
suppression such as fumarate hydratase (Costa et al., 2010), further highlighting 
the complex relationship between metabolism and cancer development.  
 Metabolic reprogramming, while necessary for the development of cancer, 
can also provide potential drug targets to aid in the treatment of cancer. Due to 
their altered metabolic programming, many cancer cells become dependent on 
metabolic pathways that are not essential for the survival of healthy cell types. 
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One example is the dependency of some tumors with c-Myc mutations on 
glutaminolysis (Bolzoni et al., 2016; Wise et al., 2008; Wise and Thompson, 
2010). These glutamine-addicted tumors are incapable of surviving without 
glutaminolysis, making the inhibition of this pathway particularly effective against 
these cancers (Effenberger et al., 2017). However, in which cancer cell subtypes 
and under which conditions this process occurs in vivo remains unclear (Yuneva 
et al., 2012) (Marin-Valencia et al., 2012).  Similarly, the reliance of some 
cancers on aerobic glycolysis makes inhibition of one or more glycolytic enzymes 
a possible approach for anticancer treatment (Sheng and Tang, 2016).  
 By targeting the downstream metabolic effects of oncogenic mutations, 
rather than attempting to inhibit the oncogene mutants themselves, several 
benefits can be had. First, the set of possible oncogenic mutations for any protein 
is potentially quite large. For example, 44 known point mutations have been 
observed in Ras across human cancers (Prior et al., 2012). Although some 
overlap is expected for small molecule inhibitors of these mutants, several 
inhibitors might be necessary to cover the entire range of clinically relevant 
mutants. However, inhibiting the mutant Ras itself may not be necessary to 
provide a benefit in cancer patients with Ras mutants. Since many of these 
mutants result in the same downstream metabolic changes, inhibitors that target 
the non-mutated enzymes in the downstream pathways allow us to side step the 
problem of developing inhibitors for each mutant Ras. Additionally, many 
signaling pathways overlap and converge on the same set of metabolic changes, 
implying that the same set of metabolic enzyme inhibitors that are used for one 
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genetic subtype of cancer can likely be reused for another genetic subtype of 
cancer as well. Therefore, even if a generic Ras inhibitor (that works on all 
mutant versions of Ras equally well) could be developed and would be useful in 
the patients with Ras mutants (or closely related proteins), the potential use of 
metabolic enzyme inhibitors in a variety of cancer subtypes makes their 
development worthwhile. However, identifying which enzymes make suitable 
drug targets requires an understanding of how metabolite profiles and 
metabolism differ between cancer and non-cancer. This problem can be solved 
using metabolomics techniques. An example of how metabolomics techniques 
can be applied to improve our understanding of cancer metabolism is shown in 
Chapter 5.  
1.4 Isotope Labeling, Metabolomics and mSIRM 
 As alluded to in previous examples, information regarding the fate of one 
or more metabolites in a metabolic network provides significant insight into the 
molecular state of that system. While conceptually straightforward, performing 
these experiments can be difficult and require ‘marking’ input metabolites to 
distinguish them from other metabolites in the system. One mechanism by which 
metabolites of interest can be marked is through isotopic labeling (Kruger and 
von Schaewen, 2003) (Wiechert, 2001) (Isin et al., 2012). 
 Every nucleus of a given element has the same number of protons (e.g. all 
nuclei with 6 protons are carbon) but not all nuclei with the same number of 
protons contain the same number of neutrons. Each instance of a nucleus with 
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the same number of protons but different numbers of neutrons are examples of 
isotopes of that element. Although the possible number of isotopes for any given 
element is theoretically large, the relationship between the number of protons 
and neutrons in a nucleus and the stability of the nucleus greatly restricts the 
number of naturally occurring isotopes of that element (Erler et al., 2012). For 
example, carbon has fifteen isotopes that can be produced naturally and 
artificially, but only three of them: 12C, 13C and 14C occur naturally. A subset of 
the naturally occurring isotopes for all elements are considered stable and either 
do not undergo radioactive decay or do so at an extremely small rate to be 
considered effectively stable (e.g. 40K). Although all isotopes of an element will 
share many chemical properties such as the number of bonds they form, 
isotopes of the same element will differ in their atomic masses and can differ in 
their radioactivity or spectral properties. Therefore, compounds with identical 
chemical structures but different isotopic compositions can differ in their physical 
properties (Jue et al., 1989) (Diem et al., 1982) (Wiechert, 2001).  
 To describe different isotopic forms of the same compound, the terms 
isotopologue and isotopomer are used. Isotopomer refers to a specific isotoped 
version of a chemical structure that considers which isotopes are present in a 
structure and their location within a structure. Isotopomers are often described 
using a nomenclature that appends which isotopes and where the isotopes are 
located to the common name or IUPAC name for a compound (e.g. [2-13C]-
propanal represents a propanal molecule with a 13C isotope at position 2). When 
all positions of one element are replaced with an isotope such as [1,2,3-13C]-
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propanal, this is called uniform labeling and can be abbreviated as [U-13C]-
propanal. Isotopologues represent sets of isotopomers that share the same 
number and types of isotopes. For example, the three isotopomers of propanal 
with exactly one 13C: [1-13C]-propanal, [2-13C]-propanal and [3-13C]-propanal 
collectively constitute one isotopologue of propanal. Isotopologues can be 
described either using isotope-resolved molecular formulas (IMFs) that are 
similar to elemental molecular formulas (EMFs) but contain isotope information 
(e.g. 12C213C11H616O1 is the IMF corresponding to the isotopologue of propanal 
with one 13C) or by using a notation that describes the isotope differences 
between sets of isotopologues using the lowest mass isotopologue (m) as a 
reference. Using this nomenclature, the one 13C isotopologue of propanal is 
described as m+13C1. Examples of isotopologues, isotopomers, and the notation 




Figure 1.1: 13C Isotopomers and Isotopologues of Propanal 
The differences between isotopomers and isotopologues can be demonstrated 
using propanal as an example. Red dots represent carbons that are 13C. 
Isotopomers are specific isotope versions of a chemical structure. There are 
three distinct 13C isotopomers of propanal containing exactly one 13C (green), 
three 13C isotopomers of propanal with two 13C (yellow) and one 13C 
isotopomer with three 13C. Isotopologues are sets of isotopomers containing the 
same set of isotopes. For example, all three 13C isotopomers of propanal 
containing exactly one 13C are all examples of the m+13C1 isotopologue of 
propanal. In this case m refers to the lowest mass isotopologue of the 
compound, in this case that is propanal consisting of only 12C, 1H, and 16O.  
 
Isotopologue and isotopomers can differ from one another in terms of their 
physical properties. All isotopologues of a compound have different exact 
masses allowing their disambiguation by mass spectrometry, while different 
isotopomers can have unique spectral features due to the different positions of 
potentially spectrally unique isotopes in the structure. These differences in the 
physical properties of isotopomers and isotopologues determine which analytical 
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methods are suitable for studying them. By selectively replacing one or more 
nuclei in a metabolite with a known isotope, isotopically labeled versions of 
metabolites can be produced that can be distinguished from the non-labeled 
versions of the same metabolite.  
 In isotope tracing, isotopically labeled compounds are produced and then 
introduced into a biological system of interest. Once introduced (e.g. through the 
diet (Sun et al., 2017) or through an intravenous bolus (Lane et al., 2015) or 
cannulation (Maher et al., 2012)), metabolism then acts upon this labeled 
compound to distribute the labeled isotopes throughout the system. By observing 
into which compounds and which compartments the label is distributed and at 
what time points, information about the state of the system (i.e. what enzymes 
are present and active, what regulatory pathways are active, etc.) can be 
inferred. Additionally, when isotope labeling is considered, enzymatic reactions 
that represent mappings of substrate compounds to product compounds also 
represent mappings of substrate isotopomers to product isotopomers and by 
extension sets of mappings of substrate isotopologues to product isotopologues 
(Arita, 2012). For example, carbon 1 of glucose becomes carbon 1 of glucose-6-
phosphate and therefore represents a mapping between [1-13C]-glucose and [1-
13C]-glucose-6-phosphate (isotopomer to isotopomer mapping) and a mapping 
between m+13C1 glucose and m+13C1 glucose-6-phosphate. Throughout a 
metabolic network, these mappings are applied at every reaction and therefore 
determine where isotope labels can ultimately be distributed across the network. 
Observed labeling patterns can be explained through the actions of enzymes by 
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tracing the path of reactions that map input isotope labels to their observed 
locations in labeled derivatives.  
 To illustrate how this tracing occurs and how it can provide information 
about the metabolic activities present in a system, consider the following 
outcomes in a cultured human breast cancer cells when grown on U-13C glucose 
enriched media, producing a distribution of 13C in lipids (Lane et al., 2009). If 
many lipids that have an even number of 13C are observed following the bolus, 
this implies that 13C-acetylCoA was introduced to pre-existing lipids or to pre-
formed lipid backbones. The best explanation for this observation is that the 13C 
glucose was metabolized via glycolysis and the TCA cycle to produced U-13C 
Acetyl-CoA which was then conjugated to existing lipids or existing lipid 
backbones. Since Acetyl-CoA has only 2 carbons, the labeled 13C must be added 
in multiples of two. Pre-existing lipids that were extended can be distinguished 
from fully de novo synthesized fatty acyls if the total number of carbons (minus 
carbons in the head group) is larger than the total number of 13C added to the 
lipids. Alternatively, or additionally, if glycerolipids with an odd number of 13C are 
enriched, a possible explanation for this observation is that some portion of the 
glucose was metabolized to yield 13C glycerol-3-phosphate, which was then 
utilized to form lipid headgroups. Since glycerol has three carbons and acetyl-
CoA has two, if glycerol were labeled, the resulting lipids will have an odd 
number of 13C. This interpretation could be confirmed using NMR to measure 
enrichment of 13C in the incorporated glycerol. This relatively simple example 
shows, interpreting these results requires an understanding of metabolism and 
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can become very labor intensive. One outstanding problem in the isotope tracing 
field is the automated deduction of which pathways best explain the observed 
distribution of label from one or more labeled precursors.  
 Although this example only used a single stable isotope as an example 
(13C), isotopic labeling and tracing can involve multiple isotopes (Yang et al., 
2017b) (Montigon et al., 2001) as well as radioactive isotopes. The earliest 
isotope labeling experiments employed radioactive isotopes to produce 
radioactive versions of input molecules. By controlling the total amount of 
radioactivity and then observing what fraction of the radioactivity was distributed 
into which compartment, the volume of distribution of those compounds  
(especially pharmaceuticals) and how they are excreted can be determined 
(Glass et al., 1980) (Huang et al., 1998) (Lister-James et al., 1996). However, 
introducing radiolabeled compounds into living systems poses several 
complications, the least of which is the potential effects of radioactivity on the 
health of these systems, especially human subjects. Additionally, since 
radioisotopes are radioactive they are constantly leaving the system through 
radioactive decay which complicates the determination of kinetic parameters 
(Williams et al., 1995) and limits the time frames over which experiments can be 
performed (e.g. some isotopes such as 11C or 15O have half-lives of ~20 minutes 
and ~2 minutes respectively (Conti and Eriksson, 2016)). This limitation is less 
relevant for longer lived radioisotopes. Finally, the use of multiple different 
radiolabels in a single experiment becomes complicated if their decay processes 
are indistinguishable. An alternative to radiolabeling is stable isotope labeling in 
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which stable isotopes in a compound are replaced with other stable isotopes. 
Common substitutions include 13C for 12C and 15N for 14N. When compounds 
have been substituted with respect to one or more different elements for use in a 
metabolomics experiment, this technique is referred to as multiple stable isotope 
resolved metabolomics (mSIRM) (Yang et al., 2017b).  
 The use of stable isotopes in mSIRM enables their relatively risk-free use 
in humans and other biological systems but with several significant 
disadvantages. First to perform tracing, it is necessary to identify not only what 
metabolites are present, but also what isotopologues and/or isotopomers are 
present as well. This only complicates the already difficult bioanalytical problem 
of identifying metabolites in complex biological samples. Our assignment 
algorithm described in Chapter 3 accounts for isotope labeling and can assign 
labeled and unlabeled data. Second, most stable isotopes are also found in 
nature and the mole fraction of an element that is represented by a particular 
isotope is the natural abundance of that element and for some isotopes this 
percentage can be small (2H = 0.000115) or relatively large (37Cl = .2424) 
(Linstrom and Mallard, 2001). The contribution from natural abundance must be 
considered when attempting to quantify the absolute amount of label present in a 
derivative (Fernandez et al., 1996) (Moseley, 2010). For example, in the 13C-
enriched lipids, some percentage of the lipids will have 1 or more 13Cs even 
without a contribution from the artificially introduced 13C. The process of 
correcting for the effects of natural abundance is uncreatively referred to as 
natural abundance correction, and determining when to correct and how to 
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correct can dramatically impact how experimental results must be interpreted. 
Furthermore, any technique for identifying metabolite isotopologues or 
isotopomers based on their concentrations must consider the effects of natural 
abundance.  
1.5 Analytical Techniques Employed for Metabolomics 
A necessary step in all metabolomics experiments is the observation, 
identification and quantification (absolute or relative) of metabolites from 
samples. Due to the structural diversity of metabolites and the wide range of 
chemical properties they possess, the systematic and comprehensive analysis of 
metabolites represents a significant bioanalytical problem that must be solved to 
allow more meaningful metabolomics experiments (Doerr, 2016). Although the 
entire range of analytical chemistry techniques have been applied to 
metabolomics experiments, nuclear magnetic resonance (NMR) (Fan and Lane, 
2011) and mass spectrometry (MS) (often in conjunction with chromatography) 
(Dettmer et al., 2007b) (Abdelrazig, 2015) (Kanani et al., 2008) (Fang and 
Gonzalez, 2014) remain the most popular techniques employed for 
metabolomics. 
 Both NMR and MS produce spectra as their output where each spectrum 
consists of multiple spectral features (peaks) that correspond to features of the 
compounds present in the sample. The two methods differ in how spectra are 
generated and what physical phenomena they observe to generate spectra. In 
NMR, spectral features corresponding to sets of magnetically equivalent nuclei 
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are generated by observing the nuclear magnetic resonance of the nuclei. All 
nuclei with a nonzero nuclear spin have an intrinsic nuclear magnetic moment 
which generates a weak magnetic field. These nuclei are “NMR active” and the 
commonly NMR-detected nuclei include 1H, 13C, 15N. These nuclei are naturally 
abundant isotopes of elements found in metabolites and 13C and 15N are 
common isotope labels. The total number of spin states for a nucleus is 2*I + 1, 
where I is the nuclear spin of that nuclei. All three of these commonly detected 
“NMR active” nuclei have spin ½ (the lowest spin that is NMR active, other higher 
spins are possible as well for other nuclei) and as a result each of these nuclei 
have two spin states: spin up (+½) and spin down (-½). In the absence of a 
magnetic field, these spin states are equal in energy but in a strong magnetic 
field, the two spin states are no longer energetically equivalent and the low-
energy spin state will become more highly populated than the high spin state at 
equilibrium. A short pulse of broad-spectrum radio frequency is then applied. The 
magnetic component of the radio frequency pulse excites the nuclei and results 
in a non-equilibrium distribution of nuclei between the spin states (i.e. more 
nuclei will be in the high energy state than at equilibrium). There is now a net 
magnetization that will decay back to equilibrium with time. As the net 
magnetization decays, it also precesses (precession occurs whether there is 
excitation or not) and an electromotive force is generated, causing a decaying 
induced current flow that can be measured. This measured current flow is called 
a free induction decay (FID) and can be fitted to a series of exponentially 
decaying sinusoids and cosinusoids (terms) using the Fourier transform. These 
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terms represent nuclei in different magnetic and electrical environments and their 
frequencies can be used to generate an NMR spectrum. Averaging multiple 
acquisitions yields spectra with good signal-to-noise ratios where each peak in 
frequency space represents a population of magnetically unique nuclei. By 
changing which frequency ranges are scanned and what pulse sequences are 
utilized, a variety of experiments can be performed using NMR; however, the 
underlying physics of how compounds are detected remains the same.  
 Unlike NMR where the same physical phenomenon is employed for 
observing compounds regardless of instrument make or configuration, mass 
spectrometry refers to any analytical technique that measures the mass-to-
charge ratio of ions. To ionize analyte compounds, a variety of techniques are 
employed each with different advantages and disadvantages. Typically, more 
harsh ionization techniques such as inductively coupled plasma (Bazilio and 
Weinrich, 2012) and chemical ionization have better ionization efficiencies but 
are destructive, while less harsh techniques such electrospray ionization are less 
efficient but relatively non-destructive. The ionization system is often the first step 
in a deployed MS system and can be placed in-line after a chromatography 
system (e.g. GC-MS, LC-MS) or sample can be directly injected into the 
ionization system (e.g. direct infusion). Some compounds become charged 
themselves during this process, while others associate with other ions to form 
adducts that are charged or associate with other molecules to form complexes 
(Venter et al., 2008) (Cuyckens and Claeys, 2004). The presence of multiple 
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adducts per ion and complexes contribute to the complexity of assigning mass 
spectra.   
Once ionized, ions can be moved using electromagnetic fields into one or 
more mass detectors. Different types of mass detectors use different physical 
properties of ions to infer the mass-to-charge ratio of ions. Common types of 
mass analyzers include: quadrupoles that are constructed of electrodes that with 
the appropriate potential applied will select for a specific m/z range of ions 
(March and Londry, 1995) (March, 2006) , time-of-flight analyzers that back 
calculate the mass-to-charge ratio of an ion based on the amount time needed 
for the ion to travel a known distance in a vacuum (Wiley and McLaren, 1955) , 
and magnetic sector analyzers that deflect ions into paths of unique radii based 
on their mass-to-charge and the strength of the magnetic field (Mattauch, 1936). 
Various types of mass analyzers are used for MS-based metabolomics, but the 
highest mass accuracy, resolution, and sensitivities are achieved using the 
Fourier transform mass spectrometry family of mass analyzers.  
The FT-MS mass analyzers consist of two different instrument types: the 
Makarov trap mass analyzer (often referred to by its trade name Orbitrap) and 
the ion cyclotron resonance (ICR) mass analyzer (Zubarev and Makarov, 2013). 
An Orbitrap analyzer consists of two electrodes -an inner and outer electrode – 
that are separated by a vacuum into which ions can be injected. Between the two 
electrodes, a large voltage potential is applied, resulting in an electrical field that 
can trap ions within the volume separating the electrodes. Once trapped, ions 
orbit the inner electrode in an elliptical trajectory, while simultaneously 
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experiencing harmonic axial motion. This axial motion has an angular frequency 
that depends on the mass-to-charge ratio of the ion, but no other parameters of 
the ions themselves. Thus, if the axial motion of the ions can be detected, the 
mass-to-charge ratios of the ions can be inferred. Axial oscillations can be 
induced in trapped ions with radiofrequency pulses that are close in frequency 
(resonant) with the axial frequencies of the trapped ions. Using properly 
constructed waveforms, effectively all ions in the trap can be excited 
simultaneously. Once excited, the oscillations of these ions induce a current in 
the outer electrode that can be detected (like an FID in NMR). The acquired 
current is a function of time but can be converted to the frequency domain using 
the Fourier transform. From these transformed frequencies, the mass-to-charge 
ratios of ions present as well as the relative intensity of the induced current for 
that ion species (a function of the number of ions of that species in the trap) can 
be inferred.  
An ICR-type analyzer is in general very similar to an Orbitrap with the 
main difference being that a magnetic field is used to trap ions in ICR analyzers 
rather than an electrical field and that the angular frequency of interest for the 
ions depends upon their ion cyclotronic frequencies (Comisarow and Marshall, 
1974). In ICR, application of a radiofrequency pulse induces the trapped ions to a 
larger cyclotron radius. As in the Orbitrap, the passing of the ions near electrodes 
in the analyzer induces the formation of a current that is captured as the ions 
decay from their larger cyclotron radii. This current is an FID that can be Fourier 
transformed and further processed to yield a mass spectrum. Typically, multiple 
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FIDs are acquired and transformed to produce a ‘scan’ and multiple scans are 
combined to generate an aggregate spectrum. On some instruments, the FID for 
a scan is a summation of multiple microscans, each corresponding to an FID 
acquired on the same set of ions in the trap. The number of FIDs per scan is 
controlled by the microscan setting.  
The superior analytical capabilities of both orbitraps and ICR instruments 
are related to their shared use of the Fourier transform to produce spectra. Unlike 
other mass analyzers where each ion’s mass-to-charge ratio (or a proxy of the 
ratio) is observed only once per ion, each FID represents multiple measurements 
of every excited ion’s mass-to-charge ratio. Although each individual 
measurement has an error component, the Fourier transform effectively 
averages all these measurements into a single observation, greatly reducing any 
non-systematic sources of error and increasing signal-to-noise significantly (this 
effect is called Fellgett’s advantage (Fellgett, 1949)). However, when the 
mathematical assumptions of the Fourier transform are not met exactly (which is 
often the case with real-world data) spectral artifacts can be introduced because 
of this mathematical processing.  
Despite their differences, both FT-MS and NMR remain popular choices 
for metabolomics experiments for several important reasons. First, both 
instruments are sensitive to a wide-range of chemical structures, which is 
necessary for observing the entire set of metabolites with as little selection bias 
as possible. NMR requires the presence of one or more NMR-active nuclei in a 
compound (effectively all metabolites thanks to 1H and 13C), while mass 
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spectrometry simply requires that a metabolite be ionizable or already ionized. 
Second, both instruments are capable of some form of quantification. NMR can 
achieve absolute quantification with the appropriate standards, while MS can be 
useful for relative quantification. Third, both NMR and mass spectrometers 
(although to a less extent FT-MS instruments) are relatively common and have 
been used extensively for chemical identification and characterization. As a 
result, large databases of chemical compounds with their corresponding NMR 
and mass spectra are available to help map spectral features to chemical 
structures, a process called assignment. However, for mass spectrometry, these 
databases can be problematic for assigning metabolite features. a problem that 
will be discussed in more detail in Chapter 3.  
While FT-MS and NMR both share many properties that make them 
ideally suited for metabolomics applications, they also differ significantly in their 
capabilities. First and foremost, NMR and FT-MS have substantially different 
detection limits. FT-MS can detect compounds with femtomolar concentrations 
under ideal circumstances (Eyles and Kaltashov, 2004)  (Groenen and van den 
Heuvel, 2006) while NMR is typically limited to compounds with micromolar 
concentrations (Gronwald et al., 2008) although in limited cases much better 
detection limits can be achieved (Spiess, 2008). For metabolomics applications, 
where the concentration of metabolites of interest are largely outside the control 
of the researcher, this difference in detection limit can greatly restrict what 
metabolites can be detected in a living system. For example, signaling molecules 
and toxins may have significant roles in living systems at very low 
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concentrations, but would be undetectable by NMR. Metabolites span a large 
concentration range from the femtomolar range (iodothyronine metabolites in 
brain tissue (Pinna et al., 2002)) to millimolar concentrations (Cubbon et al., 
2010). 
However, what NMR lacks in sensitivity it compensates for in terms of the 
amount and types of information it can provide regarding metabolites. In MS, sets 
of ions with the same mass-to-charge ratio are indistinguishable. If two ions have 
the same mass-to-charge ratio only one spectral feature will be produced. While 
identical nuclei with identical magnetic environments will result in identical 
signals, an NMR observes many NMR active nuclei per compound and even very 
similar chemical structures will produce substantially different NMR spectra. 
Additionally, the NMR spectrum of a compound depends both on the composition 
and the relative arrangement of isotopes in its structure, thus NMR can 
distinguish not only isomers from one another but also isotopomers of the same 
compound. FT-MS on the other hand, cannot resolve isotopomers of the same 
compound or isomers of the same compound without orthogonal information 
such as chromatographic retention times (Ferreres et al., 2004), chemoselective 
adduct formation (Nishikaze et al., 2017) or MS/MS (Menicatti et al., 2016). All 
three of these techniques require more complicated experimental setups, greater 
volumes of sample and ultimately greatly increased labor to collective, curate, 
and process the generated data (Chekmeneva et al., 2017).  
Furthermore, while sample preparation for any analytical technique can 
introduce artifacts or biases that result in analytical samples that do not represent 
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the biological samples from which they are prepared, FT-MS requires that 
samples also be ionized. Ionization results in a variety of artifacts that can 
complicate the interpretation of spectral data. First, not all compounds ionize 
equally well and the efficiency with which compounds ionize depends on 
experimental conditions (Rauha et al., 2001). A sample with an equal 
concentration of many metabolites with differing ionization efficiencies will appear 
as a mixture of metabolites with different concentrations to the mass analyzer. 
This effect makes mass spectrometry poorly suited for absolute quantification. 
Second, some compounds preferentially form ions of a certain charge or specific 
adducts – this can introduce biases in which compounds are detected and 
assigned (e.g. positive mode spectra will not observe negatively charged ions). 
Furthermore, ionization efficiencies and ion / adduct formation can be influenced 
by the composition of the sample. A common example of this is ion suppression 
where the presence of high concentrations of one or more compounds 
‘suppresses’ the signal of less abundant compounds (Jessome and Volmer, 
2006) (Buhrman et al., 1996). Finally, even the softest of ionization methods are 
still destructive. Ionization can induce chemical rearrangements to occur or 
cause metabolites to fragment resulting in chemical species that can be detected 
but are not representative of the biological samples from which they were 
prepared (Kingston et al., 1983) (McLafferty, 1959). Even small effects such as 
the degree of corrosion on electrospray emitters can cause ionization artifacts 
(Chen and Cook, 2007). Furthermore, FT-MS artifacts can also arise as a 
byproduct of the mathematical manipulation needed to convert observed FIDs to 
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actual spectra (Kanawati et al., 2017) (Xian et al., 2013) (Mitchell et al., 2017). 
These artifacts can lead to large interpretive errors in downstream analyses. 
Methods for handling a subset of these artifacts is described in Chapter 2.  
Due to their relative strengths and weaknesses neither NMR nor FT-MS 
alone are ideal for the entire range of expected metabolomics experiments. 
NMR’s ability to provide structural information and quantification makes it suitable 
for chemical structure determination, the characterization of newly discovered 
metabolites (if they can be isolated and concentrated sufficiently) and for the 
quantification of specific isotopomers of high abundance metabolites. FT-MS on 
the other hand is best suited for detecting low concentration metabolites or sets 
of isotopologues and situations where relative quantification is enough. This 
makes FT-MS ideal for the discovery of new metabolites. However, the lack of 
structural information provided by FT-MS to confirm metabolite assignment, the 
presence of spectral artifacts that can be confused for novel metabolites and the 
obvious absence of newly-observed metabolites in assignment databases 
requires new tools for the processing and assignment of FT-MS data. Algorithms 
for handling spectral artifacts in FT-MS are presented in Chapter 2 and an 
assignment algorithm capable of assigning molecular formulas to spectral 
features corresponding to novel metabolites is presented in Chapter 3. These 
tools are fully automated to handle the large volumes of data that can be 
produced by FT-MS in high throughput experiments. 
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1.6 The Assignment Problem and Untargeted versus Targeted 
Metabolomics 
Assignment is the process by which observed spectral features in an FT-
MS spectrum are assigned to either molecular formulas or directly to metabolites. 
Without accurate assignments, the ability to relate observed patterns in FT-MS 
datasets to phenotypes observed between samples at a biochemical level would 
effectively be impossible. Obviously, incompletely assigned spectra and 
incorrectly assigned spectra are undesirable and can result in substantial 
interpretive errors in downstream data analyses.  
 Despite the substantial analytical improvements FT-MS provides for the 
detection of metabolites, the assignment of FT-MS spectral features to elemental 
molecular formulas that represent compounds (presumably metabolites) in a 
biological sample remains a difficult step in the FT-MS data analysis pipeline. 
Some of the reasons why assignment remains difficult are intrinsic to mass 
spectrometry. First, unlike NMR, mass spectrometry cannot disambiguate 
isomers or isotopomers of a compound because they have identical mass. 
Second, each species of ion produces only one signal in an FT-MS spectrum but 
have the potential to produce multiple signals in NMR that can help cross-
validate assignment. Others are related to how these instruments are commonly 
deployed and used. The increased popularity of high throughput metabolomics 
experiments has resulted in a substantial increase in the rate of data collection 
that has outpaced the rate at which the data can be analyzed. Additionally, the 
use of FT-MS in a direct infusion environment prevents the acquisition of 
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orthogonal information from chromatography or spectroscopy to aid in metabolite 
assignment. Even if these shortcomings with existing FT-MS platforms could be 
addressed, the sheer number of theoretically possible assignments makes the 
unbiased assignment of FT-MS spectra difficult. Existing assignment methods 
are divided into two categories: targeted assignment methods and untargeted 
assignment methods.  
In targeted assignment methods, a set of expected assignments is used 
as a database against which observed spectral features can be queried. For 
metabolomics experiments, these databases are usually sets of known 
metabolites that can be populated from public metabolite databases such as 
Human Metabolome Database (HMDB) (Wishart et al., 2007), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000), 
LipidMaps Structure Database (LMSD) (Sud et al., 2006), or constructed by hand 
as is the case with PREMISE (Lorkiewicz et al., 2012). These databases can be 
tailored for the system of interest and curated to eliminate metabolites that are 
not expected in the system. Once constructed, a peak can be assigned by 
querying its observed m/z with an m/z tolerance against the set of metabolites 
(correcting for ionization and adduction). These targeted methods have the 
advantages of being easy to use, computationally cheap and relatively 
straightforward to implement. Additionally, outside knowledge about the system 
can be easily incorporated into the assignment process to aid possible 
assignments. For example, if the sample preparation was selective for lipids, the 
database of possible assignments needs to include lipids.  
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The conveniences of targeted assignment come with several significant 
disadvantages. First, newly discovered metabolites will not reside in existing 
metabolite databases and all metabolite databases are incomplete (Schrimpe-
Rutledge et al., 2016) (Mitchell et al., 2014). As a result, spectral features 
corresponding to these metabolites will either remain unassigned or worse be 
misassigned. Second, the use of tailored databases biases assignment towards 
entries in the database (Moseley, 2013). For example, if it is assumed that a 
sample consists of only lipids and a lipid-only database is used for assignment, 
all the generated assignments will be to lipids even if non-lipid compounds were 
present in the sample. Third, m/z matching alone does not provide sufficient 
information to disambiguate multiple possible assignments and is statistically 
error-prone due to the lack of cross-validating evidence (Kind and Fiehn, 2006). 
For example, determining if two peaks approximately 1 Dalton apart are 
isotopologues of the same compound or two different compounds with m/z alone 
is effectively impossible. All of these limitations become more pronounced when 
artifactual spectral features are present (Mitchell et al., 2017). For example, 
artifactual features whose appearance is correlated with sample class or the 
presence of other metabolites can result in consistent misassignments that can 
confuse downstream data analyses. Methods for detecting a particularly 
problematic artifact type that we have discovered with this sample correlation 
property in FT-MS spectra are described in Chapter 2.  
The alternative to targeted assignment is untargeted assignment, where 
no assumptions or very few assumptions are made regarding the set of possible 
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assignments. Ideally, no databases of possible metabolites would be used and 
assignments would be produced using cross-validating information within an 
MS1 spectrum. Unfortunately, no real untargeted assignment method exists. 
Many of the tools that are advertised for untargeted assignment are simply 
targeted tools with very large metabolite databases. The LipidSearch assignment 
tool is one such example of an “untargeted” assignment method that ultimately 
relies on a large database of known lipids to generate assignments (Peake et al., 
2013). While these large databases can mitigate some of the problems of 
targeted approaches, they are not a complete solution. Other so-called 
untargeted tools attempt to calculate an elemental formula from an observed m/z 
directly using heuristics derived from examples of known valid chemical 
structures. One example of this approach is the “seven golden rules” published 
by Kind and Fiehn (Kind and Fiehn, 2007). However, these heuristics can only 
accurately predict the elemental formula of monoisotopic peaks, making them 
unsuitable for the assignment of isotopologues expected in mSIRM experiments. 
At high molecular weight, the number of possible elemental formulas remains 
very large even with these heuristic rules (Watson, 2013).  
These compromises in existing untargeted tools exist as a work around for 
the extremely high computational cost of considering all possible formula 
assignments for each peak in a spectrum. The number of possible elemental 
molecular formulas increases exponentially with increasing mass and the number 
of possible isotope-resolved molecular formulas (IMFs) that must be considered 
in SIRM experiments is even larger. Simple brute force testing of all possible 
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formulas against every peak cannot possibly be done efficiently and simple m/z 
matching against such a large set of possible assignments will have an extremely 
high false positive rate.  
 However, improvements in the combinatorial mathematics underlying 
natural abundance correction (Moseley, 2010) (Carreer et al., 2013) enables the 
calculation of a natural abundance probability (NAP) for any given IMF, even 
when isotopic labeling is expected. IMFs with low NAPs are unlikely to be 
observed in an experiment and thus this NAP value can be used to avoid a brute 
force enumeration of all IMFs by allowing a smarter enumeration of only the likely 
IMFs for an experiment, which is a much smaller set than the set of all IMFs. 
Furthermore, comparisons between relative peak intensities of assigned peaks 
and the NAPs of their IMF assignments provides a possible mechanism to 
reduce false assignment. How NAP can be calculated in both labeled and 
unlabeled cases and how it can be applied to achieve untargeted IMF 
assignment is described in detail in Chapter 3. 
1.7 Applications of Metabolomics 
 Although existing methods for processing and assigning metabolomics 
data have significant deficiencies, metabolomics techniques have already been 
successfully applied to several human diseases and conditions, improving our 
understanding of altered metabolism for many biological systems with 
implications for human health.  
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 One common application of metabolomics is the identification of disease 
biomarkers for diagnostic or prognostic purposes. By comparing observed 
metabolomes of healthy and disease samples and identifying overly abundant 
metabolites present only in disease, or preferentially in disease, robust 
biomarkers can be identified, typically using a variety of statistical and 
computational techniques ranging from simple ANOVA (Farshidfar et al., 2018), 
LASSO (Chan et al., 2015) to machine learning methods (Chen et al., 2013). 
Biomarkers for a number of cancers have been identified using these techniques: 
high serum and urinary bile acids, histidine, and inosine levels are indicative of 
hepatocellular carcinoma (Chen et al., 2011); high urinary acylcarnitines (Ganti et 
al., 2012), quinolate, 4—hydroxybenzoate, and gentisate (Kim et al., 2011) are 
indicative of kidney cancer; high serum 2-hydroxybutyrate, aspartate, kynurenine, 
and cystamine are indicative of colorectal cancer (Nishiumi et al., 2012); and high 
cell or tissue levels of choline derivatives are indicative of cancer (Glunde et al., 
2004) (Beloueche-Babari et al., 2009). Sometimes the change in the 
concentration of a single or handful of metabolites are insufficient for disease 
diagnosis. In these cases, machine learning enables the use of many measured 
metabolites to collectively act as a biomarker signature for a disease (Chen et al., 
2013; Zhou et al., 2010). The ability to potentially diagnose clinically 
asymptomatic cancer patients prior to their progression to advanced disease has 
the potential to save many lives. Additionally, biomarkers can also inform 
physicians as to the aggressiveness (Giskeødegård et al., 2013) of a patient’s 
cancer. The use of metabolomics to identify potential biomarkers or metabolic 
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signatures of disease is not limited to cancer. Differential immune response to 
influenza with respect to obesity (Milner et al., 2014), markers of cardiovascular 
disease (Montgomery and Brown, 2013) (Garg, 2011), and markers of air 
pollution exposure (Jiang et al., 2016) are just a few examples.  
 In the previous examples, the observed biomarkers were assigned to 
metabolites or small molecules; however, this level of assignment is not 
necessary in all cases. Any reliably observed spectral feature that correlates with 
sample class can serve as a biomarker (Kind et al., 2007). Working at the 
spectral feature level sidesteps the difficult assignment problem, but ultimately 
limits what can be inferred about the system. For example, a collection of 
samples from glutamine-addicted tumors will have a consistent spectral feature 
corresponding to glutamine; however, inferring that the presence of that signal 
corresponds to a specific metabolic alteration that could be targeted with a drug 
or indicative of c-Myc activation is effectively impossible without accurate 
assignment.  
 In addition to biomarker discovery, the combination of stable isotope 
tracing with metabolomics is greatly enhancing our ability to construct accurate, 
quantitative models of cellular metabolism in multiple ways. First, the 
combination of labeling and metabolomics enables the disambiguation of multiple 
pools of a given metabolite in different cellular compartments (Fan et al., 2012). 
For example, mitochondrial and cytosolic pools of NADPH are 
compartmentalized but undergo indistinguishable reactions without labeling 
(Lewis et al., 2014). Distinguishing metabolites pools is particularly important as 
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the same metabolite in different compartments may have very different metabolic 
roles.. For example, cytosolic acetyl-CoA is available for lipid biosynthesis, but 
not mitochondrial acetyl-CoA, despite having the same chemical structure. 
Similarly, while both pools of acetyl-CoA could be used for protein acetylation, 
this compartmentalization limits which pool or acetyl-CoA is available to acetylate 
which proteins (Anderson and Hirschey, 2012). Second, labeling enables 
metabolites with identical structures, but with different origins to be differentiated. 
For example, Myc activation results in both enhanced glycolysis and 
glutaminolysis (Goetzman and Prochownik, 2018), which can result in lactate or 
TCA cycle intermediates respectively.. Inferring that the primary product of 
glucose metabolism is lactate and that glutamine is metabolized to create TCA 
cycle intermediates requires differentiating glucose carbons from glutamine 
carbons, which can be achieved using 13C labeling (Le et al., 2012). Presence of 
labeled lactate only when glucose is labeled would imply that glycolysis is the 
primary source of carbon for lactate biosynthesis, while the presence of labeled 
TCA intermediates only when glutamine is labeled would imply significant 
glutaminolysis activity.  
 In these cases, simply observing a high abundance of isotope label, 
irrespective of where it is located in the compound is sufficient to differentiate the 
metabolic fates of glutamine and glucose. However, more powerful inferences 
can be made when label distributions are studied more closely. Many metabolic 
pathways can be measured quantitatively using one or more labeled feed 
metabolites along with observing the concentrations of labeled versions of one or 
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more readout metabolites (Jang et al., 2018). For example, pyruvate carboxylase 
activity can be measured using [3-13C glucose] or [U-13C glucose] and measuring 
m+1 aspartate and m+1 malate levels. This technique was used to identify the 
necessity of pyruvate carboxylase for non-small cell lung cancer development 
(Sellers et al., 2015a). Likewise, purine and pyrimidine biosynthesis can be 
tracked using [1-13C]-bicarbonate, [U-15N]-glutamine, and [U-13C] glutamine by 
measuring the 13C incorporation into UTP and UDP-Glucose (Strong et al., 
1983); protein synthesis can be tracked using 2H2O and [U-13C] amino acids by 
measuring protein amino acid enrichment in proteins (Busch et al., 2006); etc. 
Additionally, observed labeling patterns can aid in the discovery of new metabolic 
pathways and the placement of newly discovered metabolites (Creek et al., 
2012) (Higashi et al., 2014).   
 In many cases, the relative enrichment of various isotopologues or 
isotopomers at isotopic steady state is enough to infer the relative activities of 
pathways. However, isotopic labeling can also be used to measure relative flux 
not at isotopic steady state by observing how quickly pools of metabolites 
become labeled when labeled precursor is introduced to a system. The higher 
the relative flux, the faster label accumulates in a pool. While computationally 
and experimentally challenging, the parameters learned from these experiments 
can aid in the production of truly quantitative models of cellular metabolism 
(Leighty and Antoniewicz, 2011). Biochemical models complete with flux 
parameters (either from dynamic flux analysis or steady state flux analysis) can 
aid in the identification of drug targets. Enzymatic steps with enhanced relative 
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flux in disease versus non-disease are prime drug targets (Boros et al., 2004) 
and changes in metabolic flux through those pathways can be used to quantify 
drug response (Harris et al., 2012).  
 Despite these potential advantages, effectively all these analyses require 
high quality data and trustworthy assignments. Diagnostic biomarkers that are 
not assigned must still be reproducible and validated, which in turn requires high 
quality data that is free of obvious data quality problems and artifacts. Confusing 
spectral artifacts with diagnostic spectral features could at best result in poor 
diagnostic accuracy or poor reproducibility and, at worst, lead to misdiagnosis. 
Biomarkers without high quality assignments are ultimately limited in what they 
tell us about the biological system they represent and more complicated analyses 
such as metabolic flux modeling or the inference of enzyme activities from 
labeling patterns requires accurate assignments. Although data quality and 
assignment remain significant unsolved problems for the metabolomics field, they 
are particularly pronounced for experiments utilizing direct infusion FT-MS. Direct 
infusion limits which orthogonal information can be acquired, which in turn makes 
assignment more difficult. Furthermore, the use of the Fourier transform can 
result in spectral artifacts in FT-MS (Miladinović et al., 2012) . Addressing these 
two significant unsolved problems and applying them to improve our 
understanding of non-small cell lung cancer (NSCLC) metabolism is the main 
goal of this dissertation. 
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1.8 Overview of Dissertation 
Although each of the different software tools described in this dissertation are 
stand-alone tools that can be used in a variety of metabolomics experiments, 
many of them were developed with the goal of analyzing a dataset collected by 
our collaborators in the Center for Environmental and Systems Biochemistry 
(CESB). This dataset was comprised of paired disease and non-disease lipid 
extracts collected from suspected NSCLC patients. The goal was to assign the 
lipids present in these samples in an untargeted manner and then investigate 
how the lipid profiles differ between the disease and non-disease samples.  
However, this analysis quickly proved to be more complicated than first 
imagined. First, several significant data quality problems were discovered that 
complicated the analysis of this data. Some of these data quality problems and 
how they were addressed is described in Chapter 2. Next, no suitable untargeted 
assignment tools existed for assigning this dataset. Several years were spent 
attempting to develop an untargeted method but only until the data quality 
problems were addressed was SMIRFE able to be developed and assign EMFs 
and IMFs to spectra generated from these samples. Chapter 3 describes the 
SMIRFE algorithm and how it was validated.  
Although SMIRFE could generate assignments in an untargeted manner, it 
could only assign EMFs and IMFs to spectra. To explore lipid profile differences, 
it was necessary to predict lipid categories from these EMFs and IMFs. This was 
achieved using the machine learning approaches described in Chapter 4. Finally, 
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with the data quality problems addressed, untargeted assignments generated 
and lipid categories for these assignments predicted, lipid profile comparisons 
could be made using the paired NSCLC dataset. The results from this analysis 
are shown in Chapter 5.  
Chapter 6 is the only research product not used directly in the analysis of the 
NSCLC dataset. In Chapter 6, the potential efficacy of a technique called 
chemoselective-derivatization is explored in silico for disambiguating MS-based 
assignment of isomeric metabolites. Additionally, the algorithms described in 






CHAPTER 2. FT-MS DATA QUALITY PROBLEMS AND ARTIFACTS 
2.1 Introduction 
Due to its potential to provide simultaneous improvements in sensitivity, 
mass resolution and mass accuracy, Fourier Transform Mass Spectrometry (FT-
MS) has the combined analytical capabilities to enable increasingly more 
complex and informative experiments in the field of metabolomics. In particular, 
FT-MS is ideally suited for the discovery of new, low concentration metabolites 
(Dettmer et al., 2007a) and the disambiguation of differently isotopically enriched 
isotopologues (Higashi et al., 2014). Despite these advantages, several data 
quality problems have limited the effective application of FT-MS for metabolite 
discovery and untargeted metabolite assignment. At the forefront of these issues 
is the presence of spectral artifacts. 
 Like any other analytical technique, FT-MS can produce artifactual signals 
that are due to instrumental or data processing limitations. These artifactual 
features obviously do not represent the underlying biochemistry of a sample and 
at best complicate data interpretation and at worst lead to incorrect 
interpretations. These effects are particularly pronounced in untargeted 
experiments where the set of expected metabolites are not known a priori; 
greatly increasing the likelihood that an artifactual feature can be mistaken for a 
metabolite feature. As untargeted experiments become increasingly larger and 
more popular in the field of metabolomics (Goodacre et al., 2004), the ability to 
distinguish true sample-specific signals from artifactual signals becomes 
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increasingly more desirable as many existing methods for assigning mass 
spectra will readily assign both artifactual and non-artifactual features alike 
(Mahieu and Patti, 2017). 
  Artifactual peaks observed in FT-MS can be divided into two classes 
based upon their origin. The first of these is chemical noise resulting from actual 
but unintended ions introduced during data acquisition. This includes 
contaminant compounds such as plasticizers and keratin (Keller et al., 2008)  as 
well as ionization byproducts such as molecularly rearranged lipids (McLafferty, 
1959). For chemical noise, the artifactual signals represents actual populations of 
ions observed in the ion trap but these populations of ions are not directly 
representative of sample analytes. These artifact types are not unique to FT-MS 
but can occur with any mass spectrometer.  
 The second class consists of artifactual peaks that do not correspond to 
actual ions. Often these artifacts arise when the mathematics used to process 
the raw data from the instrument into a spectrum make incorrect assumptions 
about that data. For example, the Fourier transform, which is used to convert 
time domain data (e.g. a decaying FID) into frequency domain data (by fitting to a 
family of decaying sinusoids and cosinusoids whose sum recapitulates the time 
domain data) assumes that the observed signal in the time-domain decays to 
zero continuously. A common way in which this assumption is violated is when 
the time-domain data is truncated due to insufficient acquisition time. Truncation 
introduces a discontinuity that will result in the generation of many additional 
sinusoid and cosinusoids terms after transformation that will appear as peaks in 
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the spectrum. These additional terms are the result of trying to perfectly fit a 
discontinuous function with the sum of many continuous functions which is not 
possible. These peaks are artifactual and are centered around a single intense 
peak and have a characteristic pattern of decreasing peak intensity as the 
distance between them and the intense peak increases in the frequency domain. 
This phenomenon is called peak ringing in FT-MS (Miladinović et al., 2012), sinc 
wiggles in FT-NMR (Hore, 1985), and side lobes in FT-infrared spectroscopy 
(Griffiths and Pariente, 1986). An example of peak ringing observed during our 
study is shown in Figure 2.1.  
 Although preprocessing techniques such as apodization can be used to 
force the observed data to conform with the mathematical assumptions of the 
Fourier transform, preprocessing can introduce more severe artifacts if done 
improperly and often reduce the analytical capabilities of the instrument (Brenna 
and Creasy, 1989). Previous studies of specific artifacts in FT-MS have focused 
on harmonic peaks (i.e. artifactual spectral peaks that arise due to frequency 
mixing of non-artifactual peaks with one another and radio frequency interference 
(RFI)) (Mathur and O’Connor, 2009) and peak ringing (Miladinović et al., 2012); 
however, these artifacts are only a subset of the artifacts observed in FT-MS 
spectra.  
 Manual investigation of our FT-MS spectra revealed both the presence of 
peak ringing artifacts as well as two other artifact types that were previously 
unreported in the literature that we have named fuzzy sites and partial ringing. All 
three artifacts (peak ringing, fuzzy sites and partial ringing) result in regions of 
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spectra with high peak density (HPD) and we collectively refer to them as HPD 
artifacts. Fuzzy sites are HPD artifacts not centered around an intense peak, but 
have many peaks in a small m/z window. Partial ringing is the subclass of HPD 
artifacts that show a symmetrical distribution of peaks centered around an 
intense peak like peak ringing but without the descending intensity pattern 
observed in peak ringing. Examples of both artifacts are shown in Figure 2.1. 
Fuzzy sites were the most commonly observed artifact across our spectra and 
were too numerous to manually identify in all samples. Towards this end, we 
developed an automated tool to identify a subset of FT-MS artifacts that have 
statistically higher peak density than surrounding spectra for the detection of 
these fuzzy sites and to a lesser extent other HPD sites.   
 
Figure 2.1: Three Types of HPD Artifacts  
We observed three subclasses of HPD artifacts. The first is the fuzzy site (A, 
Sample D), which we believe is a novel artifact type. The second is ringing, a 
well-known FT-MS artifact where a single intense peak has many side peaks (B, 
Sample B). We only observed ringing at the scan level. The third artifact is partial 
ringing which is a ringing-like artifact at the aggregate level (C, Sample A). R is 
the resolution setting used for data acquisition, µS is the microscan setting which 
determines how many microscans are per scan, and N is the number of scans 
aggregated to create the spectrum.  
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The second major data quality problem facing FT-MS is the high amount 
of error in observed peak intensities. Peak intensities, measured either by height 
or by area, should be proportional to the number of ions of that mass-to-charge 
ratio in the trap when the spectrum was acquired. This by itself is not a problem, 
except that the reported aggregate spectrum is composed of multiple scans 
added together, each of which is effectively an entire spectrum corresponding to 
a separate injection (and each of these scans is composed of microscans). When 
the scans are replicates averaging multiple scans together increases the signal-
to-noise ratio as random noise is “averaged out”. However, due to fluctuations in 
the electrospray system and inconsistent injections, the composition of ions in 
each injection can vary between scans and thus each scan is not necessarily a 
good replicate. For example, if a poor injection only injects 20% as much analyte, 
the effective concentration of ions in the trap will also be reduced to 20% and the 
peak intensities will also be scaled a similar amount. While the intensity 
differences are partially compensated for by the automatic gain control, this issue 
can still cause some peaks to disappear between scans if the concentration of 
that ion species falls below the detection limit or the effective dynamic range of 
the instrument.  
These effects result in a large relative standard deviation of intensities for 
a given peak across all the scans in a spectrum and when non-replicate scans 
are averaged together, the estimate of the mean peak intensity is skewed 
towards the most intense scan. This skewing means both the absolute intensities 
of the peaks and the relative intensities of the peaks have substantial error. An 
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improved peak picking and characterization method that is aware of these scan-
level variations and corrects for them has the potential to mitigate many of these 
effects and improve the relative intensity of the peaks. Once corrected, the 
relative intensities between sets of isotopologues can be used to aid metabolite 
assignment.  
2.2 Materials and Methods 
2.2.1 High Peak Density Artifact Detection 
We observed three unique artifact types that share the high peak density 
(HPD) property in otherwise peak-sparse spectra: fuzzy sites, ringing and partial 
ringing. Since fuzzy sites were present in most of our spectra, we primarily 
developed a tool for fuzzy site detection based on this HPD property using the 
Python programming language (Van Rossum and Drake Jr, 1995)  version 3.4 
and Numpy (Walt et al., 2011) for accelerating calculations. Starting with a 
peaklist in a Javascript Object Notation (JSON) format, the detector first parses 
and sorts the peaks in ascending order of their m/z values, needed for binary 
searching (an efficient mechanism for finding values in a sorted list close to a 
query value) of the peaklist. A 1 m/z window (top black box in Figure 2.2) is then 
slid across the spectrum in 0.1 m/z increments. At each increment, two binary 
searches are used to find all peaks within the window that are then counted to 
give a peak density metric (Step 1 in Figure 2.2 that is assigned to the middle 




Figure 2.2: Automated HPD-Site Detection 
The HPD artifact detection algorithm in three steps. In the first step, a peak 
density metric (D) is calculated for the peaklist (represented by the black line) 
using a sliding window method (1 m/z window, 0.1 m/z increment, represented in 
black). The peak density for each window is calculated and assigned to the 
mean m/z of the window to give a series of peak density values throughout the 
peaklist (represented by the red line). In the second step, a set of N+1 windows 
are slid across the peak density metrics in 0.1 m/z increments. In this case N=2 
and each pair of “reference” windows (shown in purple and yellow) flank the 
“test” window (shown in black). For each increment, the peak density statistic 
value S is calculated. S is calculated using the mean and variance of the peak 
density in the reference window (black µ and σ respectively) and the 
corresponding values from the reference windows (yellow µ and σ for the yellow 
window and purple µ and σ for the purple window). The mean of m/z of the test 
window is then assigned to S to give a series of density statistic values 
throughout the peaklist represented in blue. This metric flattens out density 
differences due to signal-to-noise differences or baseline differences and 
highlights regions of peaklists containing HPD artifacts (Figure 2.3E-H). In the 
third step, regions of spectra at least 0.3 m/z in width with a density statistic 
value above 100 are reported as possible HPD artifacts. 
 
 HPD artifacts can be found through the comparison of the actual peak 
density at a given m/z to the expected peak density derived from surrounding 
regions (Step 2). In this operation, N pairs of non-overlapping ‘reference’ 
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windows (yellow and purple boxes in the Peak Density line of Figure 2.2) 
distributed symmetrically around a single ‘test’ window (center black box in the 
Peak Density line of Figure 2.2) are moved across the spectrum in 0.1 m/z 
increments. The test window is the spectral region being tested for HPD 
phenomena using the reference windows as estimates of “expected” peak 
density. At each increment, the mean and standard deviation of the peak density 
is calculated for each pair of reference windows, with each reference window 3 
m/z in width. The test window is then assigned a density statistic value S (Figure 
2.2), a chi-squared inspired metric (i.e., the peak density normalized with respect 
to expected peak density and variance generated from surrounding regions). By 
taking the maximum value of S, sensitivity is maximized, enabling detection of 
HPD even if one pair of reference windows contains HPD. Although higher 
values of N are theoretically superior, testing demonstrated no significant 
improvement for N > 2. At the ends of the spectra, only the left and right 
reference windows are used.  
 In the final step, the continuous subdomains of m/z space at least 0.3 m/z 
in width (smaller than empirically observed HPD artifacts) and with density 
statistic values over 100 are reported (Step 3 in Figure 2.2). These reported 
regions very likely contain some form of HPD phenomena as they have 
significantly higher peak densities as compared to neighboring regions.  
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2.2.2 Peak Correspondence and Peak Characterization Algorithm Description 
The following peak correspondence and peak characterization algorithm 
was developed by Dr. Robert Flight, a staff scientist in Dr. Hunter Moseley’s 
laboratory at the University of Kentucky (Flight and Moseley, 2018).  
Raw Thermo data files were converted to mzML using Proteowizard v 
3.0.9205X.X (Chambers et al., 2012) with no modifications to the underlying 
data. For each sample, a custom data processing pipeline was employed to 
characterize the peaks detected across scans. mzML data were read into R v 
3.5.0 (Team, 2013) using the xcms Bioconductor package v 3.2.0 (Smith et al., 
2006), keeping only the primary MS scans. Based on the non-zero m/z point - 
point distances, a model relating m/z to m/z differences is created using LOESS 
(locally estimated scatter plot smoothing). Each scan is evaluated for aberrations 
in this m/z difference model as compared to the others, with outlier scans being 
removed.  
 The spectrum is divided into overlapping windowed regions of 10 points, 
where the m/z distance is based on the m/z distance model and each window is 
offset by 1 point. The non-zero points within each window are counted and those 
regions in the 99th percentile are kept and joined together. Within each of these 
reduced regions, peaks from each scan are detected by simply looking for 
patterns of two increasing points followed by two decreasing points using the 
findpeaks function from version 2.1.4 of the PRACMA (Practical Numerical Math 
Functions) R package (Borchers and Borchers, 2018). Each region may initially 
contain multiple peaks that need to be split up. Each peak center from peak 
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picking is binned into tiled regions one point apart, and the number of peaks in 
each bin counted. Groups of non-zero bins separated by zero count bins (bins 
with no peaks observed) are used as the true individual “peak regions” for 
subsequent peak characterization. 
 A two-pass normalization scheme is used to normalize the scan-specific 
peak intensities. In the first pass, those peaks present in >= 95th percentile of 
total number of scans, and >= 70% of the maximum intensity of peaks in a given 
scan are used to normalize the scans to each other. The scan with the lowest 
relative median distance to the other scans based on log-intensity differences is 
used as the reference scan. Then both the peak intensities and raw point 
intensities are normalized to the reference scan using the median log-ratio 
differences. Those peaks that show a high correlation (>= 0.5) with scan 
acquisition order are removed and the normalization scheme is repeated without 
the scan-correlated peaks. Those scans that do not have at least 25 peaks for 
normalization are also removed during the normalization procedure. 
 For each of the peak regions, the full set of normalized raw points are 
characterized by fitting a quadratic linear model of log-intensity to m/z. The peak 
centroid m/z and log-intensity are obtained directly from the linear model. These 
characteristics are reported for both the scan level peaks and the aggregate peak 
across scans. Standard deviations of the m/z and intensities are reported based 
on the scan level peak characteristics.  
 Due to unobserved peaks at relatively low intensities, the standard 
deviations are corrected in the following fashion based on a truncated normal 
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distribution, where the distribution is truncated on only one side assuming that 
measurements are missing because the peaks were below the detection limit 
(Burkardt, 2014) . A correction factor for the standard deviation is derived from 
peaks observed in all scans by randomly dropping observations from 5% to 95% 
of scans, calculating new standard deviations, and fitting a cubic linear model to 
the ratio of the intensity SDs with the omitted peaks to the original standard 
deviation. These correction factors can then be applied to the observed standard 
deviations. The corrected standard deviations can then be used to correct the 
observed mean, also assuming a truncated normal distribution.  
 Our new scan-level peak characterization methods result in more 
descriptive peaklists and peaks. The peak descriptions produced by this method 
provide direct measurements of peak m/z's and intensities at the aggregate and 
scan level, the standard deviation and relative standard deviations of these 
values across scans, and the scans that contain a given peak from the aggregate 
spectrum. Additionally, reporting only well corresponded peaks across scans 
greatly reduces the number of artifactual peaks from fuzzy sites and other 
artifacts and greatly reduces the number of peaks due to noise in the final 
spectrum. Finally, the scan normalization procedure compensates for fluctuations 
in the ionization source or injection that can cause peak intensities of 
corresponded peaks to vary greatly between scans. The resulting normalized 
peak intensities have lower RSDs than the unnormalized intensities, implying 
better consistency across scans.  An example peaklist generated by this 
approach is included in Additional Files.  
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2.2.3 Samples Analyzed by FT-MS 
Five different sets of samples were used to investigate HPD artifacts on our 
FT-MS platforms. Sample set A comprises solvent blanks with and without the 
Avanti SPLASH™ Lipidomix® Mass Spec Standard added. Sample B contains IC-
MS standards prepared from NSG mice livers. Sample C contains 
ethylchloroformate (ECF) solvent standards. Sample D are paired lipid extracts 
from human non-small cell lung cancer and non-cancer lung tissue samples. 
Sample E consisted of human plasma samples. More details regarding these 
samples, including who collected them, who prepared them, and who analyzed 
them, are described in greater detail in Appendix 1.  
2.2.4 FT-MS Instruments 
Several FT-MS instruments were analyzed to determine the instrument 
dependence of the HPD artifacts. These instruments include three Thermo 
Tribrid Fusion instruments (named Fusion 1, 2 and 3), a Thermo Fusion Lumos 
Tribrid (Lumos), a Thermo Q-Exactive+ and a Bruker SolariX instrument. Except 
for the SolariX, all instruments are orbitraps. Additional instrument details are 
described in Appendix 1 for some samples.  
2.3 Results 
2.3.1 Manual Investigation of Artifacts 
During FT-MS metabolomics data analysis, we manually inspected 
several hundred spectra and observed fuzzy sites, peak ringing, and partial 
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ringing. Fuzzy sites were the most common artifact and were present in nearly all 
spectra from our Fusion instruments. Partial ringing was more rare than fuzzy 
sites and was present in only a handful of the spectra examined. Ringing was the 
rarest of all three artifacts and were only observed in two spectra.  
Ringing is a known artifact that has been reported previously in the 
literature (Miladinović et al., 2012). Fuzzy sites and partial ringing were also 
identified as likely artifacts. Manual inspection of a selection of fuzzy sites and 
partial ringing regions consistently failed to identify peak patterns that are 
explainable by chemical phenomena (e.g. isotopologues, different charges, etc.). 
Additionally, these regions display poor peak correspondence at the scan-level, 
which also argues against a chemical contaminant explanation of these regions. 
Furthermore, the location of these artifacts was observed to differ between 
analytical samples derived from the same biological sample and were observed 
in blanks and samples with poor injections, which contain little analyte and 
solvent intensity respectively.  
2.3.2 General HPD Detection Across FT-MS Instruments 
Using the HPD artifact detector, we generated plots of peak density for a 
variety of example spectra across various FT-MS instruments (Figure 2.3). The 
trends in peak density vary between instruments, samples, and across m/z. In 
general, peak density decreases with increasing m/z and a monotonic trend was 
observed for all instruments (Figure 2.3A-D). This observation is partially 
explained by differences in signal-to-noise and decreasing digitization with 
increasing m/z due to the nonlinear relationship between the observed frequency 
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and m/z. From these plots, there exists no good cutoff based on raw peak 
density to identify HPD sites. In contrast, our statistical approach (i.e. peak 
density statistic) compensates for systematic changes in peak density, revealing 
regions of significantly higher peak densities with respect to average peak 
density of neighboring regions (Figure 2.3E-H). 
 
Figure 2.3: Peak Density and Peak Density Statistics. 
Peak density metric and statistic plots produced by our HPD-detector tool 
highlight the impact of the instrument on peak density and HPD artifact location. 
All instruments have higher peak densities at lower m/z, representing trends in 
signal-to-noise and digitization with respect to m/z in FT-MS. The sharp spikes in 
peak density correspond to HPD artifacts. The locations of these spikes on 
Fusion 1 are different before and after the firmware update (A, B), suggesting 
instrument-level data processing is related to HPD generation. E-H show the 
effectiveness of our peak density statistic metric for flattening the non-constant 
baseline observed in plots of the raw peak density. Without this correction, 
identifying HPD regions reliably is difficult. A, B, C, E, F, G were generated from 
spectra acquired using sample C. D and H were generated from spectra 
acquired using sample E (Appendix 1). 
 
 Although fluctuations in peak densities are expected due to differences in 
the distribution of compounds in m/z space, this fails to explain the large spot 
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increases (spikes) in the peak density statistic present in the spectra. These 
spikes in peak density represent HPD artifacts and thus by identifying these 
spikes, potential HPD artifacts can be detected. Additionally, these results 
demonstrate that the artifact locations differ before and after a firmware update 
on the same Fusion 1 machine (Figures 2.3A, 2.3B, 2.3E, 2.3F) and differ 
significantly between instruments. Together, these findings support an artifactual 
basis for these HPD regions of spectra and suggest an instrument-level source.  
2.3.3 Detection and Characterization of Fuzzy Sites 
At the aggregate spectrum (sum of scans) level (Figure 2.1A, 2.5A, 2.5C), 
fuzzy sites have HPD characteristics and a Gaussian-like distribution of peak 
intensities between the noise baseline and presumed signal peaks. The 
intermediate intensities of these peaks make identifying and filtering these 
regions by intensity alone difficult. Fuzzy sites, like other HPD artifacts, have 
peak m/z differences that are not explainable by isotopologue, charge, or 
harmonic patterns. Fuzzy sites vary in size from 0.5 m/z to up to 3 m/z, with 
larger fuzzy sites found at higher m/z. Typically, a spectrum with fuzzy sites 
contains multiple fuzzy sites. Collectively, these sites can represent a significant 
portion of the total peaks over a much smaller portion of the total m/z range. 
Fuzzy site location varies between analytical replicates on the same instrument 
and with sample composition (Figure 2.4). Fuzzy sites have been observed in 




Figure 2.4: Fuzzy Site Location varies with Sample Composition  
A small change in chemical composition (Sample A with and without lipid 
standards) changes fuzzy site location. With only solvent, there is a fuzzy site at 
354.8 m/z. With lipid standards, this fuzzy site shifts to 352.1 m/z. The number of 
fuzzy sites will remain constant, but will all be shifted by roughly the same m/z. R 
is the resolution setting used for the acquisition, µS is the microscan setting, and 




Fuzzy sites also have interesting properties at the scan-level. While the 
timing between scans and injection as well as inconsistencies between injections 
can result in non-perfect scan-to-scan correspondence between peaks (e.g. a 
peak is present in scan X, but not in scan Y), peaks of the same chemical origin 
should appear consistently between scans near their true m/z, roughly within the 
resolution of the instrument. However, at the scan level, the peaks in a mass 
range identified as a fuzzy site at the aggregate level have very low peak 
correspondence (Figure 2.5B). In any given scan, only sections of the fuzzy site 
region will have peaks and those sections that are populated with peaks change 
from scan to scan. However, as increasingly more scans are added together, the 
Gaussian-like distribution of a fuzzy site at the aggregate level becomes clearer 
(Figure 2.5A, 2.5C).  Furthermore, resolution does not change the presence of 
fuzzy sites (Figure 2.6). Fuzzy sites appear distinct from either peak ringing or 
partial peak ringing and represent a novel class of artifact not previously 
described in the FT-MS literature.







Figure 2.5: Fuzzy sites at the Aggregate and Scan Level  
A typical fuzzy site (A) occupies 0.5 to 3 m/z at the aggregate level and has a distinct ‘fuzzy’ appearance due to 
very high peak density (this image is identical to 2A). At the scan level, only a subdomain of the m/z occupied by 
the fuzzy site contains peaks; the subdomain with peaks varies from scan-to-scan (B). As increasingly more 
scans are aggregated together, the peak distribution converges to the pattern observed at the aggregate level 
(C). All panels were generated using Sample A. R is the resolution setting used for the acquisition, µS is the 
microscan setting, and N is the number of scans aggregated to create the spectrum.







Figure 2.6: Effect of Resolution and Microscan on Fuzzy Site Appearance  
Permuting over multiple resolution and µS settings shows that no combination of tested settings eliminated fuzzy 
sites, but these settings do change their appearance (A-I). Number of scans collected were set so that total 
acquisition time was constant (7 minutes). Higher µS increases intensity variance with minimal impact on peak 
density. Increasing resolution increases peak density but has a lesser impact on peak intensity variance. All panels 
were generated using Sample A on Fusion 1. R is the resolution setting used for the acquisition, µS is the 
microscan setting, and N is the number of scans aggregated to create the spectrum. 
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 Fuzzy sites were first observed on Fusion 1. After developing our methods 
using Fusion 1 spectra, spectra from other instruments were examined for fuzzy 
sites to determine if these artifacts were limited to only one instrument. To date, 
we have observed fuzzy sites in spectra from every non-Lumos Tribrid Fusion 
instrument examined.  However, we did not find fuzzy sites in spectra from other 
types of FT-MS instruments (Lumos, Q Exactive+, SolariX).   
 Using our largest dataset (sample D), we were able to evaluate the 
robustness of our tool with respect to identifying fuzzy sites in spectra from our 
Fusion 1 and Fusion 2 instruments. For every region reported by our fuzzy site 
detector tool, we manually inspected 50 spectra to verify if a fuzzy site was 
present or not. Additionally, the entire spectrum was completely inspected 
manually for additional fuzzy sites that were not detected by our tool. We also 
checked if fuzzy sites were observed for the common fuzzy site locations 
identified in Fusion 1 (187 m/z, 351 m/z, 468 m/z, 654 m/z, 976 m/z and 1590 
m/z) and Fusion 2 (1064 m/z and 1275 m/z). When an HPD site was predicted 
but not obvious upon visual inspection, this was counted as a false positive (FP). 
When an HPD site was not detected in one of the common fuzzy site locations 
when one was obvious visually, this was counted as a false negative (FN). When 
an HPD site was predicted in one of the common fuzzy site locations and a fuzzy 
site was observed, this was counted as a true positive (TP). When an HPD site 
was not detected in one of the common fuzzy site locations when one was not 
present, this was counted as a true negative (TN). The detailed results of this 
analysis are shown in Supplemental Tables 2.1 and 2.2 and across Fusion 1 and 
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Fusion 2 a sensitivity (#TP / (#TP + #FN)) of 92.1% and a specificity (#TN / 
(#TN+#FP)) of 33.5% was achieved. This implies that our algorithm tends to 
overpredict HPD artifacts. However, no HPD sites were consistently missed in all 
spectra, therefore identifying and removing consistent HPD sites across all 
samples will side-step the low specificity of our algorithm. 
2.3.4 Fuzzy Site Locations are Biological Unit Specific, Class Specific and 
Instrument Specific 
As shown in Figure 2.4, fuzzy site location varies between spectra and 
appears to shift significantly (a shift far greater than the resolution of the 
instrument) with changes in sample composition. The dependency of fuzzy site 
location on sample composition is a potential problem for real metabolomics 
applications of FT-MS, if fuzzy site features are not eliminated from downstream 
analyses. To demonstrate this, we compared FT-MS spectra of the lipid samples 
extracted from paired cancer and non-cancer lung tissue slices (sample D). Due 
to the differences in the concentrations of various metabolites between cancer 
and non-cancer tissues, we would anticipate that features assigned to the 
spectra of different sample classes (i.e. cancer and non-cancer) could be used to 
distinguish these sample classes. However, if fuzzy sites vary with sample class 
as well, artifactual features will also distinguish sample class without directly 
reflecting the underlying biochemical differences between these classes. These 
samples were ran in a mostly random order with respect to sample class, 
eliminating the possibility that the artifact patterns are the result of temporal batch 




Figure 2.7: HPD Regions Depend on Biological Unit, Sample Class, and 
Instrument 
Using the fuzzy site detector, HPD regions were identified in every spectrum 
from sample set D. (A) The plot shows that many fuzzy sites are consistent 
across paired cancer (red) and non-cancer (green) spectra from the same 
patient. (B) A shifting based on sample class (green versus red) is observed for 
some consistent fuzzy sites (specific example regions are shown in Figure 2.8). 
When shifts do occur such as shown in Figure 2.8 between sample classes, the 
absolute difference between fuzzy sites in m/z is too small to be obvious on this 
plot. (C) Different consistent fuzzy sites are observed for each instrument, 
Fusion 1 (black) and Fusion 2 (blue). HPD sites differ dramatically between 
instruments. Across all three plots, the scattering of inconsistent fuzzy sites 
observed largely at m/z > 1000 represent false positive regions. Spectrum 





Figure 2.8: Example Fuzzy Site Locations that Vary with Sample Class 
The location of fuzzy sites in spectra from the same biological unit can differ 
significantly based on sample class (cancer versus non-cancer). A and B 
illustrates one fuzzy site whose location varies by rough 2 m/z between sample 
class.  C and D shows a single fuzzy site whose location varies by over 70 m/z 
between sample class.  
 
 Figure 2.5 shows the location of the detected HPD regions for every 
spectrum in sample set D, illustrating a clear relationship between consistent 
HPD site location and sample origin (biological unit, i.e. patient, Fig 2.7A), 
sample class (Fig 2.7B) and instrument (Fig 2.7C). HPD regions with less 
consistency are spurious false positives.  Figure 2.8 shows clear shifts in fuzzy 
site locations within cancer and non-cancer spectra derived from the same 




This creates a potential confounding factor or batch effect in all 
downstream statistical analyses if spurious changes in sample conditions 
introduce new sample-specific artifacts. For example, machine learning methods 
such as Random Forest (Breiman, 2001) can use samples of known class to 
build classifiers that classify samples of unknown class based on spectral 
features identified in the training set of samples (more about how the Random 
Forest algorithm builds these classifiers is included in Chapter 4). However, 
these techniques rely upon an important assumption that detectable artifacts are 
not confounded with sample class. The large number of sample-specific 
artifactual peaks produced by fuzzy sites can hijack the classifier training, 
anchoring the classification to artifacts that may change due to unforeseen 
sample conditions in unknown samples or unforeseen changes in the analytical 
instrument.  
These hypothetical problems arising from artifact batch effects are clearly 
demonstrated in Table 2.1 and in Supplemental Tables 2.4, 2.5 and 2.6. Twenty 
random forests were trained on LipidSearch assignment features derived from 
spectra covering a mass range of 150 – 1600 m/z acquired from non-polar 
extracts of paired cancer and non-cancer lung tissue samples (sample D). We 
used only spectra from Fusion 1 to eliminate the instrument as a potential bias 
and we dropped features present in less than 25% of either the cancer or non-
cancer classes. Each classifier was built using the R randomForest package 
(version 4.6-14) from CRAN.  Default package options were used except with the 
number of trees set at 1000. The top features based on mean importance of 
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each feature across the 20 random forests are reported. High mean importance 
means that the classifiers heavily used this feature when predicting if a sample is 
a cancer or non-cancer sample. Consistent HPD regions are identified first by 
determining the m/z range that contain an HPD site in at least 10% of the 
samples. Features with an m/z in one of the consistent HPD regions are 
considered HPD-tainted features and are presumed artifacts. If artifact location is 
not confounded with sample class, then artifactual features should not be present 
in the importance lists for the classifiers.  
 Without HPD feature removal, 7 out of the top 30 features are HPD 
features (Table 2.1 – No Artifact Removal). Removing features observed only in 
a sample’s HPD regions results in a reduction but not complete abolition of HPD-
features in the models (Table 2.1 – Per-Spectrum Artifact Removal), since this 
removal indirectly encodes sample class via the inflation of the importance of 
features in m/z regions that overlapped with HPD sites in the other class.  Only 
when the consistent HPD regions are removed from every sample does no HPD 
feature makes it into the top 30 mean importance list (Table 2.1 – Consistent 
Artifact Removal), either directly or indirectly. With sample specific and no artifact 
removal, classification errors of 13.5% and 3.8% are achieved for cancer and 
non-cancer respectively and consistent HPD removal achieved 11.5% and 3.8%, 
representing a minor improvement in this example. The ability to retain 
classification accuracy with artifact removal implies that we are not significantly 
removing any important information through our artifact removal process, while 
increasing the likelihood that the classification is based on true biological 
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variance. The similarity between the important non-HPD features for all three 
removal methods supports this hypothesis. The mean importance lists for each 
type of artifact removal are shown in Supplemental Tables 2.4 (no artifact 
removal), 2.5 (per-spectrum artifact removal) and 2.6 (consistent artifact 
removal).  
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Table 2.1: Effects of HPD-Artifact Removal - The number of artifactual features 
used by the models and the classification results are summarized for models 
trained using various types of artifact removal. Correct assignments are 
highlighted in the green columns, incorrect in red columns. Without artifact 
removal 7 out of the top 30 features (by importance) used by the models are 
artifactual. This implies that the models are using artifactual features to 
distinguish cancer and non-cancer. With per-spectrum artifact removal, 3 out of 
the top 30 features are artifactual and have relatively low rank in the importance 
list compared to artifactual features without artifact removal (Supplemental 
Tables 2.4 and 2.5). However, no improvement in assignment accuracy is 
achieved for either cancer or non-cancer samples. With consistent artifact 
removal, there are no HPD features in the top 30 features (Supplemental Table 
2.6) and a slight improvement in accuracy is achieved (one additional cancer 




2.3.5 Peak Characterization Significantly Improves Relative Peak Intensities 
 
Figure 2.9: The effects of normalization on noise and peak intensity 
Without normalization, the estimated noise level across all scans in a spectrum 
spans nearly two orders of magnitude (Figure 2.9A). This massive variance 
across scans in the noise ratio results in an intensity RSD for noise peaks of 
more than 1.0 (Figure 2.9B). The observed RSDs for all peaks prior to 
normalization is less than the RSD observed for only noise but still unacceptably 
high. After normalization, the range of observed noise values spans less than 1 
order of magnitude and the intensity RSDs for most peaks is greatly reduced 
(blue trace in Figure 2.9B) and effectively no peaks have an intensity RSD 
greater than 1. Algorithm, data, and figure generated by Dr. Robert Flight (Flight 
and Moseley, 2018). 
 
 The effects of scan-level variance in peak intensities is shown in Figure 
2.9 and both noise and non-noise peaks have their intensities significantly 
affected. Without normalization, the estimated noise level spans nearly two 
orders of magnitude and both noise and non-noise peaks have intensity RSDs 
near 1.0, implying that the standard deviation of peak intensities for each 
correspondent peak is on the same scale as their observed intensities. After 
normalization, the observed RSDs for both noise and non-noise peaks are 
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greatly reduced, as is the range of noise cutoffs observed across the scans. Both 
findings imply that our peak characterization and normalization methods correct 
some sources of scan-to-scan variance in peak intensities and thus making each 
scan more comparable to each other scan. Finally, it was also observed that the 
most intense scans tend to have the highest noise levels.   
2.4 Discussion 
2.4.1 Origin of FT-MS Artifacts 
The scan and aggregate level properties of HPD sites strongly support an 
artifactual origin for HPD features; however, their exact origin has not been 
confirmed.  
 The detectors used in FT-MS instruments are highly sensitive, which 
introduces the possibility that radio frequency interference (RFI) can result in 
signals that are misinterpreted by the instrument to produce artifactual peaks in a 
spectrum.  However, the correlation between fuzzy site location and sample 
class is surprising. The change in fuzzy site location after a firmware update and 
the presence of fuzzy sites in every Fusion instrument we have tested could 
indicate an internal source of the RFI. An internal source could produce class-
specific fuzzy sites if the state of the components producing the RFI changes in 
some manner with sample composition. However, a more likely hypothesis is that 
the source of the RFI is the nanoelectrospray system (or other external device 
that is part of the deployed FT-MS system). The nanoelectrospray system is in 
direct contact with the sample and operates at high voltage as part of its normal 
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operation. Any interaction between the voltage of the electrospray system, the 
pulses used to ionize the sample and the sample itself could result in the 
generation of RFI signals that result in sample-specific fuzzy sites.  
Unfortunately, robustly investigating these hypotheses is difficult and ultimately 
not relevant to fixing these artifacts in already acquired data. Discussions with 
Thermo staff support an RFI origin for fuzzy sites, although the source of the 
interference remains unclear.  
 The origin of partial ringing is even less clear. Since partial ringing does 
not occur in most spectra and across multiple instruments, if it is an RFI-based 
phenomenon, the source of that RFI is likely transient and external. Due to its 
rarity and with no obvious relationship to sample class, partial ringing is less of a 
burden to data analysis. Likewise, rarity of ringing largely mitigates its harmful 
effect on data analysis. ThermoFisher Scientific had no explanation for the partial 
ringing artifacts, but did confirm that ringing was due to insufficient digitization of 
the FIDs due to a combination of hardware and software limitations regarding 32-
bit versus 64-bit encoding that results in a truncation of the FID. (personal 
communication with Mike Senko, ThermoFisher Scientific).  
 Eliminating the source of these artifacts, particularly fuzzy sites, is 
challenging. First, the radio environment that an instrument observes constantly 
changes and is often beyond the control of the instrument’s operator. Second, 
these artifacts may not be recognized until after spectral acquisition and the 
original samples are no longer available due to either consumption or 
degradation. In this case, the only option is to clean up the acquired data before 
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downstream analyses. Third, access to the raw FID data is not always available 
for a given instrument. In this case, the only option is to remove the artifact peaks 
in the m/z domain.  
 LC-MS and other approaches for gathering orthogonal information about 
features observed in MS offer an approach to mitigate the effects of these 
artifacts, but are obviously not applicable to direct injection FT-MS experiments. 
Retention times combined with m/z can often unambiguously identify metabolites 
where m/z cannot and artifactual features that are ambiguous by m/z alone will 
lack supporting chromatographic information. As a result, LC-MS is less 
vulnerable to the artifacts, but is not always suitable for the same set of 
experiments that direct injection FT-MS can be applied to. 
2.4.2 Mitigating the Effects of Fuzzy Sites on Downstream Data Analyses 
As shown in Table 2.1, HPD artifacts, namely fuzzy sites, impact data 
analysis. The resulting classifiers can effectively predict sample class; however, 
these classifiers make extensive use of peaks present in fuzzy sites and thus 
have no direct molecular interpretation. Although LipidSearch can use orthogonal 
information (chromatographic retention time, MS2), which presumably could 
prevent assignment to artifactual peaks, this information is only available for a 
small fraction of peaks (typically less than 10%) in the direct-infusion FT-MS 
spectra collected.  
 Building robust classifiers based on true biological variance therefore 
requires eliminating fuzzy site assignments from the feature list prior to classifier 
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training to mitigate any fuzzy site / sample class confounds. Removing consistent 
HPD regions from all spectra safely removes artifactual features efficiently and 
consistently. Additionally, a check on the consistency of the HPD sites minimizes 
the impact of false positives returned by our tool and effectively increases the 
sensitivity of our method. Since we could not find a fuzzy site that was 
consistently missed by our detector, the bagging process of random forest makes 
the method very robust against artifacts that do not show a clear batch effect.  
 In this example, models capable of disambiguating cancer and non-cancer 
samples were achieved (Table 2.1) regardless of HPD artifact removal. While 
this might seem to imply that artifact removal is not necessary, this interpretation 
is not the case. The presence of artifactual features in the importance lists for the 
classifiers without consistent HPD site removal implies that these models are 
using artifactual information to determine cancer or non-cancer status. Since 
these artifacts are known to vary between instruments (Figure 2.7C) and in some 
cases between sample class (Figure 2.8), a change in sample preparation or in 
which instrument is used to acquire a spectrum will limit the effectiveness of 
these artifact-informed models. Furthermore, these results highlight that when 
artifacts and other systematic errors are present, classification accuracy is not 
necessarily a complete indication of classifier quality or robustness. In this 
particular dataset, the artifactual features do not rise to the very top of the 
importance lists for any of the models, but in other datasets we have 
investigated, highly important features have been artifacts.  
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Although the removal of consistent fuzzy site regions is efficient, safe and 
consistent, it does have shortcomings. First, it will remove larger amounts of 
spectrum as the number of samples and classes increases. Second, when fuzzy 
site location consistently overlaps with non-artifactual peaks, these peaks will be 
discarded even if they are not artifactual. Without a per-peak metric for 
determining if a peak is a likely artifact or not, this is an unavoidable but 
undesired side effect. Third, not all consistent HPD regions are fuzzy sites. We 
have observed consistent HPD regions that do not contain obvious fuzzy sites, at 
least not in the spectra we manually inspected. These regions do contain high 
numbers of peaks that are too consistent across spectra, have too many peaks 
to be random noise, and have poor scan-to-scan consistency.  Examples of 
these regions are illustrated in Figure 2.10.  We hypothesize that these sites do 
contain an HPD artifact of some sort, but thresholding at the instrument level has 




Figure 2.10: Example False Positive HPD Sites  
Not all HPD positive regions contain fuzzy sites; however, the false positive sites 
do contain abnormal regions of peak density. At the aggregate level, there is no 
clear fuzzy site, partial ringing, or ringing in these examples. However, a scan-
level analysis shows a characteristic pattern of poor scan-to-scan 
correspondence for many of the peaks similar to the peaks found in HPD 
artifacts. For example, Panel A has a scattering of side peaks resembling filtered 
partial ringing. Panel B appears to be a thresholded fuzzy site with some non-
artifactual peaks as well. Panel C has a few low intensity peaks, but the central 





2.4.3 Peak Characterization Generates High Quality Peak Lists 
Dr. Robert Flight’s scan-level peak characterization algorithm addresses 
both the high peak intensity variance observed between scans and results in 
better described peaks than other peak picking software (Flight and Moseley, 
2018).  
First, normalizing each scan prior to aggregation to yield the final 
spectrum provides a substantial improvement in peak height RSD and reduces 
the ranges of observed noise levels between scans. Without scan normalization, 
peak height RSDs can exceed 1.0 implying that the standard deviation in 
observed peak heights across all scans is equal to or greater than the mean 
peak height. Without reducing this RSD, meaningful statistical comparisons of 
relative peak height between isotopologues of the same compound (which could 
be used to confirm metabolite assignments) would be effectively impossible. 
 Second, by making full use of scan-level information peak, 
correspondence can produce more informative descriptions of peaks at the 
aggregate level. For example, this method returns the measured standard 
deviation and relative standard deviations of peak intensities and m/z's across 
scans. Furthermore, this method identifies which scans contain a given peak 
from the aggregate spectrum. These improved descriptions of peaks will enable 
more sophisticated and informative downstream analyses. Having access to 
more complete statistical descriptions of these parameters will enable more 
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sophisticated and informative downstream analyses including more statistically 
robust metabolite assignment.  
2.5 Conclusions 
With our HPD site detection methods and manual investigation of many 
spectra, we have identified and characterized three distinct types of artifacts that 
produce large numbers of peaks (up to 1/3 of the peaks in a spectrum): fuzzy 
sites, ringing and partial ringing.  
Although peaks resulting from any of these artifacts could have negative 
implications for experimental interpretation, our study focused primarily on fuzzy 
sites and their detection, because they were novel artifacts that were prevalent in 
our datasets and are particularly problematic for classification studies. Fuzzy 
sites are likely the result of radio frequency interference and their location 
correlates with sample class, increasing the probability of class-specific 
misassignment and the introduction of sample-specific artifactual features. 
Ultimately, the presence of these artifacts produces brittle classifiers and 
complicates the characterization of true biological variance between sample 
classes using direct-injection FT-MS. The results presented in this study highlight 
how peaks resulting from artifacts can be misassigned by tools such as 
LipidSearch and how these misassignments can impact downstream analyses. 
The methods and tools presented in this study detect and remove fuzzy sites in a 
non-encoding manner from direct-injection FT-MS spectra (i.e. without encoding 
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sample class as absence of peaks), while providing sufficient protection from 
fuzzy site artifacts with existing assignment methods.  
 In addition to the artifact detection and removal tools, a peak 
characterization method was developed that can significantly improve peak 
intensity RSDs and produce more informative peaklists than other methods 
without human intervention. These more informative peaklists describe each 
peak parameter statistically and can be generated very efficiently, making our 
approach compatible with large high-throughput metabolomics experiments. 
Combined with our artifact detection and removal tools, the ability to provide 
accurate statistical descriptions of detected peaks and to correct for scan-to-scan 
variances will provide the high quality peaklists necessary for more complicated 





CHAPTER 3. SMALL MOLECULE ISOTOPE RESOLVED FORMULA ENUMERATOR 
(SMIRFE) – A TOOL FOR UNTARGETED MOLECULAR FORMULA ASSIGNMENT 
3.1 Introduction 
Advances in Fourier-transform mass spectrometry (FT-MS) provide 
substantial simultaneous improvements in mass accuracy, mass resolution, and 
sensitivity (Eliuk and Makarov, 2015). Theoretically, these combined capabilities 
provide several analytical and interpretive improvements including the ability to 
resolve distinct isotopologues of metabolites and perform multi-isotope natural 
abundance correction (Carreer et al., 2013) (Moseley, 2010), improved 
assignment accuracy (Kind and Fiehn, 2006), and the detection of low 
concentration metabolites (Eyles and Kaltashov, 2004). For the metabolomics 
field, these improvements permit the use of multi-isotope labeled precursors in 
multiple stable isotope resolved metabolomics (mSIRM) experiments (Yang et 
al., 2017b). These experiments provide richer information that be used to 
elucidate unknown metabolic pathways (Creek et al., 2012) (Higashi et al., 2014), 
quantify relative metabolic fluxes through connected pathways (Hiller et al., 
2010), identify multiple pools of metabolites in different compartments (Fan et al., 
2012), and identify the active metabolic pathways under various cellular 
conditions such as cancer versus non-cancer (Sellers et al., 2015b).  
 However, these more informative experiments require that the spectral 
features representing isotopologues of metabolites observed in these 
experiments are accurately assigned. As discussed in the background, the 
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assignment of FT-MS spectra remains an unsolved problem in metabolomics 
(Wishart, 2011). Existing spectral assignment tools are largely targeted and rely 
upon databases of known metabolites as sources of possible assignments. 
Although orthogonal information from tandem-MS or chromatography can be 
used to aid in assignment, many of these targeted tools use simple m/z-based 
queries against metabolite databases to generate assignments. Assignments 
generated from m/z queries alone are poorly cross-validated even with high 
mass resolution (Kind and Fiehn, 2006) and acquiring orthogonal information in 
direct infusion experiments is challenging. Furthermore, existing metabolite 
databases are incomplete (Mitchell et al., 2014), which limits the assignment of 
unknown metabolites and biases assignments towards the set of metabolites 
represented in a given database (Moseley, 2013). 
 An alternative approach is untargeted assignment, where assignments are 
generated without databases of known metabolites. This would enable the 
assignment of unknown metabolites and reduce assignment bias; however, 
enumerating all possible assignments for an observed spectral feature is an 
immense computational challenge. This limitation is especially pronounced in 
SIRM experiments where the enrichment of labeled isotopes makes otherwise 
low abundant isotopologues detectable. Furthermore, untargeted assignments 
must still be cross-validated in some manner to reduce the set of possible 
assignments for a spectral feature to a likely set of possible assignments. One 
approach for this is to compare the intensities of observed spectral features to 
one another to identify likely isotopologues of the same metabolite. However, the 
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data quality problems discussed in Chapter 2 result in artifactual peaks that when 
confused for isotopologue peaks can complicate this process and the high 
variances in observed peak intensities makes robust intensity comparisons 
difficult.  
 Using Dr. Flight’s improved peak characterization methods from Chapter 
2, these data quality problems in FT-MS metabolomics data sets have been 
addressed (Flight and Moseley, 2018). The improved peaklists generated by 
these methods combined with the combinatorial mathematics underlying natural 
abundance probabilities (NAPs) used for natural abundance correction in SIRM 
experiments provides an avenue for developing an untargeted assignment 
method that can use sets of isotopologues within an MS1 as cross-validating 
information. We have developed a method based on this principle called Small 
Molecule Isotope Resolved Formula Enumerator (SMIRFE) that integrates this 
methodology to provide cross-validated and statistically evaluated elemental 
molecular formula (EMF) and isotopologue-resolved molecular formula (IMF) 
assignments for FT-MS spectra without additional orthogonal information nor 
databases of known metabolites.   
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3.2 Materials and Methods 
3.2.1 SMIRFE Algorithm Overview 
 
Figure 3.1: Flowchart of the SMIRFE Algorithm 
SMIRFE can be divided into two main components. The first is the combined 
generation of an EMF search space and an isotope component lookup table. 
The second is a peaklist assignment algorithm. The component lookup table 
stores the NAPs and masses of all isotope combinations for each element to be 
used during assignment and IMF enumeration. The high abundance IMF 
database represents all likely IMFs in the EMF search space. Peaklist 
assignment uses this database of IMFs to generate possible EMFs present in 
the spectrum which are then used to inform a targeted IMF search for each EMF. 
The untargeted component of the search is highlighted in green and the targeted 




The number of elemental molecular formulas (EMFs) and corresponding 
isotope-resolved molecular formulas (IMFs) for an EMF search space is 
prohibitively large to recalculate for every spectrum to be assigned. For CHONPS 
(carbon, hydrogen, oxygen, nitrogen, phosphorus and sulfur) stable isotopes 
alone, very large IMF search spaces greater than 1029 are typical for molecules 
of 1400 Daltons or less. Instead, SMIRFE first generates a representation of 
EMFs in the search space given a set of possible labeled isotopes and a user-
provided description of the search space. The resulting EMF search space, 
which can still be quite large, is specific for that search space and labeled 
isotopes but can be reused between similar experiments. With this EMF search 
space, untargeted EMF assignment followed by targeted IMF assignment on an 
input peaklist can be performed efficiently. The organization of these steps is 
represented in Fig 3.1 and will be discussed in more detail. 
3.2.2 SMIRFE Nomenclature 
 The output from SMIRFE is a mapping of peaks in a spectrum to distinct 
IMFs and a measurement of the statistical reliability of that assignment. 
Throughout SMIRFE, it is necessary to keep track of which groups of IMFs 
belong to which EMFs. On the surface, this seems straightforward as each IMF 
belongs to exactly one EMF, but this becomes more complicated when multiply 
labeled forms of multiply adducted forms of EMFs are present. To organize IMFs 
during SMIRFE analysis, IMFs are grouped into EMF supercliques, EMF cliques 
and EMF subcliques as shown in Figure 3.2. An EMF superclique is defined as 
all IMFs that have the same EMF. For example, the EMF superclique for C6H12O6 
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contains all IMFs sharing the EMF C6H12O6.  An EMF clique is defined as all IMFs 
that have the same EMF and the same adduct. EMF cliques subdivide an EMF 
superclique. For example, all IMFs of C6H12O6 that are adducted with sodium 
belong to the [Na+]-C6H12O6 EMF clique. An EMF subclique is defined as all IMFs 
that have the same EMF, the same adduct, and have the same number of 
labeled isotopes (i.e. are ‘identically-labeled’). EMF subcliques subdivide EMF 
cliques. For example, all IMFs of C6H12O6 that are adducted to sodium and 
contain two 13C due to labeling belong to the 13C2 subclique of the [Na+]-C6H12O6 
EMF clique. 
Because EMF supercliques, EMF cliques and EMF subcliques are defined 
in terms of EMFs, IMFs of isomeric compounds (which by definition have the 
same EMF) are grouped together into EMF supercliques, EMF cliques and EMF 
subcliques. For example, although all IMFs of glucose will belong to the C6H12O6, 
EMF superclique, all IMFs of all isomers of glucose will also belong to the 






Figure 3.2: Organization of EMF Supercliques, Cliques and IMFs 
All IMFs of a given EMF belong to one superclique which is further divided by 
adduct into cliques which are further subdivided into subcliques based on 
labeling. For example, all glucose IMFs belong to the same superclique, but will 
be subdivided into one or more cliques based on which adducts of those IMFs 
are observed (e.g. Na+ IMFs in one clique, H+ adducts in the other). The 
number of subcliques changes based on which isotopes are presumed labeled. 
In the unlabeled case, there is only one subclique for each clique, but when one 
or more isotopes are potentially labeled, the number of subcliques increases 
quickly. If 13C is labelable in C6H12O6, there will be 7 possible subcliques 
representing sets of IMFs with 0 to 6 13Cs from labeling and their isotopologues 
from natural abundance. 
 
SMIRFE uses the natural abundance probability (NAP) and relative 
natural abundance probability (relative or relNAP) of IMFs both for IMF 
generation and for assignment scoring. The NAP of an IMF is the probability of 
observing the set of isotopes present in that IMF by random chance alone 
assuming that all isotopes have a probability of occurring equal to their natural 
abundance, i.e. their expected relative frequency in the biosphere. Labeling 
introduces a non-natural source of specific isotopes and thus relative NAP must 
be used to quantify the probability of observing a labeled IMF when one or more 
isotopes can be labeled. These values are calculated as follows (Moseley, 2010) 
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Where for a given number of nuclei (Emax) for an element E with a set of stable 
isotopes (ki) with known natural abundances (NA), the elemental NAP for a given 
combination of isotopes is calculated with Equation 3.1. The NAP of an IMF 
(Equation 3.2) is the product of each element’s NAP in the IMF. Without labeling, 
this NAP is referred to as the absolute NAP. When labeling is present, labeled 
isotopes must be removed from the calculation of NAP for the element(s) of the 
labeling isotope(s). This effectively changes Emax and the isotope counts for a 
labeled IMF. NAP values for isotope combinations can be calculated and stored 
in a lookup table for later use. Therefore, within SMIRFE, any isotope 
combination has its NAP calculated only one time. Also, while absolute NAP and 
relative NAP are interchangeable without labeling, comparisons between relative 
NAP is always used when comparing IMFs. 
3.2.3 Isotope Component Lookup Table Creation 
Throughout SMIRFE, highly accurate absolute NAPs and masses for the 
set of isotopes for any given element are needed to calculate various NAPs and 
masses of IMFs. Although the total number of isotope combinations for each 
element is large, it is much smaller than the number of possible IMFs and can be 
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calculated once and stored for future use. The first step in both the untargeted 
search space generation and in the actual assignment algorithm is to generate 
this lookup table. The lookup table is sub-divided by element and for each 
element every possible combination of isotopes for that element is stored along 
with the mass of that component, it’s absolute NAP, and the number of atoms it 
contains. The masses in this table are calculated using the mpmath high-
precision math library (Fredrick Johansson, 2018) in Python and the absolute 
NAPs are calculated using the multinomial calculation shown in Equation 3.1. 
The number of components stored in this table grows exponentially as the search 
size increases, but the table is only megabytes in size and can be stored in 
JavaScript Object Notation (JSON) format.  
3.2.4 Untargeted EMF Search Space Creation 
SMIRFE requires an internal representation of an EMF search space that 
can be queried to produce probable high NAP IMF assignments for a given peak. 
This search space consists of several components. First is a high level 
description of the search space provided by the end user that specifies the max 
count for each element in the space, the maximum mass to consider 
(max_mass), the minimum NAP (min_NAP) to consider (i.e. IMFs with NAP 
below the min_NAP do not need to be enumerated),  and the set of labeled 
elements in the search space (e.g. C:100, H:230, O:40, max_mass:1600, 
min_NAP:0.4, labeled:[‘C’]). From this description, SMIRFE constructs an N-
dimensional integer lattice where each unique N-tuple of integers represents 
exactly one EMF in the space. For example, (6,12,6) would represent the EMF 
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C6H12O6 in the above search space. The number of tuples in a possible search 
space grows exponentially with increasing dimensionality, but the enumeration of 
integer lattices can be done quickly using existing functions from the Numpy 
Python package (Walt et al., 2011). The set of all unique tuples is equal to the set 
of all possible EMFs in the search space; however, many of these EMFs are not 
consistent with known rules for valid chemical structures. For example (1,100,0) 
corresponds to the EMF C1H100, which very likely does not exist as the number of 
hydrogens exceeds the maximum number of valence electrons from non-
hydrogen atoms in EMF (i.e. 1 carbon contributes 4 valence electrons max which 
is not enough to make covalent bonds to 100 hydrogens). As EMFs are 
generated during lattice enumeration, EMFs that fail to comply with known hard 
rules about valence electrons are removed. Heuristics based on patterns 
observed in the HMDB and KEGG further restrict possible EMFs.   
The second component of the search space representation is the set of 
high abundance IMFs for each possibly valid EMF. The IMF generation 
procedure can be modeled as a depth first search on the complete tree of 
possible isotope components possible with that EMF, with each level in the tree 
representing the components of a given element. Components of labeled 
elements are treated as having a NAP of 1, while components of unlabeled 
elements below the min_NAP are pruned prior to traversal. A depth first search is 
then performed to find all paths through the tree for which the product of the NAP 
of all nodes in the path exceeds the min_NAP and the sum of the mass of the 
nodes in the path is below the max_mass. Every such path represents exactly 
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one IMF for the given EMF, The IMF and its mass is then stored in an SQLite 
(Owens, 2006) database for use in SMIRFE. As NAP can only decrease along a 
path and mass can only increase along the path, traversal can be short-circuited 
whenever a nascent path has a NAP below the min_NAP or mass above the 
max_mass. Once all IMFs have been enumerated for all EMFs, an index is built 
for the IMF database on IMF mass. These two components combined with the 
adduct description provided to the assignment algorithm completes the internal 
representation of the search space needed for SMIRFE.  
3.2.5 Preliminary EMF Search 
Searching all peaks in a spectrum against all possible IMFs for any 
sufficiently large search space quickly becomes computationally intractable. For 
example, C6H12O6 has 1,119,744 possible isotopologues; however, without 
extensive labeling, most of these isotopologues are too low in abundance to be 
detected based on natural abundance probabilities. Searching for all these 
isotopologues would not only be wasteful, but would also generate many false 
assignments. This search can be constrained by observing that for a given 
labeled version of an EMF, there is only one most-abundant IMF that must be 
present if that labeled EMF exists in the sample. For example, without labeling, 
the monoisotopic version of C6H12O6 is the most abundant IMF of glucose and 
must be observed if unlabeled glucose is present in the sample. If only m+13C1 
glucose was observed and no 13C labeling source is present, it can be inferred 
that this assignment is spurious and should be ignored. However, if a 13C labeling 
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source is present, detection of the m+13C1 glucose isotopologue is possible 
without observing the monoisotopic version.  
By searching each peak in a spectrum against the untargeted EMF search 
space generated previously and testing if each returned IMF is a most abundant 
IMF of a possible labeled EMF based on the user-provided labeling pattern, a set 
of possible EMFs in the spectrum can be generated. The set of possible adducts 
is user specified (e.g. Na+, H+, K+, NH4+), and, for every peak, the database 
query is performed for each adduct as the adduct’s mass must be accounted for 
during searching. This set of possible EMFs informs the more targeted IMF 
search in the next step of SMIRFE assignment. To further eliminate spurious 
assignments, only peaks present in most scans (>90%) are used for building this 
possible EMF set. This effectively eliminates the possibility that noise is included 
in this search and restricts the search to peaks corresponding to high-abundance 
IMFs. IMFs that do not correspond to the most abundant are stored as a source 
of random assignments needed for statistical testing (i.e. even false positives are 
useful in the right statistical situation). Limiting this search to only peaks that are 
present in 90% of scans has the potential to reduce sensitivity; however, peaks 
that are present in fewer than 90% scans are still assignable to IMFs of these 
possible EMFs in the next step of the algorithm.   
3.2.6 Targeted IMF Searching 
With possible EMFs identified, the next step is a more targeted search for 
the IMFs of those EMFs. This is done at the subclique level and for every 
possible subclique for every clique for that EMF, the possible IMFs are 
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enumerated in order of descending relative NAP (to a minimum relative NAP). 
For each IMF, peaks with matching m/z are tentatively assigned to that IMF. If 
there are multiple possible matching peaks (very rare), the peak with the closest 
matching mass is assigned.  
Given the limitations of m/z-based matching, IMFs after the first IMF must 
meet additional requirements to be tentatively assigned. First, the nth IMF may 
only be assigned if the scans in which the nth IMF was observed overlap 
significantly (>90%) with the scans in which the n-1th IMF was observed. 
Second, since labeling may only increase the relative abundance of an IMF but 
never decrease it, IMFs should be observed in the order in which they are 
enumerated (i.e. it does not make sense to see an IMF with a lower relative NAP 
but not see an IMF of the same subclique with a higher relative NAP). Third, the 
nth IMF must have at least one intensity ratio with another IMF in the subclique 
with a score greater than the 95th percentile of the random intensity ratio scores 
of the non-matching, non-most abundant IMFs stored from the EMF search step. 
The third rule is omitted in the case where an IMF may be more heavily labeled. 
For example, if 13C is presumed labeled and the m+13C2 subclique of Na-glucose 
is being enumerated, the m+13C3 isotopologue might be observed but does not 
have to have a matching intensity ratio as it could represent either 13C2 from 
labeling and 13C1 from natural abundance (in which case it should have a 
matching intensity ratio) or 13C3 from labeling and no 13C from natural abundance 
(in which case it may not have a matching intensity ratio). If at any point one of 
these rules is broken, further enumeration of the subclique is terminated.  
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Anytime a subclique contains two or more IMFs, it is possible to evaluate 
the likelihood of observing a set of IMFs that match the intensity ratios observed 
for that subclique at random. This is reported as an e-value and is calculated 
using Equation 3.4. 
[𝐸𝑞 3.3A]: 𝐑 = {Log10(IA,j) − Log10(IB,j)|∀ j ∈ scans, IA > 0, IB > 0} 
[𝐸𝑞 3.3B]: Mlog_ratios = median(𝐑) 
[𝐸𝑞 3.3C]: σlog_ratios
2 = variance(𝐑) 
[𝐸𝑞 3.3D]: χA,B =




[𝐸𝑞 3.3E]:  𝑆𝐴,𝐵 = 1 − 𝑐ℎ𝑖2𝑐𝑑𝑓(χ𝐴,𝐵, 𝑑𝑓 = 1) 
Equation 3.3 - The score for a pair of isotopologues A, B (SA,B) in the same 
subclique can be calculated using a chi-squared statistic XA,B. Mlog__ratios is the 
median observed ratio of the log10 intensities of A and B across all scans 
containing both A and B. σlog_ratios 
2 is the variance of the observed scan level 
log10 intensity ratios for A and B. These log ratios of observed peak intensities is 
compared to the log10 ratio of the NAPs of A and B.  
 
[Eq. 3.4 𝐴]: 𝑺 = {
𝑆𝑨, 𝑩
𝜎𝑟𝑎𝑛𝑑𝑜𝑚 𝑝𝑎𝑖𝑟 𝑠𝑐𝑜𝑟𝑒𝑠
2 |∀𝐴, 𝐵 ∈ 𝑰, 𝐴 ≠ 𝐵}  
[𝐸𝑞. 3.4 𝐵]: 𝐸 = 1 − 𝑐ℎ𝑖2𝑐𝑑𝑓(𝑺 ∗ 𝑺𝑇 ,  𝑑𝑓 = |𝑺|) 
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Equation 3.4 - Every subclique containing at least two isotopologues can be 
assigned an E value E, which represents the probability that random pairs of 
isotopologues would have the same distribution of chi squared statistics as the 
observed subclique. This calculation requires constructing the score stat vector S 
for all unique pairs of isotopologues in the subclique (I). The variance for these 
statistics is the variance of the random pairs of isotopologues constructed earlier 
from the invalid isotopologue assignments. A combined chi-squared statistic is 
then calculated for the subclique by multiplying S by its transpose with which the 
E value can be calculated. This formulation enables the future correction of 
potential correlation between isotopologue pair statistic values and does not 
require modification if the underlying isotopologue pair scoring function is 
changed.  
3.2.7 Dataset for Validation 
The method for generating our validation dataset was adapted from 
previously published method for performing ethylchloroformate (ECF) amino acid 
derivatization (Yang et al., 2017b). Two replicate samples were prepared and 
spectra were obtained for both samples using a Tribrid Fusion Orbitrap at 500k 
resolution and from 150 to 1000m/z. Additional details for the preparation of 
these samples is included in Appendix 1 (Sample C). Spectra were characterized 
using the peak characterization methods described in 2.2.2. 
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3.2.8 Manual Inspection of Spectra 
Both reference spectra were examined to verify the presence of peaks 
corresponding to expected derivatives of the amino acids known to be present in 
the sample and the absence of any large spectral defects. Although fuzzy site 
FT-MS artifacts are present in the spectrum (Mitchell et al., 2017), these artifacts 
do not overlap with any of the important non-artifactual peaks. Peaks 
corresponding to derivatives of 19 of 20 amino acids (or 18 of 19 as isoleucine 
and leucine are isomers) were observed. No peaks were observed that would 
correspond to the expected Na+ or H+ adducts of cysteine. The regions of 
spectra where peaks corresponding to these amino acids are expected to occur 
are shown in Figure 3.3.  







Figure 3.3: Regions of Spectra Showing Absence of Cysteine  
The H+ adduct of ECF derivatized cysteine has a theoretical monoisotopic mass of 294.100586, while the Na+ 
adduct has a theoretical monoisotopic mass of 316.082531. Shown in panels A, B are the regions of spectra 
corresponding to the hydrogen-adducted cysteine derivative in the amino acid (AA) samples 1 and 2 respectively. 
Panels C, D show the sodium-adduct region in AA samples 1 and 2 respectively. For the hydrogen adduct, in both 
A and B the peaks at 294.10598 or 294.10595 are intense but are too far from the expected m/z to be reasonably 
assigned to a cysteine derivative. In C and D, the peak at 316.082 has an m/z very close to the expected m/z of the 
sodium adduct but this peak is not very intense. If this peak was the monoisotopic isotopologue of the cysteine 
derivative, the instrument has insufficient dynamic range to observe the less abundant isotopologues 




3.3.1 EMF Search Space Growth 
The number of possible IMFs in a given EMF search space, without 
limitations on NAP, valid EMF, and mass, quickly makes a brute force 
enumeration of all IMFs impossible. For example, the search space C: 100, N: 7, 
O: 40, H: 230, P: 3, S: 3, contains 1.021x1029 possible IMFs! However, since the 
partial EMF search space must only contain highly abundant IMFs for those 
partial EMFs, the number of possibilities can be greatly reduced by enforcing a 
minimum relative NAP for the IMF entries in the database. When labeling is 
considered, the effect of the NAP filter is reduced, but the database remains a 
manageable size and has enough performance to be queried efficiently with 
observed m/z’s from a spectrum. For example, the search space used to assign 
our reference spectra with a min_NAP of 0.4 contains 13,045,817 IMFs with no 
labeling, but increases to 53,102,054 with 15N-labeling. The size of SMIRFE 





Figure 3.4: NAP and Labeling Effects on SMIRFE Search Space Size 
The size of an EMF search space in terms of IMFs grows with increasing mass. 
When min-NAP is low, the number of IMFs grows exponentially (red) and many 
EMFs have many IMFs in the database. When min_NAP is too high, databases 
are smaller but incomplete. Full enumeration of the entire mass range is 
impossible (blue) due to the relative abundance of m and m+13C1 decreasing 
with increasing mass. For our spectra, which have a max m/z of 1000, a 
min_NAP of .4 (green) is sufficient. Database size remains small as less 
probable IMFs are not enumerated but each EMF has its most abundant IMF. 
Labeling can dramatically increase database size (yellow) as the min_NAP 
restriction is lifted on labeled elements. Rules on valid molecular formulas keeps 
database generation tractable but are more permissive than NAP based rules. 
 
3.3.2 Assignments for the ECF Derivatized Spectra 
Using a C:130, N:7, O:40, P:3, S:3, H:230, max_mass: 1600, min_NAP: 
0.4, labeled_isotopes: 15N, the EMF search space was constructed using 
SMIRFE for the ECF derivatized spectra. This database was used to identify 
likely EMFs in the spectrum, which were then followed by a targeted IMF search 
for those EMFs. Na+ and H+ adducts were considered for every peak. From 
previous studies, the expected derivatives of each amino acid with ECF are 
known (Yang et al., 2017b). Of the 20 amino acids present in the solution 
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(representing 19 derivatives with distinct formulas – leucine and isoleucine are 
isomers), the expected derivatives of 18 out of 19 of those formula-distinct amino 
acid species were assigned by SMIRFE. No assignments were made to cysteine 
which was confirmed to be absent in the spectrum and likely was lost during 
sample processing. The 15N-labeled versions of these derivatives were also 
identified as well as multiple adducted versions of both labeled and unlabeled 
versions. The distinct IMFs identified for each amino acid are summarized in 
Supplemental Tables 3.1 and 3.2 
3.3.3 Assignment Ambiguity 
Intensity ratio scoring combined with scan subsetting and a tight m/z 
match tolerance significantly narrows the number of possible assignments for a 
peak. Without these filters, the number of possible assignments for a peak can 
be large even with high mass accuracy (Figure 3.5). At low m/z, when the 
number of possible EMFs and therefore IMFs is relatively small, this can result in 
unique IMF assignments for those peaks; however, at higher m/z when the 
number of possible assignments is very large, unique assignments are rare. 
Multiple assignments can be disambiguated by their e-value in many cases. In 
our test case, every expected EMF has at least one assignment that had the best 
e-value for a peak and many of the observed IMFs for the expected EMFs were 
the best assignment for their peak (82.4% for sample 1 and 82.6% for sample 2).  
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Figure 3.5: Theoretical and Experimental Possible Assignment Ambiguity - By 
scanning the 15N-labeled database described previously for masses between 0 
and 1000 in .1 m/z increments assuming three different levels of accuracy, 1ppm 
(blue), .1ppm (orange) and .01ppm (green), the relationship between the number 
of possible assignments and mass accuracy can be explored. For all levels of 
accuracy, increasing mass increases the number of possible assignments. This 
is obvious for the 1ppm result, but all three levels of accuracy tested have this 
behavior. This behavior is partly due to the presence of more EMFs at higher m/z 
but also because a ppm definition of mass error results in a higher absolute mass 
error for larger masses. A similar behavior was observed in the assignments for 
our experimental spectra where peaks with higher m/z have more possible 
assignments (panel B). The number of possible assignments for a peak in real 
world spectra can be considerably higher than expected from the results in panel 
A where no adduction and a relative NAP filter are applied.  Peaks with zero 
possible assignments either correspond to noise, artifacts, compounds whose 
elemental composition includes elements not included in the search space, or 
compounds with low relative abundances for which only the most abundant 
isotopologue is detectable. 
3.3.4 Assignment m/z Error 
From the set of IMF assignments for expected EMFs in our example 
dataset, the patterns in mass error can be investigated. Both spectra were 
acquired using the same Thermo Tribrid Fusion instrument for which the stated 
mass accuracy is 1 ppm. The observed mass errors fall within this specification 
for 100% of the assigned IMFs for the validated EMFs. For the set of all 
assignments, validated plus unvalidated assignments and including all possible 
assignment for each peak, only 34 of 24215 fall outside the 1 ppm error 
specification. When only the best assignment for each peak is considered (lowest 
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E-value), only 1 of 975 assignments have a ppm error over 1ppm. These results 
are consistent with previous findings that high mass accuracy alone cannot 
provide unambiguous metabolite assignments (Kind and Fiehn, 2006).  
The mass error across m/z is not constant (as might be expected from 
miscalibration) and instead changes with m/z. During manual investigation of 
these spectra, it was observed that peaks near intense peaks in m/z space often 
had a larger mass error than peaks far away from other intense peaks. This 
effect can be attributed to coulombic interactions between ions and can be 
quantified with Equation 3.5: 







The repulsion expression is derived from Coulomb’s law but as the distance 
between ion clouds in the orbitrap is not known, the average distance between 
two clouds can be estimated by the different in their precession frequencies fi 
and fj. In our example, we cannot directly obtain the precession frequencies 
either, but a proxy frequency can be derived from the observed m/z and the 
estimated digital resolution. The force on an ion in cloud i depends also on the 
number of ions in cloud j (assuming they are all charge z=1). Summing this force 
across all other ion clouds for each ion cloud i gives a net repulsion term for each 
cloud. Ions with higher repulsion experience more of a net interaction with other 
ions that can potentially introduce error into their observed m/z’s. These repulsive 
mass errors can exceed 1 ppm in size (Philip Remes et al., 2016). The mass 
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error with respect to m/z and repulsion on the validated IMF assignments are 
shown in Figure 3.6. 
Figure 3.6: Mass Error versus m/z and Repulsion - For the set of IMFs 
corresponding to expected EMFs in our test case, the mass error of those 
assignments can be calculated. The Fusion instrument has a stated 1ppm 
accuracy and most of the observed mass errors fall within this specification. The 
observed mass errors are not constant (and thus not easily correctable) and they 
change with respect to m/z (A – ECF Replicate 1, C – ECF Replicate 2). Mass 
error does correlate with the measured repulsion (see eq. 3.5) for the peak which 
estimates the net columbic forces on the ion cloud corresponding to that IMF (B – 
ECF Replicate 1, D – ECF Replicate 2). Correcting for both an m/z dependent 
and repulsion dependent m/z error without standards in an untargeted context, 
while difficult, could substantially improve the ability to differentiate plausible IMF 




3.4.1 SMIRFE Algorithm 
Although more untargeted than existing assignment methods, SMIRFE is 
not a completely untargeted assignment tool (i.e. can search all possible EMFs 
and all possible IMFs for any number of any elements for all possible labelling 
patterns). Enumerating all possible IMFs even for relatively small search spaces 
quickly becomes intractable both in terms of runtime and storage space. The 
hybrid untargeted / targeted approach employed by SMIRFE leverages the best 
of both methodologies with the main limitation being the need of the end-user to 
specify the EMF search space to search. Given that most biomolecules are 
CHONPS-based, a search space for CHONPS plus expected adducts (in this 
case Na= and H+ adducts) only with element counts large enough to cover 99%+ 
of known biomolecules in the desired mass range will be applicable for most 
experiments. When an additional element is needed, this is usually known ahead 
of time and can be trivially added (i.e. if you are looking for vanadium containing 
metabolites, you know to add vanadium to the search space).  
In these more complicated search spaces, the hybrid untargeted / targeted 
assignment method employed by SMIRFE becomes advantageous. Since the 
untargeted EMF database must only contain the most abundant IMFs for the 
EMFs in the search space, the runtime and storage cost of expanding a search 
space is minimized. Additionally, since these databases are reusable, the cost of 
building a large database is amortized across all experiments that can utilize it. 
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Despite these improvements in performance, large heavily-labeled EMF search 
spaces will take considerable resources to generate and triply- or quadruply-
labeled full-size search spaces are likely impractical to enumerate.  
As mentioned previously, m/z-based matching alone is error prone without 
cross-validating information supporting the assignment of an IMF. SMIRFE 
utilizes the relative intensity ratios observed between pairs of assigned IMF 
peaks and compares these ratios to the ratio of the relative NAP of the assigned 
IMFs as a source of cross-validating information. While absolute peak intensities 
are not necessarily trustworthy in mass spectrometry, the relative peak intensities 
can be made trustworthy through proper preprocessing. Scan subsetting 
effectively enforces that IMFs of the same EMF appear in the same scans. This 
additional rule filters out nonsense groups of peaks that happen to match on 
intensity and mass.  
Unique to SMIRFE is the ability to quantify statistically the fit of the 
generated assignments. This is achieved using the e-value calculation that 
comes from the clique score. Although the ‘correct’ assignment is not always the 
best scoring assignment, the e-value still captures how likely an assignment that 
is compatible with the peaks could have occurred at random. These e-values are 
useful in downstream analyses built upon SMIRFE assignments.  
3.4.2 Implications for Experimental Design 
The ability to assign a FT-MS spectrum depends highly on the quality of 
the spectrum. As SMIRFE assigns FT-MS spectra in a fundamentally different 
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manner than targeted tools, spectra can be collected in a way that optimizes 
them for assignment by SMIRFE. First, additional MS1 scans should be acquired 
whenever possible. Additional MS1 scans improve aggregate peak 
characteristics that in turn enable better intensity ratio comparisons, but also 
improve the likelihood that scan subsetting will eliminate spurious assignments. 
Since SMIRFE cannot currently use MS2 data in any manner to improve 
assignment accuracy, MS2 time can be used for additional MS1 scans. However, 
this recommendation may change, if future versions of SMIRFE are developed 
that use intensity comparisons between observed MS2 peaks to reduce MS1 
EMF assignment ambiguity.  
Second, since SMIRFE attempts to assign sets of IMFs of an EMF, it is 
necessary to have enough dynamic range to observe at least two or more IMFs 
for each EMF. A dynamic range of at least 1000 is sufficient for many examples, 
but higher dynamic range is always advantageous. While not always possible, 
ensuring that one or more peaks do not dominate the spectrum ensures that the 
effective dynamic range of a spectrum is maximized. However, because 
overloading of ion traps and orbitraps can result in space charge effects that limit 
mass accuracy and resolution, effective dynamic range must be balanced 
against effective mass resolution. Alternatively, rather than acquiring a spectrum 
for the entire m/z domain in a single acquisition, multiple overlapping spectra for 
subdomains of m/z can be acquired, assigned and reassembled to yield an 
assigned spectrum for the desired m/z domain. This splitting should provide each 
sub-spectrum with improved effective dynamic range at the cost of increased 
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processing times (Southam et al., 2016). The improved quality of the MS1 data 
provided by this technique could be combined with MS2 to improve assignment 
accuracy without requiring all MS2 time being allocated for additional MS1 scans.  
Additionally, the design of metabolomics experiments should keep in mind 
that, strictly speaking, SMIRFE does not assign metabolites to spectra but rather 
EMFs and IMFs that correspond to metabolites. Simply looking up these 
assigned formulas in a metabolite database can produce metabolite 
“assignments”, but with many of the same caveats of targeted assignment. 
Machine learning and/or experimentally validated rules can enable the mapping 
of assigned formulas to metabolite classes, potentially circumventing this 
limitation in a less targeted manner. Once assigned to classes, differential 
abundances of metabolites classes could be determined using SMIRFE 
assignments. However, existing tools for predicting metabolite classes typically 
require metabolite structure information, which SMIRFE cannot provide.  
3.4.3 Mass Accuracy and SMIRFE 
Despite the use of NAP-based cross-validating information to support 
SMIRFE generated IMF assignments, the m/z of a peak is still important for 
determining which IMFs it could possibly match. For targeted assignment tools, a 
mass accuracy of 1 ppm is typically sufficient to achieve unique assignments 
(although not necessarily correct assignments) up to approximately 800 m/z. Due 
to the large number of possible assignments that SMIRFE considers, a 1 ppm 
accuracy does not always translate into unambiguous assignments even when 
additional information is considered.  
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Furthermore, a 1 ppm mass error while small in absolute terms is very large 
in relation to the resolving power of FT-MS instruments. If the mass error and 
resolution were on similar scales, the score of a clique could incorporate the 
“goodness” of the m/z matching to further disambiguate multiply assigned peaks. 
Our investigation of the mass error trends in our example spectra revealed that 
the mass error depends both on m/z and on proximity of peaks to other intense 
peaks in a spectrum. Thus, the 1 ppm designation of “accuracy” is illusionary, 
since multiple sources of error can sum above 1 ppm.  Further studies are 
needed to develop robust methods of correcting both the m/z and repulsion 
component of the mass error for the IMF assignments. Ideally this correction 
needs to be feasible with limited knowledge about the composition of the sample 
to enable its use in an untargeted experiment.  
3.5 Conclusions 
SMIRFE is a novel assignment algorithm that enables an unprecedented 
level of untargeted assignment for direct-infusion FT-MS spectra. SMIRFE uses 
a hybrid untargeted / targeted assignment approach that considers effectively all 
EMFs in a specified search space in a preliminary untargeted search that informs 
a more targeted IMF search. This hybrid approach minimizes the computational 
cost of assignment, saves considerable storage space while enabling the 
relatively untargeted search of all reasonable EMFs. Additionally, SMIRFE can 
assign labeled spectra and disambiguate between labeled sub-populations of 
IMFs within a spectrum containing unlabeled and labeled species.  
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At higher m/z, the number of possible assignments considered by SMIRFE 
results in multiple assignments for many peaks.  E-values can aid in 
disambiguating multiple assignments but ultimately improvements in mass 
accuracy will greatly facilitate disambiguation by limiting the number of possible 
assignments that are considered in the first place. These improvements in mass 
accuracy will likely come from both improvements in mass spectrometry 
instrumentation and better methods for correcting mass error due to m/z shifts 
and ionic repulsion. 
The IMF and EMF assignments provided by SMIRFE will ultimately require 
classification into metabolite classes for class-level enrichment studies to be 
performed. Additional tools that can perform these predictions from assigned 





CHAPTER 4. MACHINE LEARNING METHODS FOR LIPID CATEGORY AND CLASS 
PREDICTION 
4.1 Introduction 
Lipidomics is the subdiscipline of metabolomics focused on the study of the 
lipidome - the set of lipid metabolites and their roles within the metabolome 
(Wenk, 2005). Unlike other categories of metabolites that are largely grouped 
based on their structures, lipids are defined by their low solubility in water and 
collectively represent a structurally and chemically diverse set of metabolites with 
various roles in healthy and pathological cellular function. By virtue of their 
diversity, seemingly every life process involves lipids including but not limited to: 
maintenance of cellular structure, membrane fluidity (Singer and Nicolson, 1972), 
intracellular, extracellular and hormonal signaling (Zechner et al., 2012) 
(Morrison and Farmer, 2000), energy metabolism (Adeva-Andany et al., 2018) (J 
R Neely and Morgan, 1974), and disease processes (De Pablo and De 
Cienfuegos, 2000) including cancer (Zhang and Du, 2012) (Ray and Roy, 2018). 
Thus, through lipidomics, more complete modeling of cellular metabolism and a 
better understanding of physiological and pathological processes at the 
mechanistic level can be achieved (Lydic and Goo, 2018).  
 Despite the potential benefits, the rigorous analytical investigation of the 
lipidome in real-world biological samples remains difficult. Lipid features must 
first be reliably observed in samples and these features must be accurately 
assigned to a lipid structure and/or lipid category. As was the case with the 
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detection and assignment of metabolites in general, this represents a significant 
bioanalytical chemistry problem due to the high structural diversity of lipids, their 
wide range of observed concentrations, and differences in lipid profiles between 
different compartments and with time (Horvath and Daum, 2013) (Aviram et al., 
2016) (Fahy et al., 2005). The analytical capabilities of mass spectrometry, 
particularly FT-MS, make it suitable for the resolved detection of lipid features in 
lipidomics studies (Köfeler et al., 2012). Although untargeted assignment tools 
such as SMIRFE can assign observed lipid features to elemental molecular 
formulas, inferring to which category of lipid these features belong remains 
difficult, especially for direct infusion experiments, where orthogonal 
chromatographic data is unavailable to confirm molecular formula assignments or 
disambiguate lipid isomers. Knowing what lipid categories are represented in a 
sample is necessary for lipidomics experiments concerned with differences at the 
lipid category level. 
 Targeted assignment tools attempt to solve the lipid categorization 
problem indirectly. Rather than assigning spectral features to formulas and then 
to lipid categories, tools such as LipidSearch (Köfeler et al., 2012) and PREMISE 
(Lorkiewicz et al., 2012) assign spectral features to metabolites of known lipid 
categories. As discussed in Chapter 3, targeted assignment methods have 
several shortcomings that our untargeted formula assignment tool SMIRFE 
circumvents (Mitchell et al., 2019). However, untargeted formula assignment 
does not provide assignments to metabolites, from which lipid category can be 
inferred. Instead a method for predicting lipid category from untargeted molecular 
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formula assignments from SMIRFE would provide the necessary lipid category 
information while offering the benefits of untargeted assignment.  
 Although lipids as a whole are defined by their physical properties, each 
category of lipid is a set of lipids that share certain chemical substructural 
features. The prediction of lipid category from known lipid structures is 
straightforward. Automated tools such as ClassyFire (Djoumbou Feunang et al., 
2016) use machine learning methods to automatically assign lipid category to 
provided structures; however, structural information cannot be directly acquired 
from SMIRFE. Ultimately, the classification of molecular formulas into specific 
lipid classes remains an unsolved problem that can prevent the effective 
biochemical interpretation of SMIRFE-generated formulas derived from 
lipidomics-focused FT-MS spectra. 
 Manually constructing rules that map elemental molecular formulas to one 
or more lipid categories is a daunting proposition that would most likely result in 
rules that are fragile, incomplete, and incorrect. Previous success at predicting 
potential lipid features automatically using ratios of heteroatoms (Brockman et 
al., 2018) strongly suggests that a similar technique could be applied to predict 
lipid categories from assigned molecular formulas. Fortunately, the prediction of 
lipid category from molecular formulas can be stated as a supervised machine 
learning problem.  
In supervised machine learning, models are constructed that can predict a 
‘label’ for a given input. Inputs are represented by feature vectors which are a 
mathematical representation of features or properties of the input. For example, 
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predicting biological sex (i.e. male or female) from the height and weight of an 
individual can be stated as a supervised machine learning problem. In this 
example, the biological sex of the person is the label to be predicted and the 
height and weight are features represented in a feature vector (e.g. <5’11’’, 
190lbs>).  
The first step in solving many supervised machine learning problems is 
the collection of a training dataset, which is composed of many examples of 
inputs of known label. From each entry in this training dataset, a feature vector 
must be constructed. Continuing with the sex prediction example, this would 
mean obtaining records (e.g. medical or DMV records) that record the height, 
weight and gender of many people. Which features are included in the feature 
vector representation of the entry must be decided based on what information 
can be readily acquired about an entry (e.g. we cannot include structural 
information in our feature vectors as we cannot get structural information easily 
from SMIRFE assignments) and which information is expected to aid in 
classification (e.g. blood type could be included in our feature vectors for 
predicting biological sex but is unlikely to be helpful). Second, this training 
dataset is then used to fit a mathematical model that can predict label from any 
feature vector, based on patterns between features in the training feature vectors 
and their known labels. Different machine learning models vary dramatically in 
how they approach the fitting of this model to the training data. Once trained, the 
performance of these models can be evaluated and then applied to new datasets 
to make predictions (Kotsiantis et al., 2007).  
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Although many algorithms exist for generating models that solve 
supervised machine learning problems, one of the most popular algorithms is the 
Random Forest algorithm (Breiman, 2001). In Random Forest, anywhere from 10 
to hundreds or thousands of decision tree classifiers (Breiman et al., 1984) are 
constructed and each decision tree considers only a subset of the feature vectors 
present in the training dataset.  This subsetting of the training dataset is referred 
to as bagging. Individual decision trees can be thought of as flow charts that 
provide a set of rules that enable label prediction from an input vector (e.g. if 
height < 5’3’’ and weight < 140lbs predict label “female”). The rules learned by 
each tree may differ as each tree was trained using different bags of feature 
vectors and different subsets of features. The maximum complexity of the rules 
represented by each tree is governed by a set of user-provided parameters, 
which limit how many features each tree can use and the maximum size (depth) 
of a tree. These parameters that control model generation are called 
hyperparameters. When presented with a new feature vector to classify, a 
Random Forest model applies the rules represented by each tree to the new 
feature vector. Each tree then votes for the label it predicts and the label with the 
most votes is the label predicted by the Random Forest model.  
Random Forest has been successfully applied to other supervised 
machine learning problems in metabolomics (Chen and Yu, 1994) (Wang-Sattler 
et al., 2012) and has several properties that make it ideal for our use-case. First, 
the bagging process implemented by Random Forest protects against overfitting 
and enables the direct measurement of classifier accuracy similar to explicit 
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cross-validation (Svetnik et al., 2003) using a metric called out-of-bag accuracy 
(described in more detail in the materials and methods). Second, bagging and 
the construction of many classifiers mitigates problems that arise when training 
datasets are unbalanced with respect to the number of examples for each label 
(see Table 4.1 Number of Examples, each lipid category is not equally 
represented) (Svetnik et al., 2003). Finally, the individual decision trees 
constructed by Random Forest are expected to excel at learning classification 
rules based on discrete data such as atom counts, which are expected in our 
feature vectors. For these reasons, Random Forest is an ideal candidate for the 
generation of models that can predict lipid category and class for SMIRFE 
assigned EMFs.  
4.2 Materials and Methods 
4.2.1 Structure of Chemically-Descriptive Feature Vectors 
 In our application each feature vector represents an elemental molecular 
formula from a metabolite database or an assigned EMF from SMIRFE. The 
features that comprise the feature vector was selected to be computable from 
only an EMF assignment (i.e. no information from MS2 or chromatography to 
provide structural information). These features include the atom count for each 
CHONPS element, the sum of atom counts for other elements, and the 
theoretical monoisotopic mass and individual decimal places from this mass (e.g. 
the tenths place, the ones place, and the tens place. These individual digit places 
are included in case there are patterns in the distribution of these digits that could 
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inform lipid category or class. To ensure that all molecular weights for all entries 
were comparable, every entry had its theoretical monoisotopic molecular mass 
re-calculated using isotope molecular masses from NIST (Wieser et al., 2013) 
(Berglund and Wieser, 2011) . Each element atom count is an integer, but for 
different elements the expected atom count range can vary significantly. For 
example, only a handful of phosphorus or sulfur atoms are expected for any 
given lipid, but a fully saturated hydrocarbon of mass 1600 Daltons would have 
114 carbon and 230 hydrogen. The theoretical monoisotopic mass is a floating-
point number between zero and a few thousand Daltons, while each digit will be 
represented as an integer between 0 and 9.  As a result, each feature in our 
feature vector will be on a different scale. Although these could be normalized to 
remedy the differences in scale, which is a requirement for some machine 
learning algorithms, the Random Forest algorithm does not have this limitation. 
An example feature vector representing an EMF is shown in Figure 4.1. 







Figure 4.1: Example Feature Vector  
Example construction of a feature vector for the EMF C16H32O2, corresponding to palmitic acid - In a real-world 
application, the EMF would be provided from an assignment method such as SMIRFE and the compound it represents 
may not be known. The first step in constructing the feature vector is to calculate the theoretical monoisotopic mass for 
that EMF. Calculating the theoretical mass for an EMF rather than relying upon the observed mass for the 
corresponding spectral feature, eliminates the potential confound of mass error at the classification step. Using the 
monoisotopic mass is necessary so that isotopologues of the same EMF can be classified using the same classifiers. 
In the second step, the number of hydrogens missing in the formula due to unsaturation is calculated. Finally, the 
theoretical monoisotopic mass, the number of missing hydrogens, and the EMF are used to construct the feature 
vector. The coloring and bolding of the numbers in the example feature vector reflect the sources of these values.  




4.2.2 Derivation and Organization of Training Datasets 
 In addition to the selection of proper feature vectors and the selection of 
an appropriate machine learning algorithm, the quality of a machine learning 
model depends heavily on the quality of the training data from which the model is 
constructed. Training datasets should be large, contain examples of both true 
positives and true negatives, and cover most of the expected feature space. 
Additionally, training data must be organized in the appropriate manner.  In this 
case, the training data should have the training inputs mapped to both high-level 
lipid categories (e.g. glycerolipid, phospholipid, etc.) and further subdivided into 
more specific “main classes” (e.g. monoradylglycerols, eicosanoids, 
secosteroids, etc.).  
 The LIPIDMAPS database is the largest lipid-specific repository of 
metabolite structures and every entry in LIPIDMAPS is assigned to both a high-
level lipid category and a lower-level lipid class. There are 7 lipid categories, 
which are further subdivided into 79 distinct classes.  Each entry represents 
either an observed lipid or a predicted lipid and contains an elemental formula for 
that lipid and its assigned lipid category and lipid class. Therefore, entries from 
LIPID MAPS are sources of true positives for our training dataset. LIPID MAPS is 
also subdivided into two databases: the LIPID MAPS Structure Database (LMSD) 
and the LIPID MAPS In-Silico Structure Database (LMISSD). The LMSD contains 
both manually verified and computationally generated lipids and is freely 
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available for download, while the LMISSD is composed completely of 
computationally generated lipids. Unlike the LMSD, the LMISSD is not directly 
downloadable and a web scraper written in R (Ihaka and Gentleman, 1996)  
using the RSelenium package (Harrison, 2016)  was used to extract every 
LMISSD entry with its lipid category, lipid class, and molecular formula.   We 
downloaded the LMSD in September, 2018, which contained 42,004 entries.  We 
webscraped the LMISSD in September, 2018, obtaining 1,131,106 entries. 
 However, true positives are only one half of a training dataset.  True 
negatives are also needed for the construction of robust models. In this case, a 
true negative is a biological formula that is not a lipid. The human metabolome 
database (HMDB) (Wishart et al., 2007) contains many examples of biological 
formulas of known class and is freely downloadable. By filtering out and 
removing known lipids from the HMDB, a set of false negatives were constructed. 
These entries, of course, do not have a lipid category or lipid class assigned to 
them, so an extra category and class called ‘non_lipid’ was assigned to these 
entries. The downloaded version 4.0 of the HMDB on September, 2018, which 
contained 114,089 entries, with 22,657 entries being non-lipids. 
 Since in-silico generated lipids may not necessarily exist in biological 
systems, it is prudent to construct two example training datasets: HMDB 
non_lipids + LMSD (referred to as LMSD training set) and HMDB non_lipids + 
LMSD + LMISSD (referred to as LMISSD training set). Since isomers of lipids 
can have the same molecular formula but have a different structure that can even 
belong to different lipid categories and lipid classes, each training dataset was 
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deduplicated by mapping each formula to all observed lipid categories and 
classes for each formula. A large portion of the entries in both the LMSD and 
LMISSD are isomers of other entries of the same lipid class and category. The 
final LMSD + HMDB non_lipid training dataset resulted in 16,215 unique entries 
as compared to 30,692 for the LMSD + LMISSD + HMDB non_lipid training 
dataset.  
4.2.3 HMDB-Derived Molecular Formula Convex Hull Construction 
Given a set of points in an N-dimensional space, there exists exactly one 
unique polygon of minimal volume that encloses all the points in the space. In 2-
dimenions, a convex hull is the shape formed by stretching a rubber band around 
a collection of points. In three dimensions, it is the same as tightly wrapping a 
collection of points in wrapping paper. A convex hull can be used to aid in the 
generation of formulas that are similar to known metabolite formulas in elemental 
composition, but are not known metabolite formulas. 
For every formula in the HMDB composed only of CHONPS elements and 
with a molecular weight below 1600 Daltons, each formula was mapped to a 
single 6-dimensional integer tuple that represents that entry’s EMF (e.g. 
(6,12,6,0,0,0) represents the EMF C6H12O6). This is identical to the integer lattice 
constructed to enumerate EMFs in the SMIRFE algorithm described in Chapter 
3. The convex hull enclosing these points was then calculated using the Python 
implementation of the qhull algorithm (Barber et al., 1996). Each point enclosed 
by the convex hull represents an EMF that is similar to a known metabolite’s 
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EMF. All these enclosed points were enumerated and converted back to EMFs to 
generate a set of EMFs that are similar to known metabolite EMFs. Feature 
vector representations of each EMF were then generated that can be classified 
using our machine learning models.  
4.2.4 Experimentally-Derived Molecular Formulas from Human Lung Cancer 
Samples  
Paired cancer and non-cancer tissue samples used for this analysis are 
described in Appendix 1. SMIRFE was used to assign all samples in the dataset. 
SMIRFE uses patterns in the intensity ratios of suspected isotopologues of the 
same elemental molecular formula and how these patterns compare to predicted 
intensity ratios based on isotope natural abundances. SMIRFE assignments 
were generated for 192 samples up to 1600 m/z, representing 127,338 unique 
EMFs. Feature vectors were generated for each of these EMFs that can be 
classified using our machine learning models.  
4.2.5 Machine Learning Classifier Construction 
Two approaches were explored in regards to the organization of models 
trained for lipid category and lipid class prediction. The first of these was the 
construction of a pair of monolithic models for the lipid categories and lipid 
classes. In this formulation, each model takes each feature vector and attempts 
to classify it into one of the many lipid categories or classes at once (i.e. attempts 
a multi-class classification - is this feature vector a glycerolipid or a sterol or a 
sphingolipid or a…). The alternative approach was to train a collection of many 
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binary classifiers for each lipid category and class (i.e. attempts to classify into 
only one category or class at a time - is this feature vector a sterol – yes or no?). 
In this formulation, models can be arranged as a hierarchy, with class models 
organized under their respective category models (e.g. the steroid class is under 
the sterol category). The differences in the organization of these models is shown 
in Figure 4.2. 
Both the monolithic models and the hierarchical models were constructed 
using the Random Forest implementation from sklearn (Pedregosa et al., 2011), 
a well-implemented and commonly used machine learning library in Python. Both 
sets of models were trained using the default hyperparameters for Random 
Forest, except the number of trees was set to 500. Training the monolithic 
models was straightforward. For the category model, a Random Forest model 
was trained using all feature vectors in the training data and their lipid categories. 
For the class model, a Random Forest model was trained using all feature 
vectors in the training data and their lipid classes.  
The training of the hierarchical models was more complex. For a given 
category or class, all feature vectors in the training dataset were divided into two 
sets. One set are all feature vectors that map to that category or class (true 
positives), the other were all other feature vectors that did not map to that 
category or class (true negatives). Using these examples of true positives and 
true negatives, a Random Forest model is trained to perform this binary 
classification (i.e. for a class X is the given feature vector an instance of X – yes 
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or no). This process is repeated for all categories and classes in the training 
dataset.  
 
Figure 4.2: Organization of Hierarchical and Monolithic Models 
In a monolithic organization, there exists one model for classifying feature 
vectors into lipid categories and another model for lipid classes (Panel A). This 
organization is simpler with fewer models to train as compared to the hierarchical 
organization of models (Panel B). In the hierarchical organization, there are more 
models in total, but the class models are organized under their respective 
category model.  
 
4.2.6 Evaluation of Lipid Classification Performance 
Although Random Forest attempts to build a model that accurately 
predicts labels (i.e. in this case lipid categories or classes) from input feature 
vectors, these models are not perfect. Sometimes the predicted label for an input 
vector is the correct label (a true positive) and at other times the predicted label 
for an input feature vector is incorrect (a false positive). The number of true 
positive and false positive results for a category or class can be used to calculate 
a model’s precision for that class where precision equals the number of true 
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positives divided by the number of true positives plus the number of false 
positives. This can be evaluated by classifying the feature vectors in the training 
data and recording the number of true positives and false positives returned by 
the model. A high precision means that when a label was returned by a model, it 
was likely the correct label. Precision was calculated in this manner for every 
model in the hierarchical models.  
Another metric for evaluating model performance is the out-of-bag 
accuracy. This value is calculated automatically by the Random Forest 
implementation in sklearn during training. Recall that each tree in the Random 
Forest is not trained using the entire training dataset. Instead each tree is only 
trained on a subset of the entire training dataset (this is the “bag” of samples 
referred to by “out-of-bag”). The out-of-bag accuracy is the average accuracy for 
all trees in the Random Forest model on each training feature vector considering 
only the trees in the Random Forest model that did not use that feature vector 
during training. In this case, accuracy is simply the percentage of predicted labels 
that matched the known label (e.g. what percentage of feature vectors 
representing Glycerolipids [GL] that were classified correctly). Out-of-bag 
accuracy was calculated for both the monolithic models and the hierarchical 
models.  
By these metrics, models that have high precision produce very few 
incorrect classifications, but may not produce many classifications total. Models 
with high out-of-bag accuracy produce many correct classifications at a global 
level but may do poorly on any individual label. Therefore, models with both high 
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precision and high out-of-bag accuracy are desirable as they produce many 
classifications with few false positives.  
4.3 Results 
4.3.1 Monolithic Classifier Performance on Training Datasets 
Using the LMSD + HMDB_non_lipid dataset, the performance of a 
monolithic classifier for lipid category and lipid class was tested. Even with 500 
trees, the monolithic random forest models were only able to achieve an out-of-
bag accuracy of 74.9% for lipid category and 87.3% for lipid class. Including the 
LMISSD resulted in an out-of-bag accuracy of 83.1% for lipid categories and 
80.1% for lipid class. In both datasets, the presence of many non-lipid entries 
inflates the lipid class accuracy as all non-lipid entries map to the non-lipid class. 
Although monolithic classifiers may have the theoretical advantage of being 
simpler to implement, train, and deploy, their usefulness is limited by their 
relatively lower classification performance. 
4.3.2 Hierarchical Classifier Performance on Training Datasets 
 For both training datasets (LMSD + HMDB_non_lipid and LMSD + 
LMISSD + HMDB_non_lipid), the out-of-bag accuracy and precision for each lipid 
category are shown in Table 4.1, while the class level results are shown in 
Supplemental Table 4.1. For all categories, the LMSD + HMDB_non_lipid trained 
models achieved high precision and high accuracy for all lipid categories. 
Classification performance for lipid class varies between classes but is in general 
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excellent for classes with enough examples. The LMISSD-trained models 
achieved similar precision and accuracy for all categories (Table 4.2) and classes 
(Supplemental Table 4.2) compared to the LMSD-trained models. Although 
individually high accuracy or high precision would not necessarily indicate a well-
trained model, the combination of high accuracy and precision across the models 
implies that the combined classification performance is robust and can be 





Table 4.1 LMSD + HMDB non_lipid Model Performance (Category) 
LMSD + HMDB_non_Lipid Model Performance (Category) 
Category Precision 




Fatty Acyls [FA]  0.841 0.901 2031 
Glycerolipids [GL]  0.996 0.995 532 
Glycerophospholipids[GP]  0.995 0.996 1886 
Polyketides [PK]  0.767 0.885 1376 
Prenol Lipids [PR]  0.989 0.971 473 
Saccharolipids [SL]  1.000 0.998 102 
Sphingolipids [SP]  0.999 0.993 1404 
Sterol Lipids [ST]  0.934 0.972 824 
non_lipid  0.928 0.799 7587 
 
Table 4.2 LMSD + LMISSD + HMDB_non_Lipid Model Performance (Category) 
LMSD + LMISSD + HMDB_non_Lipid Model Performance (Category) 
Category Precision 




Fatty Acyls [FA]  0.838 0.939 2031 
Glycerolipids [GL]  0.996 0.993 2715 
Glycerophospholipids [GP]  0.979 0.980 9766 
Polyketides [PK]  0.773 0.934 1376 
Prenol Lipids [PR]  0.989 0.983 473 
Saccharolipids [SL]  1.000 0.999 102 
Sphingolipids [SP]  0.976 0.976 3089 
Sterol Lipids [ST]  0.931 0.983 824 
non_lipid  0.930 0.882 7587 
 
Tables 4.1 and 4.2: Classifier Accuracy and Precision Analyses – Most lipid 
category and class models achieved excellent accuracy above 90% and 
excellent accuracy above 93%. Polyketides had worse accuracy and precision in 
both models (88.5% and 76.7% accuracy in precision in the LMSD models) and 
fatty acyls had high accuracy but lower precision (90.1% accuracy and 84.1% 
precision).  The polyketides represent a very diverse set of structures compared 
to other lipid classes which explains this discrepancy. The number of examples 
of each category highlights the unbalanced nature of this dataset and motivated 
the use of Random Forest for these models. Inclusion of the LMISSD (Table 4.2) 
provided no additional examples of Fatty Acyls, Polyketides, Saccharolipids, or 






4.3.3 Hierarchical Classifier Performance on Theoretical Molecular Formulas 
 Brute force enumeration and testing of all points within the convex hull 
constructed around all CHONPS-only molecular formulas in the HMDB identified 
110,857,519 formulas. While a brute force approach was computationally 
expensive, requiring several thousand hours of CPU time, it was necessary due 
to memory constraints with more complex methods. Classifying these formulas 
with the LMSD + HMDB_non_lipid models resulted in 8.34% assigned to a lipid 
category or class, 67.31% assigned to non_lipid and 26.34% receiving no 
classification. Results for each category are summarized in Table 4.3. The 
LMISSD models predicted lipid categories for 13.44% of the provided formulas, 
66.36% were assigned to non-lipids and 25.08% were assigned to no category 
(Table 4.4). Note, due to the ability to assign formulas to multiple categories, the 
percentages do not sum to 100%. The LMISSD models predicted 4 of the 7 





Table 4.3 LMSD + HMDB non_lipid Model Performance for Convex Hull 
(Category) 
LMSD + HMDB_non_lipid Model Performance for Convex Hull (Category) 
Category Predictions % of Hull Formulas 
Fatty Acyls [FA]  475,516 0.429 
Glycerolipids [GL]  8,205  0.007 
Glycerophospholipids [GP]  1,145,418 1.033 
Polyketides [PK]  84,333 0.076 
Prenol Lipids [PR]  18,684 0.016 
Saccharolipids [SL]  6,708 0.006 
Sphingolipids [SP]  7,494,579 6.761 
Sterol Lipids [ST]  18,643 0.017 
non_lipid  74,621,680 67.31 
no category 29,202,459 26.34 
Table 4.4 LMSD + LMISSD +HMDB_non_lipid Model Performance for Convex 
Hull (Category) 
LMSD + LMISSD +HMDB_non_lipid Model Performance for Convex Hull 
(Category) 
Category Predictions % of Hull Formulas 
Fatty Acyls [FA]  393,314 0.354 
Glycerolipids [GL]  56,116 0.051  
Glycerophospholipids [GP]  1,735,925 1.566 
Polyketides [PK]  118,968 0.107 
Prenol Lipids [PR]  15,881 0.014 
Saccharolipids [SL]  2,795 0.002 
Sphingolipids [SP]  12,568,226 11.34 
Sterol Lipids [ST]  15,670 0.014 
non_lipid  73,562,707 66.36 
no category 27808607 25.08 
 
Tables 4.3 and 4.4: Model Performance for Theoretical Molecular Formulas - 
The formulas within the convex hull surrounding the HMDB metabolites 
represent a very large set of possible metabolites formulas. Lipid categories 
were predicted for every formula within the hull. For all categories, more 
formulas were predicted for each category than existed in the training dataset, 
indicating that the models have generalized beyond the training dataset. The 
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extent of this generalization varied depending on the training dataset. For 
example, saccharolipids (the category with the smallest number of examples in 
the training dataset) was predicted more frequently in the LMSD based models 
than in the LMISSD models, while sphingolipids were more frequently predicted 
in the LMISSD trained models. Although the distribution of predicted lipid 




4.3.4 Hierarchical Classifier Performance on Experimentally-Observed 
Molecular Formulas 
 The distribution of the assigned lipid categories on molecular formulas 
enumerated from a human lung cancer FT-MS dataset is shown in Tables 4.7 
and 4.8 for the LMSD based classifier. SMIRFE generates many possible 
assignments for each peak at higher m/z as the number of possible formulas 
increases dramatically with increasing m/z. As a result, a relatively small 
percentage of formulas are assigned to a lipid category but many peaks have at 
least one formula that was assigned to a lipid category. For the LMSD models, 
the ability to predict lipid category and class drops substantially after about 1200 
m/z. This is due to the low number of entries in the LMSD at higher m/z.  
  When the masses of the peaks are shifted by +21 m/z to mimic a gross 
miscalibration error, the number of SMIRFE assignments is increased, from 
127,338 to 131,690 total formulas and the number of predicted lipids increases 
as well from 32,688 to 34,755 (Tables 4.5 and 4.6). This result implies that the 
lipid classifier cannot be used alone to screen out bad assignments when lipids 
are expected, instead other orthogonal data must be used to verify the quality of 




Table 4.5 LMSD + HMDB_non_lipid Model Performance for Unshifted 
Assignments 
LMSD + HMDB_non_lipid Model Performance for Unshifted Assignments 
Category Predictions 
% of Assigned 
Formulas 
Fatty Acyls [FA]  639 0.502 
Glycerolipids [GL]  795 0.624 
Glycerophospholipids [GP]  8062 6.331 
Polyketides [PK]  28 0.022 
Prenol Lipids [PR]  1054 0.827 
Saccharolipids [SL]  166 0.130 
Sphingolipids [SP]  21586 16.952 
Sterol Lipids [ST]  358 0.281 
non_lipid  54389 42.71 
no category 40683 31.95 
Table 4.6 LMSD + HMDB_non_lipid Model Performance for Shifted Assignments 
LMSD + HMDB_non_lipid Model Performance for Shifted Assignments 
Category Predictions 
% of Assigned 
Formulas 
Fatty Acyls [FA] 258 0.1951 
Glycerolipids [GL] 923 0.7001 
Glycerophospholipids [GP] 9517 7.227 
Polyketides [PK] 37 0.0281 
Prenol Lipids [PR] 1160 0.8808 
Saccharolipids [SL] 233 0.1769 
Sphingolipids [SP] 22370 16.99 
Sterol Lipids [ST] 257 0.1952 
non_lipid 51863 39.38 
no category 45663 34.67 
 
Tables 4.5 and 4.6: Model Performance for Experimental Molecular Formulas- 
SMIRFE assignments were generated for the NSCLC dataset described in 
Appendix 1 (Sample D). SMIRFE assignments are generated in an untargeted 
manner without using a database of known lipids. For the peak masses across 
all peaklists, 127,338 total EMFs were assigned and then classified. 32,688 total 
lipid category classifications were made with the most commonly assigned 
categories being glycerophospholipids and sphingolipids. A similar result was 
observed in the convex hull results as well, potentially indicating that this is an 
artifact of the classification method or possibly that these lipid categories are 
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much more diverse than other categories. When each peak was shifted by 21 
m/z, roughly 3% more formulas were assigned and 6% more lipids were 
classified. This small relative increase in SMIRFE assignments is likely due to 
the increased search space density with a 21 m/z shift.  More importantly, the 
large number of artifactual assignments reflects the necessity of high-quality 
data prior to classification. Methods that can predict high quality assignments 
correctly are not necessarily protected from the effects of low-quality spectral 
data that can cause misassignment.  
 
4.3.5 Cross-Sample Assignment Correspondence Improves Assignment Quality 
 Limits in mass resolution and intensity resolution and the immense size of 
the search space considered by SMIRFE at high masses leads to ambiguous 
assignments for many peaks. When mass error is present, ambiguous and 
incorrect assignments can be generated. However, the correct assignment for a 
peak should be assigned more consistently for a consistently observed feature in 
the dataset. Therefore, how well an assignment corresponds across samples in a 
dataset is a potential avenue for selecting high quality assignments. Figure 4.3 
shows histograms of assignment correspondence for elemental molecular 
formulas derived the spectra of the lung cancer dataset. Higher correspondence 
is observed in the unshifted assignments versus the shifted assignments and the 




Figure 4.3: Assignment Correspondence Histograms 
Correct assignments are expected to occur more consistently within a set of 
samples than incorrect assignments. As shown in Panel A, below 400 m/z, very 
few assignments are made in the shifted spectra and none of the assignments 
correspond. As m/z increases (Panels B-D), shifted spectra have increasingly 
more assignments and by chance some of these assignments correspond in 
multiple samples. However, at up to 1200 m/z, there are more well 
corresponding formulas in the unshifted assignments than in the shifted 
assignments. These results imply that assignment correspondence can be used 
to select high correct assignments up to a given mass cutoff. In this dataset, this 





4.4.1 Classifier Organization and Performance 
 As shown in the results, a monolithic, multi-lipid-class predictive model 
failed to achieve top performance for the task of classifying assigned molecular 
formulas into lipid categories and classes.  I hypothesize that this is due to the 
inability of a single classifier to represent all these boundaries completely and 
accurately. This single classifier must not only learn how to separate lipids from 
non-lipids, but it must also subdivide the lipid feature space into discrete spaces 
representing each category and further subdivide these category spaces into 
class spaces. Much of this subdivision can be done explicitly during training. For 
example, the diacylglycerols are a sub-class of the larger category of 
glycerolipids and a less powerful classifier can easily identify the diacylglycerols 
from other glycerolipids when it must only learn that single decision boundary. As 
a result, our organization of more specialized predictive models had superior 
performance. Initially, this behavior can seem counterintuitive but is consistent 
with the concept of ensemble learning from machine learning where collections 
of more specialized classifier models often outperform fewer larger classifier 
models when properly organized. The hierarchy of models that are constructed 
mirror how a human would approach the classification problem (Fahy et al., 
2005). For example, if a molecular formula is known not to be of the sphingolipid 
category, a human will not attempt to assign this formula to a sphingolipid class; 
however, a monolithic model will attempt to do so. This wastes computational 
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power and increases the likelihood of incorrect prediction of both class and 
category.  
 The final models produced by our tool achieved both high accuracy and 
high sensitivity on the training dataset. Of course, performance on training data 
does not paint a complete picture of model performance, but for Random Forest 
which implements bagging, these metrics predict performance on inputs similar 
to the training data (Janitza and Hornung, 2018). Models with both high accuracy 
and high sensitivity are unlikely to produce incorrect lipid assignments, but may 
be overly conservative and fail to generate a non_lipid assignment for some 
inputs. While this behavior is undesirable, it is preferable to less conservative 
models that will yield many incorrect lipid category and class predictions. 
4.4.2 LMSD Versus LMISSD Trained Models 
One method for improving the performance of a machine learning model is 
to provide larger amounts of training data, which in turn enables more informed 
and more accurate decision boundaries to be determined. For this reason, 
models were trained using both the LMSD and LMISSD, which has nearly 25 
times the number of entries as the LMSD. However, LMISSD trained models did 
not offer substantially improved performance as compared to the LMSD-only 
models on the training datasets. Although the LMISSD contained many entries, 
the input training set only doubled in size after isomeric entries were removed, 
implying that little information was added regarding the distribution of formulas in 
lipid category or lipid class space.  Another possible explanation for this 
observation is that the LMISSD contains substantially more entries, but for only 4 
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out of the 7 categories in the LIPIDMAPS database and that the decision 
boundaries for these categories were already well-determined by the LMSD only 
models.  
4.4.3 Classifier Generalization 
 A benefit that machine learning models have over traditional database 
lookups are their ability to infer rules that can be applied to never observed inputs 
to make accurate predictions. This ability was demonstrated with both the LMSD- 
and LMISSD-constructed models. Both models produced lipid category and class 
predictions for experimental and theoretical molecular formulas not present in the 
training dataset. However, the generalizability of the models depends heavily on 




Figure 4.4: Mass Limitations of Training Datasets 
Both the LMSD and LMISSD are heavily biased towards lipids with a mass 
below 1200 Daltons (Panels A and B respectively). This effect becomes clearer 
once entries are deduplicated to yield only unique formulas (Panels C and D). 
Some entries exist out to 3000+ Daltons, but the bulk of the formulas still reside 
in the sub 1200 mass range (these high mass entries may represent lipid 
conjugates that are not lipids for our purposes since they will not be observed in 
mass spectra up to 1600 m/z unless multiply charged but still represent a 
difference in the training datasets). When combined, the bias is still present in 
the combined set of unique formulas (Panel E). Additionally, the LMISSD does 
not have entries from all the lipid categories.  
 
 Despite having similar performance on the training datasets, the LMISSD 
and LMSD trained models showed distinct behavior on the convex hull 
metabolites. The LMISSD assigned many more sphingolipids than the LMSD 
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models and in general, the categories with more examples in the training dataset 
were more frequently predicted. This could be due to a bias in the trained models 
from the unbalanced training data or could reflect the relative amount of 
structural diversity possible within each class, i.e. the number of possible 
sphingolipid formulas might truly be larger than the number of possible sterol 
formulas. However, the percentage of hull formulas predicted for each category 
was similar between the two models, implying that they are overall very similar. 
Both models predicted roughly the same number of not lipid formulas implying 
that the overall lipid versus non-lipid decision boundaries of the two models are 
very similar. Discrepancies between the two models can also be attributed to the 
presence of predicted lipids in the LMISSD that do not exist – this could confuse 
classifiers if the predicted lipids and the validated lipids suggest different decision 
boundaries.  
 Ultimately the ability of both models to make accurate predictions will be 
improved with larger training datasets. With more examples that more 
exhaustively span lipid formula space, the more accurate and generalizable the 
models constructed using these same methods will become.  However, given the 
marginal improvement with a doubling of the training dataset from the LMSD 
versus LMISSD, improvements may be marginal without a vastly larger training 
dataset. 
4.4.4 Mass Error and Classification Results 
 Ideally, a substantial mass error would result in no formulas being 
assigned by SMIRFE or that the assigned formulas fail to classify. As shown with 
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our NSCLC dataset, a large mass error does not eliminate all assignments nor 
completely abolish our ability to classify the resulting, almost certainly incorrect, 
assigned formulas.  
 Given the very large search space that an untargeted tool must search to 
generate assignments, almost any m/z has many possible assignments, given 
the theoretical molecular formula search space. Since a systematic error does 
not change the mass difference between isotopologues, patterns of 
isotopologues for these incorrect formulas can still be identified and assigned. 
Thus, without extremely high mass resolution to restrict the set of possible 
assignments considerably, which still may not be effective (Kind and Fiehn, 
2006), a constant mass error will still produce assignments. Furthermore, current 
variance in peak intensities is not low enough to prevent artifactual assignment at 
higher m/z.   
As was seen from the classification results of the convex hull formulas, 
approximately a quarter of the generated formulas appeared to be lipids to the 
models. This could reflect the true distribution of lipids in possible formula space, 
but more likely it represents limitations of our models. Nonsense formulas that 
can arise from m/z error or from the convex hull method cannot be properly 
learned as they are very different from the training set data. Although the ability 
of our models to produce no classification for an input feature vector protects 
against this effect, it is not perfect. The same models that learn real 
(biochemically relevant) metabolite formulas correctly may fail to properly handle 
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nonsense formulas that SMIRFE can assign to peaks with high mass error and 
noise or artifactual peaks. 
Therefore, lipid classification alone should not be used to filter out features 
in datasets. Information such as how many times a formula is observed across a 
dataset and observed correlation between features classified to the same lipid 
category and/or class should be included as well. Features considered 
trustworthy by other methods can then be classified for further analysis. Since 
relatively small mass errors can introduce correct assignments (Kind and Fiehn, 
2006), high cross-sample formula correspondence is an indication (though not 
definitive proof) of accurate (or at the very least consistent) assignments.   
4.4.5 Implications for Experimental Design 
 The ability to predict lipid category and class from molecular formula 
assignments without the need for cross-validated metabolite assignments, 
enables simpler experimental designs as the volume of information needed to 
perform class or category level comparisons is lessened. As molecular formula 
can be assigned from direct infusion FT-MS MS1 spectra directly and in a cross-
validating manner, chromatography and other cross-validation information is not 
necessary for class or category level comparisons when using these models. 
However, the quality of the analyses will depend heavily on the quality of the 
assigned molecular formulas.  
 SMIRFE leverages patterns in the relative heights of isotopologue peaks 
for the same elemental molecular formula to determine what molecular formulas 
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best explain features observed in a spectrum. Although SMIRE is not necessarily 
limited to only high-end mass spectrometers such as FT-MS instruments, only 
these instruments provide enough mass accuracy and resolution to observe and 
characterize relevant sets of isotopologues. This restriction is becoming 
increasingly less relevant as high-performance spectrometers become more 
available. Additionally, SMIRFE and subsequent lipid prediction does not enable 
the robust assignment of metabolite structures to spectral features and this will 
still require additional information from orthogonal experiments.  
4.5 Conclusions 
 Untargeted lipidomics has the potential to produce more informative 
datasets that will aid in the construction of more complete models of cellular 
metabolism. This in turn enables a better understanding of both healthy and 
disease processes. A necessary step in many of these analyses is the 
assignment of lipid category or class to an observed lipid feature. When multiple 
orthogonal sources of information are available (i.e., MS + chromatography, NMR 
+ chromatography, MS/MS), lipid category and class assignment can be inferred 
from trustworthy metabolite assignments.  
 The application of machine learning algorithms enables the construction of 
models that can accurately and precisely assign lipid labels to observed spectral 
features that have been assigned to a molecular formula. Unlike other 
approaches that leverage metabolite databases directly for lipid assignment, 
these models have the capacity to infer lipid category and class for entries not 
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present in existing databases. This capacity is essential for untargeted 
metabolomics experiments as database incompleteness can lead to a biasing of 
lipid classification and in turn biological interpretation. Since these models are 
informed by the existing metabolite databases during training, their capacity to 
compensate for database incompleteness is not unlimited as observed with our 
LMSD informed models having limited efficacy at higher mass ranges. The 
inclusion of additional sources of empirically observed lipids in these mass 
ranges may extend the useful mass range of this methodology. LMISSD-
informed models did not suffer from this limitation, but had decreased accuracy 
and specificity, potentially attributable to unrealistic entries in the LMISSD.  
 The high out-of-bag accuracy and precision achieved by these models on 
the training datasets suggest that the predicted lipid categories generated by 
these models on experimentally-derived molecular formulas are likely to be 
trustworthy. The distribution of predicted lipid categories on the convex hull 
formulas, the majority of which are nonsensical formulas, demonstrates the 
conservativeness of our models for all lipid categories except sphingolipids. 
Thus, machine learning-based approaches will allow for more untargeted lipid 
profiling analyses than existing database-centric methods, even with the more 
limited data that can be acquired using direct injection MS1 alone. Similar 
methods could be applied to the classification of other major types of 
biomolecules or to identify potential contaminants or non-biological compounds 
detected in complex biological samples. However, the quality of the predictions 
made by such methods remains limited by the ability to generate high quality 
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assignments in an unbiased manner for high m/z ranges that a relevant to lipid 
profiling. Methods such as SMIRFE combined with cross-sample 




CHAPTER 5. CLINICAL IMPLICATIONS OF DIFFERENTIAL LIPID EXPRESSION IN NON-
SMALL CELL LUNG CANCER (NSCLC) 
5.1 Introduction 
Lung cancer remains the most common cause of cancer death worldwide 
(Kanitkar et al., 2018) with approximately 85% of newly diagnosed lung cancers 
belonging to the non-small cell lung cancer subtype (Molina et al., 2008). The 
high mortality of lung cancer and NSCLC is partially explained by the relative 
asymptomatic progression of disease resulting in most patients presenting with 
advanced-stage disease at the initial diagnosis. Although improvements have 
been made both in the treatment, prevention, and early diagnosis of NSCLC, 5-
year survival rates for NSCLC remain low (16.4%) (Kanitkar et al., 2018).   
         Current treatment options for NSCLC vary depending on disease stage at 
diagnosis and the presence of one or more genetic markers. For low stage 
disease, surgery remains the most common and most effective treatment option 
(Uramoto and Tanaka, 2014), especially when combined with chemotherapeutic 
drugs (Betticher, 2005). For advanced stage disease, chemotherapy (Sandler et 
al., 2000) (Pirker et al., 1995) (Wozniak et al., 1998) represents the primary first-
line treatment option despite relatively poor improvements in patient survival, 
partially due to the development of chemotherapy resistance (Chang, 2011). 
Additionally, radiotherapy is also often used for inoperable NSCLC 
(Vansteenkiste et al., 2013).  
Many of the recent advances in the treatment of NSCLC have focused on 
the development of targeted therapies that inactivate one or more specific 
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biomarkers expressed by certain subtypes of NSCLC. Among these targets are 
epidermal growth factor receptor (EGFR) (Paez et al., 2004) (Shepherd et al., 
2004), which is often mutated in NSCLC tumors in patents of East-Asian origin 
(Chang et al., 2006), vascular endothelial growth factor (VEGF) (Piperdi et al., 
2014) (Ferrara et al., 2005), and anaplastic lymphoma kinase (ALK) also known 
as ALK tyrosine kinase receptor (Crino et al., 2011) (Kim et al., 2014). These 
targeted therapies offer more effective treatment options as compared to 
traditional chemotherapy and with decreased side-effects, but not all NSCLC 
patients express these biomarkers and thus are not candidates for these 
treatments. In addition to these targeted therapies, drugs that target the PD-
1/PD-L1 immune checkpoint to enhance anti-cancer T-cell response are a 
promising treatment for advanced NSCLC (Sunshine and Taube, 2015). While 
not side effect free, this approach offers improvements in survival and much 
fewer side-effects than traditional chemotherapy (Sgambato et al., 2016). 
However, overall survival of advanced NSCLC remains poor (Spigel et al., 2015).  
 Although many NSCLC patients fail to express these particular 
biomarkers, the observation that metabolic alterations are common in all human 
cancers implies that there are measurable and perhaps drug targetable 
differences between the metabolism of NSCLC cells and their non-transformed 
counterparts (Hanahan and Weinberg, 2011) (Ray and Roy, 2018) (Sellers et al., 
2015b). The process by which cancer cells acquire these altered metabolic 
phenotypes is known as metabolic reprogramming and is now considered to be a 
hallmark in the development of cancer (Hanahan and Weinberg, 2011). Previous 
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studies have observed metabolic reprogramming in NSCLC (Sellers et al., 
2015b) (Hensley et al., 2016).  
 First, glucose metabolism is markedly altered in NSCLC. Labeling studies 
have shown that both glycolysis and the TCA cycle are highly active in NSCLC 
tumors and that the rate of glucose oxidation in NSCLC tumors exceeds the rate 
of oxidation in surrounding non-cancer tissue (Hensley et al., 2016). Maintaining 
these high rates of oxidation requires replenishing TCA cycle intermediates that 
are often shunted towards anabolic processes. Previous studies have 
demonstrated that this is achieved, in part, through enhanced pyruvate 
carboxylation (Sellers et al., 2015b). Studies have also shown that NSCLC 
tumors also oxidize a variety of other substrates with preference for non-glucose 
substrates increasing with higher perfusion rates (Hensley et al., 2016). The 
relatively low amount of 13C enrichment observed in NSCLC intracellular acetyl-
CoA from U-13C glucose labeling experiments implies that the majority of the flux 
through PDH comes from non-labeled precursors (i.e. not derived from U-13C 
glucose) such as lactate from the tumor microenvironment (Faubert et al., 2017).  
 Additionally, lipid metabolism is known to be altered in NSCLC as well. 
Key enzymes for lipid metabolism such as ATP citrate lyase (ACLY) (Osugi et al., 
2015), fatty acid synthase (FASN) (Uramoto et al., 1999) and Stearoyl CoA 
desaturase 1 (SCD) (Huang et al., 2016) are all known to be differentially 
expressed in NSCLC as compared to non-cancer tissue. Increased activity of 
these enzymes enables the enhanced production of many lipid classes in 
NSCLC tumors and their overexpression correlates with clinical outcomes. For 
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example, FASN expression in early stage NSCLC is indicative of poor outcomes 
and tumor aggressiveness (Wang et al., 2002) (Visca et al., 2004), SCD 
expression promotes tumor development and aggressiveness (Noto et al., 2013) 
(Huang et al., 2016), and ACLY expression is associated with survival in young 
NSCLC patients but poorer survival in older populations (Csanadi et al., 2015). 
Each of these enzymes is required for one or more metabolic steps needed to 
produce lipids and inhibition of one or more of these enzymes remains a 
promising drug target in NSCLC patients.  
 Sterols are the subset of lipids that share a common four ring structure 
and are essential for many biological processes including: membrane fluidity, 
hormonal signaling, inflammation, and the regulation of cellular metabolism. All 
endogenously produced sterols in humans are produced by the mevalonate 
pathway. The first step of this pathway is the condensation of acetyl-CoA with 
acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA 
is then reduced to mevalonate by the enzyme HMG-CoA reductase and this step 
is the rate limiting step for the pathway. Statins are inhibitors of HMG-CoA 
reductase that are used clinically for the reduction of plasma cholesterol levels. 
Although statins are not currently recommended for the treatment of cancer, 
some epidemiological studies have observed that patients prescribed statins 
have better overall survival for a variety of cancers (Nielsen et al., 2012) 
including NSCLC (Hung et al., 2017), even at late stages (Lin et al., 2016). 
However other studies have failed to recapitulate these findings in controlled 
double-blinded studies (Seckl et al., 2017). Contributing to this controversary are 
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the many effects of statins that could potentially be therapeutic including a dose-
dependent effect on angiogenesis (Weis et al., 2002), anti-inflammatory effects 
(Diomede et al., 2001), and immunomodulating effects (Sadeghi et al., 2001).  
 Previous studies have observed that sterol production is often upregulated 
in many cancers and high serum cholesterol levels are correlated with the 
development of some cancers (Jamnagerwalla et al., 2018) (Kitahara et al., 
2011). Increased sterol production has been attributed to both upregulation of 
HMG-CoA reductase (Gustbée et al., 2015) and SREBP-2 (Li et al., 2016b), a 
master regulator of sterol biosynthesis. Due to their relatively limited side effects, 
a potential chemotherapeutic role for statins in NSCLC could represent a 
significant improvement when combined with existing treatment options. Also, 
drugs such as nitrogenous bisphosphonates that inhibit later steps in the 
mevalonate pathway (Tsoumpra et al., 2015) could have similar cancer 
chemotherapeutic potential in NSCLC. 
 Overall, understanding the metabolic differences between NSCLC and 
non-cancerous lung tissue represents a major first step in constructing more 
complete models of NSCLC development and ultimately the development of 
more effective therapeutics. Advances in mass spectrometry, namely Fourier 
transform mass spectrometry (FT-MS), provides simultaneous improvements in 
terms of sensitivity, resolution, and mass accuracy. These combined analytical 
capabilities provide significant analytical improvements, including the ability to 
resolve distinct isotopologues of detected metabolites and the detection of lower 
concentration metabolites. However, leveraging these analytical improvements to 
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generate tangible and biologically-interpretable results remains difficult. The lack 
of highly descriptive peak characterization, the presence of spectral artifacts in 
FT-MS spectra (Mitchell et al., 2017), and the lack of untargeted assignment 
methods that are not biased due to the incompleteness of existing metabolic 
databases (Mitchell et al., 2014) (Schrimpe-Rutledge et al., 2016) have limited 
the ability to capitalize on the analytical advantages of FT-MS to improve our 
understand of NSCLC lipid metabolism. However, using methodologies 
presented in Chapter 2, many of these data quality problems have been 
minimized and the SMIRFE algorithm from Chapter 3 enables elemental 
molecular formula assignment of FT-MS spectra without relying upon existing 
metabolic databases. Additionally, the lipid classifier tool from Chapter 4 allows 
the prediction of lipid category to these assigned formulas. 
         Using our improved data processing tools,  SMIRFE (Mitchell et al., 2019)  
and the lipid category predictor, we have assigned and classified consistently 
observed spectral features from a large set of paired disease and non-disease 
samples from suspected NSCLC patients into lipid categories. Differential 
abundance analysis of categorized lipid features reveals a significant increase in 
sets of sterols and glycerolipids and a significant decrease in 
glycerophospholipids and sphingolipids in disease versus non-disease tissue. 
The increase in sterol lipids was most interesting as it suggests a possible role of 
existing pharmaceutical such as statins and nitrogenous bisphosphonates in the 
treatment of NSCLC that is consistent with previous epidemiological studies 
regarding the use of the drugs in NSCLC. 
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5.2 Materials and Methods 
5.2.1 Description of Paired Human Suspected NSCLC and Non-Disease Tissue 
Samples 
 Paired disease and non-disease tissue samples were acquired from 
patients with suspected stage I or IIa primary NSCLC at both the University of 
Kentucky and the University of Louisville. Lipid extracts were prepared from 
these samples and analyzed by direct infusion ultrahigh resolution mass 
spectrometry on two Thermo Orbitrap Tribrid Fusion instruments (Fusion 1 and 
Fusion 2). Additional details are provided in Appendix 1 (Sample D). 
5.2.2 Peak Characterization and Assignment 
 Raw Thermo data files were processed using the peak characterization 
method described in 2.2.2. Peak characterization resulted in 100 spectra (50 
patients) from Fusion 1 and 76 spectra (38 patients) from Fusion 2. SMIRFE was 
used to generate assignments for all spectra.  
5.2.3 Categorization of Assigned Formulas 
  Assigned molecular formulas were classified into one or more lipid 
categories using the lipid classifier tool from Chapter 4. This tool uses a family of 
Random Forest classifiers trained on entries from the LipidMaps (Sud et al., 
2006) and HMDB (Wishart et al., 2017) databases. Entries from LipidMaps 
represent examples of known lipids and their categories, while the non-lipid 
entries from the HMDB were used as examples of known non-lipid biological 
compounds. For every category in LipidMaps, using the Random Forest 
154 
 
implementation from sklearn (Pedregosa et al., 2011), a machine learning library 
in Python, a classifier was trained. Each classifier was trained with default 
settings except that the number of trees for each forest was increased to 500. 
The feature vectors for each formula consisted of the element counts in the 
formula for CHONPS elements, the number of halogens in the formula, the 
number of hydrogen equivalents (number of hydrogens + number of halogens), 
number of unsaturation sites, the monoisotopic mass of the formula and the tens, 
ones, and tenths place of the monoisotopic mass. For each category, classifier 
accuracy and precision were estimated on the training dataset. For all categories, 
good accuracy and precision were achieved and are summarized in Table 4.1 
5.2.4 Consistently Assigned Spectral Feature (corresponded-peak) Generation 
and Differential Abundance Analysis 
First, corresponded peaks were identified by finding the set of peaks 
across all samples that represent a disjoint set of isotopologue assignments. Any 
two peaks that share at least one IMF assignment can be collapsed into a 
corresponded peak. This can be done recursively (i.e. corresponded peaks with 
sharing IMFs can be collapsed) until all possible corresponded peaks that can be 
collapsed have been collapsed. When no more collapsing can occur, each 
resulting corresponded peak represents a disjoint set of isotopologue 
assignments to one consistently assigned spectral feature. In Fusion 1, 3242 
such corresponded-peaks were identified in total across all 100 spectra, with 756 
corresponded-peaks present in 25% or more disease or non-disease samples. In 
Fusion 2, 4257 corresponded-peaks were identified across all 76 spectra, with 
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733 corresponded-peaks present in 25% or more disease or non-disease 
samples. LIMMA (Smyth, 2005) and SDAMS (Li et al., 2019) were both used to 
identify corresponded-peaks that are differentially abundant between the disease 
and non-disease samples. For Fusion 1, LIMMA and SDAMS identified 250 and 
179 significant corresponded-peaks respectively, with 161 significant peaks in 
common and 268 significant peaks combined. Of these 268 significant peaks, 
211 were classified into at least one lipid category and 11 were classified into 
multiple lipid categories. The 11 multi-classified peaks are dropped from further 
differential analyses. In Fusion 2, 200 and 140 corresponded-peaks were 
identified for LIMMA and SDAMS respectively, with 125 significant peaks in 
common and 215 significant peaks combined. Of these 215 significant peaks, 
185 were classified into at least one lipid category and 9 were classified into 
multiple lipid categories. The log2 fold changes for each categorized 
corresponded-peak between disease and non-disease was then calculated. P-
values were calculated using a hypergeometric test and adjusted for multiple 
testing using the Benjamini-Hochberg technique (Benjamini and Hochberg, 
1995).  
5.3 Results 
5.3.1 PCA and Correlation Shows Separation of Disease and Non-Disease 
Samples 
 Principal component analysis (PCA) is a technique that represents high 
dimensionality data in a lower dimensional space where each dimension 
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represents an orthogonal ‘component’ of the variance between the input data. 
PCA was performed using the normalized intensities of the corresponded-peaks 
present in each sample for each peak present at least 25% of the samples for 
each class, revealed a clear, if imperfect, boundary between disease and non-
disease samples along principal component (PC) 2 (Figure 5.1). This implies that 
a significant portion of the variance observed in the second principal component 
(PC2, 13% explained variance in Fusion 1, 12.3% in Fusion 2) represents 
biological variance between the two classes of samples. Correlation heatmaps 
between the samples further supports this claim (Figure 5.2). Normal samples 
cluster well together with high correlation observed between most normal 
samples and other normal samples. Correlation within the disease class were 
less strong but still differentiated disease samples from normal. Lower correlation 
between cancer is somewhat expected given the large amount of heterogeneity 
observed in cancer versus non-cancer as has been previous shown (Paz-Yaacov 
et al., 2015). In both groups, samples that appear to correlate with neither 
disease nor non-disease were detected. These samples likely have data quality 










Figure 5.1: PCA by Disease 
PCA performed on the normalized intensities of the corresponded-peaks present 
in at least 25% of a sample class shows a clear separation between disease and 
non-disease that is most obvious along PC2 in both Fusion 1 (Panel A) and 
Fusion 2 (Panel B). This separation is not present along PC1. The grouping of 
samples by disease class in PCA space clear indicate that the corresponded-
peak intensities capture some of the biological variance between disease 
classes. Note that cancer and non-cancer appear flipped between Fusion 1 and 
Fusion 2. This is normal with PCA as different PCA plots do not have the exact 
same principal components (PC1 in Fusion 1 is not the same as PC1 in Fusion 
2), causing the sign of principle components to arbitrarily flip. 







Figure 5.2: Correlation Heatmaps by Disease 
High correlation is observed between most non-disease samples and other non-disease samples. Good correlation is 
also observed amongst most cancer samples, but with two obvious groupings of samples present in both Fusion 1 and 
Fusion 2 datasets. In both disease classes, a smaller number of samples have poor correlation with samples from 
either class. Overall, the correlation between cancer samples is less strong than the correlation between non-disease 
samples.




5.3.2 Differential Abundance of Lipid Categories Between Disease and Non-
Disease Lung Tissue 
         Four distinct categories of lipids were identified with differentially abundant 
assignments between disease and non-disease: Glycerolipids [GL], 
Glycerophospholipids [GP], Sphingolipids [SP] and Sterols [ST]. Statistically 
significant fold changes were observed for glycerolipids, sphingolipids, and 
sterols in both Fusion 1 and Fusion 2. In Fusion 1, 59 consistently assigned 
sterol IMFs were observed, 46 of which were upchanged in disease (p=2.06e-
18); 79 of 146 glycerolipid IMFs were upchanged in disease (p=1.69e-18) and 36 
of 53 sphingolipid IMFs were downchanged in disease (p=1.41e-14). In Fusion 2, 
33 of 50 sterol IMFs were upchanged in disease (p=5.99e-9), 62 of 125 
glycerolipids were upchanged in disease (p=6.67e-10) and 33 of 49 sphingolipids 
were downchanged in disease (4.11e-17). Although differential fold changes 
were observed for one fatty acyls and some glycerophospholipids, as a group, 
they were statistically insignificant (p=1). These fold changes patterns are shown 
in Figures 3A-D at the category level and summarized in Supplemental Tables 
5.1 and 5.2. In cases where an IMF is observed in disease but not in non-
disease, the fold changes are very high due to imputation of missing values. For 
lipid categories that are mixed up and down, the up and down sub-populations 
correlate with m/z. (Figure 5.3E, F). 
 At the class level, 44 of 46 sterol categorized lipids in Fusion 1 and 33 of 
33 of sterol categorized lipids were of the sterol [ST01] class. Querying the top 5 
most abundant unique EMFs of the upchanged sterol IMFs from Fusion 1 and 
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Fusion 2 against PubChem (6 total unique EMFs, 4 in common) indicate that 
these formulas may correspond to known unsaturated sterol esters. Sterol esters 
are included in the [ST01] sterol class in LipidMaps.  
  







Figure 5.3: Log Fold Change by Category and m/z 
The Log 2-fold change of consistently assigned, classified, and significantly changed lipids are shown in panels A and 
C with respect to m/z. From panel A, there is a population of glycerolipids and sterols that are highly up changed in 
cancer. A similar pattern was observed in Fusion 2 spectra as well (panels B and D). Extremely high fold changes are 
observed for some IMFs as seen in panels A and C. This is artifactual and occurs when an IMF is observed in disease 
but not in non-disease. Zooming in on the features that have Log2FC less than 6, these artifactual fold-changes are 
ignored, and the same trend can be observed in sterols and glycerolipids (Panel C). The distribution of lipids with 
significantly changed concentrations between disease and non-disease with respect to m/z is shown in Panels E and F 
for Fusion 1 and Fusion 2 respectively. 




5.3.3 Lipid Class Correlation and Co-Occurrence Heatmaps 
In addition to log fold changes observed in corresponded-peaks at the lipid 
category level, correlations between corresponded-peak normalized intensities 
were examined across all samples (Figure 5.4). Specifically, correlation values 
between features were calculated using samples with non-zero values for both 
features. The resulting correlation values were normalized by the information 
content, i.e. the fraction of samples used in the correlation calculation.  At the 
lipid category level, all corresponded-peaks of a category correlate strongly with 
at least a subset of the other corresponded-peaks of the same category. Strong 
intra-category correlations are expected, if regulation of these lipids is controlled 
at the category level and if the corresponded-peaks are consistently and 
accurately assigned to lipid categories. Multi-classified corresponded-peaks were 
dropped from these analyses for this reason. Within the glycerolipid category, 
two subgroups of strongly correlated glycerolipids are observed and in sterols, 
one strongly correlated and one weakly correlated subgroup is observed. The 
sterols and the glycerolipids of the triradylglycerol class were strongly correlated 
suggesting a potential shared regulatory mechanism between these two types of 
lipids. 
 Patterns observed in the co-occurrence heatmaps of the lipids by class 
and category revealed more interesting findings. Although the sterols were 
correlated with one another, two distinct groups of sterols are observed in the co-
occurrence plots. This suggests that there are two distinct populations of 
samples with different sterol abundances. Additionally, these two sterol groups 
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have distinct patterns of co-occurrence with other lipid categories.  One sterol 
group has some co-occurrence with glycerolipids.  The other sterol group has co-
occurrence with the sphingolipids. 

























Figure 5.4 Continued 
 
 
Figure 5.4: Peak Correlation and Peak Occurrence Similarity 
Shown in panel A is an information-informed correlation between corresponded-peak normalized intensities grouped 
by lipid category for Fusion 1. Obvious strong correlations are seen between members of the same lipid category for 
many members of the same lipid category. Correlation however is only part of the picture. Shown in panel C is the 
occurrence similiarity of lipids by lipid category and class for Fusion 1 (i.e. how often lipids are observed together). 
Although all sterols were correlated with one another two distinct sets of sterols are observed to co-occur with one 
another. These subsets of co-occuring sterols also co-occur with sets of lipids of other categories. Visually similar 
patterns of intra-category correlation and co-occurrence are observed in Fusion 2 (panels B and D). 





5.4.1 Assignment Ambiguity, Sparsity and Corresponded-Peak Generation 
 Although SMIRFE can generate assignments in a completely untargeted 
manner and rule out many incorrect assignments using ratios of relative peak 
intensities, SMIRFE often does not provide unique unambiguous assignments for 
observed peaks, especially at higher m/z. The ambiguous assignments from 
SMIRFE are a largely unavoidable consequence of the massive search space 
considered by SMIRFE and current limitations on peak intensity variances that 
can be achieved with existing instruments. In many cases, the set of 
assignments provided for a peak at high m/z is likely to contain the correct 
assignment, but also many incorrect assignments as well.  
 Furthermore, even if all peaks were unambiguously assigned, a second 
significant problem arises in that the set of features observed between samples 
can change significantly. Any given feature is unlikely to be observed across all 
samples in a dataset even if that feature is non-artifactual. This high variance in 
observed features between samples can be attributed to variance between 
biological units from which samples are acquired (in our case human patients), 
variance in sample preparation, and spectrum acquisition that can lead to the 
loss and gain of features.  
 Corresponded-peak generation and filtering corresponded-peaks to those 
present in 25% of samples for a given class provides a partial solution to both 
problems by selecting only consistently assigned features present in multiple 
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samples. This subsequent reduction in feature sparsity allows for the meaningful 
use of more traditional statistical approaches such as PCA that do not handle 
high data sparsity well.  
5.4.2 Sample Correlation Analysis Shows Evidence of Metabolic 
Reprogramming in NSCLC 
The dysregulated proliferation of cancer cells requires metabolic 
reprogramming to occur, enabling the production of metabolites necessary for 
biological processes important for cancer development. The number of distinct 
dysregulations of metabolic programs that can lead to a pro-cancer state is likely 
large and, even among a cohort of patients with the same type of cancer, 
metabolic reprogramming is expected to vary significantly. As a result, the lipid 
profiles of non-disease samples are expected to be more similar to one another 
than the lipid profiles of disease samples from the same patients.  
 This hypothesis is supported by the correlation patterns observed in 
Figure 5.4. Although individual genetic, metabolic, and environmental variance 
leads to some differences between lipid profiles of non-disease samples, the 
majority of the non-disease samples show higher correlation to one another with 
respect to the normalized intensities of shared corresponded-peaks as compared 
to the correlation between disease samples. Additionally, the number of common 
corresponded-peaks in non-disease was higher than the number of common 
corresponded-peaks in the disease samples, arguing that in general, the non-
disease samples have similar lipid profiles to one another. The disease samples 
on the other hand displayed weaker correlation to one another with two distinct 
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clusters of correlation observed. The top left most cluster corresponds to primary 
lung tumors of various subtypes and the other cluster was mixed between 
primary lung tumors, metastases from other organs and granulomas. Weaker 
correlation is expected amongst the disease class given that lipid profiles in 
cancer are likely to display higher variance (given the many ways that metabolic 
reprogramming can occur).  
 Although metabolic reprogramming will perturb the lipid profiles of cancer 
as compared to non-cancer, not all components of cellular metabolism are likely 
to be affected and thus some correlation should be observed between disease 
and non-disease samples. This is observed in our analysis as well, suggesting 
that there are lipid profile similarities between disease and non-disease as 
expected for samples derived from the same tissue and the same patients.  
Conversely, random incorrect assignments would not result in these observed 
correlation patterns, thus strongly implying that the SMIRFE assignments and 
corresponded-peak generation selects for highly consistent assignments that 
capture the biological variance between disease classes.  
5.4.3 Lipid Category Correlation and Correspondence 
 The de novo synthesis of many lipid categories is controlled by a single 
rate limiting enzyme early in their biosynthetic pathway (e.g. sterols – HMG-CoA 
reductase, sphingolipids – serine palmitoyltransferase (Rütti et al., 2009), 
glycerolipids – glycerol-3-phosphate acyltransferase (Wendel et al., 2009)). 
Precursors from these pathways are further metabolized to yield subclasses of 
these lipids and are similarly regulated largely at the class level. As a result, 
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changes in the activities of these rate-limiting enzymes result in large changes in 
lipid concentrations at the class and category level. This effect is observed in 
Figure 5.4A where high correlation is observed within lipid categories and 
classes (i.e. if one sterol is upchanged, most sterols are upchanged). This 
correlation pattern is most strongly observed with sterols and the 
triradylglycerolipid subclass of glycerolipids (the triradylglycerolipid class contains 
mostly triacylglycerides). Furthermore, the triradylglycerolipid subclass and the 
sterol categories are strongly correlated with one another, implying that these 
lipid categories and classes are co-regulated. A possible mechanism for this co-
regulation is through steroid response element binding proteins (SREBPs), which 
are involved in regulating key enzymes in the sterol and glycerolipid biosynthetic 
pathway (Ericsson et al., 1997). Both SREBP-1 and SREBP-2 have been 
implicated in the control of lipid biosynthesis (Wen et al., 2018) and previous 
studies have shown that altered SREBP-1 signaling due to B7-H3 (aka CD276, 
an immune checkpoint protein) overexpression is correlated with aggressive 
NSCLC and increased glycerolipid production (Luo et al., 2017).  
 Strong correlation patterns within groups of predicted lipid categories 
would not be expected from random assignments or from incorrectly categorized 
lipids. The weaker correlation patterns observed among sphingolipids and 
glycerophospholipids could imply more incorrect assignments for these lipid 
categories (which is expected for sphingolipids due to our machine learning 
model’s tendency to overpredict that lipid category) or could represent more 
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complex regulatory mechanisms or a mixture of scavenging and de novo 
synthesis.  
 Correlation however is only part of the picture. Although all lipid categories 
were strongly correlated to other members of their same category or class, not all 
members of each class are observed to co-occur with one another. Two distinct 
populations of sterols are clear in Figure 4B, one large and one small population 
of sterols that co-occur with one another. Additionally, each population of sterols 
co-occurs with other lipids from the other categories, implying that there are two 
distinct lipid profiles observed across the samples. The origin and clinical 
implications of these two lipid profiles is unclear, but one population could 
correspond to lung cancer that is known to respond to statins.  
5.4.4 Reproducibility across Instruments and Clinical Environments 
In this study, two sets of samples were analyzed using two different 
Thermo Tribrid Fusion instruments. Samples from Fusion 1 were derived only 
from patients undergoing resections at the University of Louisville while Fusion 2 
samples were derived from patients undergoing resections at the University of 
Kentucky and the University of Louisville. In both sets of samples, the same 
gross changes in lipid profile between disease and non-disease were observed. 
Furthermore, as shown in Figure 5.5, many differentially abundant IMFs were 
observed in both Fusion 1 and Fusion 2 (110 IMFs representing 48% of all IMFs 
observed in both instruments). Although the sets of abundant IMFs do not 
completely overlap between the two instruments, the assignment and lipid profile 
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similarities across biological and analytical replicates suggest the reproducibility 
and consistency of these results.  
 
Figure 5.5: Differentially Abundant IMF Overlap Between Instruments 
325 unique differentially abundant IMFs were observed across Fusion 1 and 
Fusion 2 samples. 158 (48%) of these IMFs were shared between Fusion 1 and 
Fusion 2, 110 were observed only in Fusion 1, and 57 were observed only in 
Fusion 2. In our experience, Fusion 1 is the more sensitive of the two 
instruments and a difference in sensitivity between instruments is a hypothesis 
explaining some of these discrepancies. 
 
5.4.5 Potential Clinical Implications 
 Our study identified clear differences in the relative concentrations 
between disease and non-disease samples derived from the same patients. Most 
notably, the relative concentrations of a subset of glycerolipids and sterols 
(Figure 5.4B) were significantly and consistently higher in the disease samples 
as compared to control. Although the disease class contains several granuloma 
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samples, most of the samples are cancer. Given the key roles that these lipids 
have in membrane structure and function and are needed for cancer cells to 
divide, the observation that these lipid categories are upchanged in disease is 
not unexpected. Alterations in lipid metabolism are common in cancer and 
increased sterol concentrations are observed in many cancers. 
Although interfering with the production of either class of lipids could 
potentially have therapeutic roles in the treatment of NSCLC, sterol metabolism 
is the easiest to target with existing pharmaceuticals. Two classes of drugs that 
are already used clinically, statins and nitrogenous bisphosphonates, inhibit 
enzymes in the mevalonate pathway from which all endogenous sterols are 
derived (Wiemer et al., 2007) (Istvan and Deisenhofer, 2001). Although neither 
class inhibits the uptake of exogenous sterols, bile acid sequestrants, which 
reduce the amount of available exogenous sterols, have not been demonstrated 
to improve NSCLC outcomes in the same manner as statins. The previous 
epidemiological studies that have suggested a possible protective or therapeutic 
role for statins in NSCLC and other cancers have not provided direct evidence 
that statins improve outcomes by targeting the mevalonate pathway. Statins are 
known to have other off-target effects such as inhibition of angiogenesis (Garjani 
et al., 2012), anti-inflammatory effects (Blake and Ridker, 2000), and these off-
target effects differ with high and low dosing strategies (Skaletz-Rorowski and 
Walsh, 2003) and may not directly involve the inhibition of sterol biosynthesis 
(Dulak and Jozkowicz, 2005). While our results do not directly support a claim 
either way that statins have an anti-cancer effect through the inhibition of the 
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mevalonate pathway, increased sterol production in cancer versus non-cancer is 
a prerequisite for such a hypothesis to be true. More importantly, our methods 
provide a potential avenue to explore the effects of statins and other 
pharmaceuticals on lipid profiles in an untargeted and comprehensive manner.   
The mechanisms resulting in the observed lipid profile changes from our 
study remain unclear and could be the object of future studies. Increased sterol 
and glycerolipid concentrations are consistent with direct (constitutively active 
mutants) or indirect (downstream signaling) activation of EGFR, which promotes 
glycerolipid and sterol biosynthesis (Sukhanova et al., 2013) (Gabitova et al., 
2013); SCD, which is required for some glycerolipids and sterol esters (Bené et 
al., 2001); and ACLY, which is essential for sterol biosynthesis (Zaidi et al., 
2012). As mentioned previously, SREBPs might also be involved in these lipid 
profile changes (Luo et al., 2017) (Ericsson et al., 1997). Furthermore, if the 
presence of upchanged sterol esters can be verified, the enzyme ACAT-1 
becomes a promising target in NSCLC. Previous studies have shown in 
pancreatic cancer that inhibition of ACAT-1 prevents the conversion of 
cholesterol to sterol esters, which results in apoptosis due to elevated 
endoplasmic reticulum stress (Li et al., 2016a). 
One possible hypothesis explaining the observed differences is that 
acquisition of a high concentration sterol and glycerolipid metabolic phenotype 
may be necessary for the development of NSCLC. Therefore multiple distinct 
genetic lesions may result in this metabolic phenotype. Thus, pharmaceutical 
intervention that directly targets the sterol component of this phenotype may be 
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beneficial for a variety of genetically distinct NSCLC subtypes. Alternatively, 
these lipid profile differences may be a byproduct of other disease processes and 
not directly contributory to the development of disease. In this case, these 
metabolic changes would still be useful as biomarkers for genetic subtypes of 
NSCLC.  
5.5 Conclusion 
 The use of untargeted assignment tools such as SMIRFE combined with 
machine learning models for the prediction of lipid categories enables 
comprehensive lipid profiling in human derived samples from molecular formula 
assignment alone. Ambiguous assignments from SMIRFE and the high feature 
sparsity intrinsic to such studies can be largely mitigated using corresponded-
peak generation and filtering out inconsistently observed corresponded-peaks. 
Corresponded-peak generation improves assignment consistency and accuracy, 
which can be confirmed through patterns of observed correlation between 
categories and classes of assigned lipids.  
 Subsequent differential abundance analysis, performed using the filtered 
corresponded-peaks, identified a consistent and significant difference in lipid 
profiles between disease samples and controls. Most notably, both glycerolipids 
and sterols are significantly and consistently observed in higher relative 
concentrations in disease tissue than in neighboring non-disease tissue. These 
findings are consistent with known genetic lesions observed in NSCLC and with 
common metabolic alterations observed in cancer metabolic reprogramming.  
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 Furthermore, the change in sterol profile between disease and non-
disease has the potential to be clinically translatable. Statins and other 
mevalonate pathway altering drugs, which are known to improve outcomes in 
NSCLC patients, could be altering these lipid profiles as part of their mechanism 
of action. Although further studies are necessary to confirm this hypothesis, the 
ability to detect and quantify lipid profiles in an untargeted manner provides the 
capability to directly observe the metabolic effect of pharmacological 
interventions targeting the mevalonate, with respect to NSCLC lipid profiles.  
 Which genetic markers correlate to our observed molecular phenotype 
remains unclear, but future genomic or transcriptomics datasets from a similar 
cohort of patients combined with our lipid profiling approach could identify the 
genetic markers for this metabolic phenotype. The possibility that multiple genetic 
lesions could result in the same or similar metabolic phenotype implies that anti-
mevalonate pathway therapies could have a direct chemotherapeutic or adjuvant 




CHAPTER 6. CHEMICALLY AWARE SUBSTRUCTURE SEARCH (CASS) 
6.1 Introduction 
 The high volumes of complex spectral data generated by large scale FT-
MS metabolomics experiments require automated assignment tools such as to 
assign these datasets in an efficient manner. Untargeted tools such as SMIRFE 
are desirable to reduce assignment bias and for the assignment of previously 
unreported metabolites. However, both SMIRFE and targeted tools ultimately 
cannot assign spectral features to metabolite structures directly. At best, 
assignment tools such can only provide trustworthy isotopically resolved or 
elemental molecular formula assignments to peaks. When these assignments 
are ambiguous the set of possible metabolites corresponding to that peak is 
possibly very large but even an unambiguous assignment may represent more 
than one metabolite structure due to structural isomerism.  
 To overcome this difficulty, additional information must be obtained to 
accurately assign metabolite mass spectra to metabolite structures. Tandem 
mass spectrometry is often used to obtain chemical substructures of a given 
metabolite via its fragmentation pattern. Unfortunately, the data produced by 
tandem-MS requires very complicated, predictive algorithms for metabolite 
assignment and differences in fragmentation patterns generated by different 
instruments, in algorithms used for data analysis, and in data interpretation 
hampers the reproducibility and accuracy of these methods (Nesvizhskii et al., 
2007). However, libraries do exist for interpreting metabolomics tandem-MS data, 
 177 
 
especially when high resolution is used (Yang et al., 2017a) (Huan et al., 2015). 
Chromatographic retention times either from GC or LC can also aid in metabolite 
assignment but cannot be obtained in a direct infusion experiment. An approach 
for obtaining structural or substructural information that is compatible with direct 
infusion MS1 experiments is therefore desirable.  
 Chemoselective adduct formation (i.e. CS-tagging) refers to a family of 
techniques where metabolites are derivatized in a predictable manner depending 
upon their functional group composition. Which functional groups are derivatized 
and what derivatives are formed depends upon which chemoselective reagent or 
reagents were added to the sample. Chemoselective reagents exist for many 
functional groups present in metabolites, such as carboxylate (Ye et al., 2009), 
carbonyl (Fu et al., 2011) (Mattingly et al., 2012) amino (Guo and Li, 2009) and 
sulfhydryl (Gori et al., 2014). This derivatization process produces an identifiable 
pattern in the mass spectra that can be used to infer the presence of one or more 
of these functional groups in a metabolite corresponding to an observed spectral 
feature. These reagents can also be isotopically labeled to produce more unique 
and identifiable patterns. Although all structural isomers of the same formula will 
have the same mass, not all these isomers will have the same functional group 
composition and thus functional group composition derived from CS-tagging can 
provide limitations on which metabolites could be assigned to that feature.  
 Using untargeted assignment methods such as SMIRFE in combination 
with CS-tagging effectively provides both an assigned formula and a predicted 
functional group composition for potential metabolite spectral features in an FT-
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MS spectrum. However, the lack of functional group composition annotations in 
existing metabolite databases makes utilizing this information to aid in 
assignment difficult. The ideal solution to this problem is to add these annotations 
to existing databases which requires designing an algorithm to identify functional 
groups in database representations of metabolites (typically .mol format (Haider, 
2010)]). Tools such as CheckMol (Haider, 2016) can partially solve this problem 
but are hard-coded to only identify a pre-determined set of functional groups. If a 
functional group of interest (or another substructure) is not present in this pre-
determined list, the actual CheckMol program must be modified to include it. 
Making these modifications without introducing error limits the usefulness of this 
tool.  
 Ideally, a generalized solution that does not rely on pre-determined lists of 
functional groups is needed. Such a tool would also be useful for other 
applications beyond just functional group identification. By restating the functional 
group identification problem as a graph theory problem, in which a chemical 
structure is represented as a collection of nodes representing atoms and vertices 
representing bonds, the problem of finding functional groups becomes identical 
to the maximum common subgraph isomorphism problem in graph theory (i.e. 
given a two graphs Ga and Gb determine if Gb is a subgraph of Ga) (Raymond 
and Willett, 2002). Our algorithms called Chemically Aware Substructure Search 
(Mitchell et al., 2014) and its improved version Biochemically Aware Substructure 
Search solves the MCSI problem efficiently for chemical structures. Using these 
algorithms, functional group annotated versions of KEGG Compound and the 
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HMDB were constructed that can be queried with molecular formula and 
functional group composition.  
Additionally, the atom coloring method developed for reducing the 
computational complexity of the CASS algorithm has potential applications for 
identifying NMR equivalent nuclei and the construction of useful metrics of 
chemical similarity (Trainor et al., 2018).  
6.2 Materials and Methods 
6.2.1 Database Access and Parsers 
A copy of the HMDB database was downloaded in May 2014 as a flat file 
of concatenated and annotated .mol files (.sdf format). The KEGG Compound 
database was not available for download in any consolidated format but was 
instead web scraped using a Python program through the KEGG REST interface. 
The output from this scraping was a collection of .mol files.  
Because we could not find a recent functional group database that fit our 
design criteria (Haider, 2010; Kotera et al., 2008),we created one from scratch. 
.mol files corresponding to each functional group from CheckMol were created 
manually using JChem. Since functional group structures often have positions 
that can be occupied by a set of elements (i.e. an alkyl halide has a position that 
can be ‘any halogen’) a nomenclature for describing these conditions was added 
for our functional group mol files. Lists of valid elements for a position can be 
specified using ‘|’ while ‘!’ designates an invalid element type (e.g. “H|O|N” 
means hydrogen or oxygen or nitrogen at that position, “!H” means any element 
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but hydrogen). Additionally, functional groups often refer to specific chemical 
substructures within a larger chemical context. The carbonyl substructure -C=O 
for example is either an aldehyde or a ketone due to its surrounding chemical 
structure. These contextual atoms must be present for a chemical substructure to 
be identified but are not part of the substructure. Contextual atoms are 
designated by an asterisk (e.g. “C*” is a contextual carbon). The ability to 
designate contextual atoms allow the clean determination of overlapping 
functional groups. The descriptive abilities of this nomenclature exceed the 
simplistic wild-card atom designations in previously published chemoinformatics 
toolkits such as SMARTS (Daylight Chemical Information Systems, 2008) but 
render the mol files non-compliant with the standard. 
Our non-compliant mol files and the non-compliant mol files from the 
HMDB required developing a dedicated parser. Our parser returns for every mol 
file a molecule object which consists of multiple atom and bond objects. Internally 
atoms are uniquely identified by an integer index value. In many database mol 
files, implicit hydrogens are often excluded to reduce the size of the files. Since 
hydrogens are often part of the functional group descriptions, these implicit 
hydrogens are added in accordance to standard connectivity and valence 
methods (Weininger, 1988). This procedure does not account for pH or pK in 
these calculations and hydrogens are added to produced non-charged molecules 
unless the .mol file specifies a charge.  
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6.2.2 Adjacency Matrix Representations 
The graph theory algorithms in CASS and BASS require numerical 
representations of each chemical structure. The two most common 
representations for graph-like objects are adjacency lists and adjacency 
matrices. Both representations describe which vertices (bonds) connect which 
nodes (atoms) and they differ in their runtime and memory requirements. The list 
representation saves space but the adjacency matrix is faster for determining if 
two nodes are connected by a vertex. In the adjacency matrix representation, the 
value of the element i,j in the matrix represents the order of the bond connecting 
atoms i and j (by index) or zero if no bond exists. Thus, testing if two atoms are 
connected or not can be done in constant time by retrieving the element i, j from 
the matrix and testing if it is non-zero. Examples of adjacency matrices are 







Figure 6.1: Algorithm Overview and Example Matrices 
Chemical structures can be represented as colored graphs, which in turn can be 
converted into adjacency matrices. The diagonal of an adjacency matrix can be 
loaded with information about the nodes. A mapping matrix (M) represents which 
atoms in the functional group or substructure are mappable to the atoms of the 
larger query compound. The mapping matrix represents all possible mappings 
and thus M must be enumerated or searched to generate the specific mappings 
that represent isomorphisms (i.e. map the functional group completely onto the 
compound chemical structure). 
 
6.2.3 Substructure Search Algorithm Description 
 The starting point for the development of our algorithm was the original 
Ullmann algorithm for solving the MCSI problem (Ullmann, 1976). The presence 
of a typo in the description of the algorithm in the original manuscript and the 
presence of numerous ‘goto’ statements in the original pseudocode complicated 
our translation of the original algorithm Figure 6.2 into a modern control flow 
representation shown in Figure 6.3. We deviated significantly from the Ullmann 
algorithm during the development of CASS and BASS. 








Figure 6.2: Pseudocode and Control Flow of the Original Algorithm 
Panel A shows the original pseudocode for the Ullmann simple enumeration algorithm. “:=” denotes assignment. Panel 
B shows the control flow diagram corresponding to this pseudocode. Blue lines represent ‘goto’ statements. In modern 
computer programming, explicit goto statements are discouraged both to improve readability and maintainability but 
also to prevent errors. The variable “SKIP2B” does not exist in the original pseudocode but was needed for control flow 
purposes. 








Figure 6.3: Modernized Pseudocode and Control Flow for the Ullmann Algorithm 
Panel A shows the modernized pseudocode with better named variables and no “goto” statements. While modernizing 
the pseudocode, we identified a typographical error in line 2, step 7 in the Ullmann algorithm on page 33 of the original 
publication. This line is marked † in the pseudocode. Panel B shows the corresponding control flow structure.  




Given two adjacency matrix representations (Aa and Ab) of the graphs Ga 
and Gb representing a query metabolite structure A and a generic substructure 
B, the first step in our algorithms is the construction of the mapping matrix M 
(Figure 6.1). M has dimensions b x a where a and b are the number of atoms in 
A and B. Since B must be substructure of A, a > b. M[i,j] = 1 if atom i in B has a 
compatible element type with atom j in A and if atom j in A has as many or more 
bonds than atom i in B. M[i,j] = 0 if either condition is false. These restrictions 
greatly reduce the number of 1s in M which has a direct effect on runtime. It is 
this step where our expanded element types for our .mol files is important. If an 
entire row of M contains only zero, this means there is at least one atom in B that 
cannot be mapped to any atom in A and thus B cannot be a subgraph of A.  
 The matrix M represents all possible mappings of the atoms of B to the 
atoms A. Only a subset of the mappings of B to A represent actual 
isomorphisms. Each isomorphism corresponds to a M’ matrix that contains only 
one non-zero value per row. Possible isomorphisms can be generated by 
enumerating M to yield many M’ where each M’ represents a version of M where 
there is exactly one 1 per row. In the original Ullmann algorithm each M’ is made 
explicitly by copying the entirety of M and then modifying the elements of the 
copy. Instead, our algorithm uses two 1 dimensional vectors v and u. v records 
which atoms in B are mapped to atoms in A (v[2] = 3 means atom 2 in B is 
mapped to atom 3 in A), u keeps track of which atoms in A are currently used in 
a mapping and cannot be mapped to another atom. This approach saves 
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considerable runtime by eliminating all copying and manipulation of M. Every 
unique v where each M[v[i],j] is 1 represents a unique M’.  
 Each M’ is tested to represent an isomorphism by comparing Aa to Ab 
using the information stored in v. If (∀ 0 =< i =< |v|, ∀ 0 =< j =< |v|) ( AB i,j = AAv[ 
i],v[j] ) then v represents an isomorphism between B and A and a copy of v, v’ is 
stored in a list of known isomorphisms. This approach requires a linear number 
of operations compared to the original Ullmann algorithm that used matrix 
multiplication and thus a polynomial number of operations to test for 
isomorphism. In some applications, simply knowing that a single isomorphism 
exists is enough. In this case, our algorithm can be short-circuited to return the 
first isomorphism found. The complete pseudocode and control flow for our 
algorithm is shown in Figure 6.4. 
 







Figure 6.4: Pseudocode and Control Flow Diagram for CASS 
Panel A shows the pseudocode for our CASS (and BASS) algorithm. The lack of matrix copies and multiplication 
saves both runtime and memory. Panel B shows the control flow for CASS which is cleaner than the modernized 
Ullmann algorithm. The short-circuiting step is marked with a †. Short circuiting allows the algorithm to terminate early 
when only one isomorphism must be found. Also, partial mappings are tested during enumeration as shown in step Δ. 
This testing of partial mappings greatly reduces the amount of enumeration that occurs as most partial mappings are 
invalid and not further enumerated.   




Once the set of all v’ is known, overlaps between found isomorphisms are 
then determined. For two isomorphisms Ve and Vf, the set O = Ve union Vf 
represents the indices of A to which atoms in B are mapped. If |O| = |Ve| = |Vf| 
then Ve and Vf are equivalent isomorphisms representing mirror images of the 
same substructure. If |O| = |Vf| and |O| > 0 then F overlaps with E and if |O| = 
|Ve| and |O| > 0 then E is a subgraph of F. Understanding which functional 
groups overlap has implications for the chemical properties of the detected 
functional groups. For example, all carboxylic acids contain a hydroxyl group but 
that hydroxyl group does not have the same properties of a hydroxyl group of an 
alcohol. In this case the hydroxyl group of a carboxylic acid would be identified as 
a subgraph alcohol and this information can be carried into other analyses. 
Additionally, functional groups that have planes of symmetry such as anhydrides 
must have these mirror images accounted for to arrive at the correct counts of 
each functional group. Functional groups that do not represent a single specific 
chemical structure such as Alkyl halides are excluded from these comparisons. 
These “super” functional groups were manually identified.  
 The set of functional groups for every metabolite complete with 
“overlapping” and “subset” designations must only be calculated once. These 
results are stored in an SQLite database with a column for every functional group 
that contains the number of those groups found per database entry and the 
molecular formula for that entry. This database can be queried using information 
expected from CS-tagging FT-MS experiments. 
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6.2.4 Aromaticity and Resonance Detection 
 A feature added to the original CASS algorithm in BASS was the ability to 
describe resonant and aromatic bonds in chemical structures. Resonant and 
aromatic bonds are inferred from the KEGG atom types of the atoms. The KEGG 
atom type system assigns a string to each atom in a chemical structure based on 
the atoms to which it is bonded and the context that contains that substructure. 
For example, the oxygen of a carboxylate has the type “O6a” and the carbon of a 
carboxylate has the type “C6a” and bonds between atoms with the types “O6a” 
and “C6a” are therefore known to be resonant. Similarly, atoms of type C8x and 
N5x are within an aromatic ring so bonds between atoms of these types are 
aromatic. Resonant and aromatic bonds are represented by “R” and “A” 
respectively in a molecule’s adjacency matrix.  
 Inferring resonant and aromatic bonds in this manner is straightforward for 
entries from KEGG but entries from the HMDB and other databases do not have 
these annotations. The solution to this problem is to use CASS/BASS and a set 
of reference structures corresponding to KEGG atom types to “apply” these 
KEGG atom types to unannotated structures. Each reference structure 
represents the chemical substructure that corresponds to one or more KEGG 
atom types. Regions of a query compound that are isomorphic to a reference 
structure share the KEGG atom types of the reference structure. Thus, adding 
KEGG atom type annotations simply requires a set of reference structures that 
are properly annotated. For most KEGG atom types these reference structures 
were constructed by hand, but for aromatic KEGG atom types reference 
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structures were created programmatically. This was achieved by first finding all 
cycles in all compounds from KEGG containing only aromatically annotated 
atoms. Second any overlapping cycles in the same compound were merged until 
the set of distinct aromatic cycles are found for each compound. Third, each 
substructure in the set of aromatic cycles is then “extended” out by one bond to 
capture the local structure around the aromatic substructure. This is to account 
for electron withdrawing or adding effects of additions to the aromatic cycle. This 
process yields a set of aromatic reference graphs complete with aromatic KEGG 
atom type annotations.  
6.2.5 Node Coloring and Stereoisomer Detection 
 The CASS/BASS algorithm can also be used to determine if two 
structures are stereoisomeric by observing that a stereoisomer of a given 
structure A must be isomorphic to B when the stereochemistry of bonds are 
ignored. Testing for isomorphism is computationally very costly as effectively all 
substructures of A must be compared for isomorphism to all substructures in B. 
To minimize this cost a technique called node coloring was developed to filter out 
A, B pairs that cannot be stereoisomers of one another.  
 Node coloring assigns to every atom in a structure a ‘color’ that describes 
the local substructure around that atom out to a depth of d bonds. The depth d-
color of an atom is expressed in terms of the d-1 colors of the neighboring atoms 
and the bond order of the connecting bonds. The d0 color of an atom is defined 
as the element type of that atom. All atom colors can therefore be defined 
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recursively from this base case. Optionally stereoisomer information and charge 
information can be added to these colors. 
 If A and B are stereoisomers, the set of all dk colors observed in A must 
be observed in B since all stereoisomers contain the same substructures. If even 
a single color at depth k is observed in A but not in B, then A and B cannot be 
stereoisomers. Additionally, when constructing the mapping matrix, atoms must 
have identical dk colors to be mappable to one another. Thus, through node 
coloring many A, B pairs can be rejected outright for stereoisomerism and the 
cost of testing remaining pairs can be greatly reduced.  
6.2.6 Optimal CS-Tagging Strategy Analysis 
Although currently many CS-reagents are available to researchers, what 
the ideal set of functional groups to identify to best enable the disambiguation of 
isomeric metabolites remains unknown. Using our functional group annotated 
metabolite database, the ideal sets of functional groups to identify can be 
constructed using an iterative approach.  
 Starting with the set of all one-functional group strategies, the 
performance of that strategy is calculated by determining what percentage of the 
database entries could be uniquely identified if their molecular formula and some 
information about the number of that functional group were known. The top 50 
best-performing strategies are kept in the first iteration to create the first 
generation of parent strategies. The parent strategies are then expanded to 
generate all pairs of parent strategies with each new functional group to generate 
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new child strategies. All child strategies that do not exceed the performance of 
the parent strategy by a user-defined amount are eliminated and surviving 
strategies become the parents for the next iteration. This continues for a set 
number of iterations or until no new child strategies exceed the performance 
cutoff. As two functional groups can perform synergistically, (wherein a strategy 
with functional groups 1 and 2 performs much better than expected from 
functional groups 1 and 2 individually), the number of child strategies kept in 
each iteration must be sufficiently high to enable synergistic strategies to be 
encountered.  
 Additionally, functional group adducts may not be formed 
stoichiometrically and the ideal strategy should take this into account. For 
example, although citrate contains three carboxylates and any one (or possible 
two) of these carboxylates could be derivatized, derivatizing all three 
carboxylates is unlikely due to steric constraints. Therefore, strategy analysis can 
be performed in one of three modes: stoichiometrically – CS-tagging determines 
the exact number of a functional group in a compound, pseudostoichiometrically 
– CS-tagging can distinguish one or two instances of a functional group but three 
or more are indistinguishable, and non-stoichiometrically – where CS-tagging 
determines if at least one instance of a functional group is present or not. 
Furthermore, strategy analysis was performed considering various combinations 
of distinct, overlapping and subgraph functional groups to account for the 
possibility that CS-reagents react with chemical substructures similar to, but not 
exactly, their intended targets. The optimal strategies generated by this analysis 
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can help inform which commercially available reagents should be used in 
metabolite experiments and guide development of new reagents. 
6.2.7 Computational Platforms Used 
All timed analyses were done on three identical machines with dual Xeon 
X5650 processors @ 2.67GHz and 24 GB of 1333 MHz ECC memory running 
Fedora 18 “Spherical Cow”. All three algorithms were implemented in Perl 5.16.3 
and SQLite v3.7.13 with DBI 1.631 was used in all programs interacting with an 
SQLite database. 
6.3 Results 
6.3.1 Computational Performance of CASS/BASS 
The performance of the Ullmann algorithm and our algorithm for a set of 
representative database compounds and functional groups are shown in Figures 
6.5 and 6.6. The runtime required to identify instances of functional groups in 
these compounds depends largely on the number of possible node mapping 
count (m, the sum of all entries in the M matrix) which is summarized in Table 
6.1. In all examples, the Ullmann algorithm is slower than our algorithm for the 
same inputs. Additionally, the runtime of the Ullmann algorithm depends on m in 
an exponential manner while our algorithm has a pseudo-linear dependency on 
m. This pseudo-linear dependency becomes clearly polynomial (of degree 2 with 
an R2 of .99944) when the time needed to identify alkenes in each compound in 
the HMDB is plotted versus m for each compound. This polynomial behavior, if 
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rigorously and mathematically confirmed, could have implications for the ongoing 
debate regarding the theoretically best computational complexity achievable for 
the common subgraph isomorphism problem (Schöning, 1987) (Torán, 2004).  
 Short circuiting improves the runtime of our algorithm’s performance 
sporadically but sometimes dramatically (Figure 6.7). The benefit of short 
circuiting is difficult to predict as the order in which M is enumerated determines 
when short circuiting can occur. Short circuiting can have a dramatic 
improvement on the time needed to confirm that two structures are 
stereoisomers compared to the non-short-circuiting variant (Supplemental Table 
6.1). For stereoisomers, node coloring out to a depth of 4 bonds substantially 
reduces the possible node mapping count further enhancing the performance of 
CASS for stereoisomer detection.  
Table 6.1 Possible Node Mapping Counts for Test Compounds and Functional 
Groups 
Possible node mapping count (m) 
Database compounds Functional group 
 CA Epoxide Alkene Alcohol 
Deoxycytidine 46 22 18 26 
R-3-Hydroxybutyric acid 25 11 8 15 
2-Hydroxybutyric acid 25 11 8 15 
Deoxyuridine 47 23 18 26 
1-Methylhistidine 34 16 14 20 
Cortexolone 84 46 42 155 
2-Methoxyestrone 71 41 38 46 
Deoxycorticosterone 70 45 42 43 
1,3-Diaminopropane 18 6 6 13 
2-Ketobutyric acid 23 11 8 13 
Table 6.1: Possible Node Mapping Counts for Test Compounds and Functional 
Groups – the value of the possible node mapping count is shown for every 
compound, functional group pair. Larger values of m represent more possible 





Figure 6.5: Runtime Analysis of the Ullmann Algorithm 
In all cases, the time needed for the Ullmann algorithm to find all instances of a 
functional group in a query compound requires exponential time with respect to 
m. Alkenes (C) were relatively quick to identify compared to the other functional 
groups (A,B,D) but still had an exponential trend. These finding imply that the 
Ullmann algorithm’s runtime does not scale sufficiently well to enable the 





Figure 6.6: Runtime Analysis of the CASS Algorithm 
The time needed for CASS to identify the instances of functional groups in the 
test compounds appears pseudolinear for small values of m (A, B, C, D). 
Pseudolinear scaling represents a significant improvement over the Ullmann 
algorithm’s exponential scaling. Additionally, the CASS algorithm was 
significantly faster in absolute time than the Ullmann algorithm for the same task. 
The ability of the CASS algorithm to scale to large comparisons is shown in 
panel E. The time needed to find all alkenes in the HMDB demonstrates that 
CASS actually has polynomial scaling with respect to m but will remain 





Figure 6.7: Effects of Short Circuiting on CASS Runtime 
Short circuiting allows CASS to terminate the search for isomorphisms when the 
first isomorphism is found. When the number of possible isomorphisms is large, 
short circuiting can save a large amount of time, but when they are relatively 
rare, the effect is minimal. This effect explains why common functional groups 
such as Alkenes show a substantial time improvement with short circuiting but 
epoxides do not. Short circuiting is most suitable for determining 
stereoisomerism.  
 
6.3.2 Systematic Isomer and Stereoisomer Analysis 
Using our combined HMDB and KEGG metabolite database the number of 
distinct molecular formulas in each database and shared between both 
databases were determined. This identified 6094 formulas unique to the HMDB, 
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5521 unique to KEGG and 3788 formulas shared between the two databases. 
These shared formulas were then tested to determine if they were isomers in 
neither, both or only of those databases. This identified that 39% of these 
formulas were isomers in neither, 32% were isomers in both and 29% were 
isomers in only one database.  
Additionally, the trend in isomeric content over time in both databases and 
our combined database were determined. The HMDB’s isomeric formulas 
content and our combined database has plateaued at 43 and 46% respectively. 
KEGG has reached a 28% isomeric content. The inclusion of pharmaceutical and 
synthetic compounds in KEGG possibly explains this observation. Additionally, in 
all three databases, the number of isomeric entries is much larger than the 
number of isomeric formulas, implying that on average a single isomeric formula 
is represented by several isomeric entries in the databases (Figure 6.8).  
The composition of the databases with respect to stereoisomerism was 
determined as well. Entries with duplicate names were excluded from this 
analysis as they likely represent identical compounds. The HMDB and KEGG 
both include stereoisomers with 1.14% and 9.43% of each database consisting of 
stereoisomers. The combined database has a percent stereoisomerism of 8.3%. 
This difference can again be explained by the portions of the metabolome 
represented by each database. The HMDB contains mostly lipids which have 
many structural isomers but few stereoisomers, while KEGG has many sugars 




Figure 6.8: Isomer Distribution in HMDB and KEGG 
Shown in panel A is the distribution of isomeric compounds per formula in the 
HMDB. In the HMDB, many isomeric formulas correspond to more than 40 
compounds and some have more than 100! This is largely due to the presence 
of many isomeric lipids in the HMDB that share the same formula. The 
distribution is very different in KEGG as shown in panel B. Only three formulas in 
KEGG map to more than 35 formulas. This implies that compounds in KEGG will 
be easier to disambiguate than compounds in HMDB using CS-tagging and 
elemental molecular formula. This also implies that lipids as a category could be 
more difficult to disambiguate with CS-tagging than other classes of metabolites.  
 
6.3.3 CS-Tagging Strategy Analysis 
The optimal strategies for 3,5, 10 or 15 functional groups under 
stoichiometric, pseudostoichiometric and non-stoichiometric conditions with 
different allowed forms of overlap were determined. In all analyses, a maximum 
of 15 iterations were performed with the top 15 strategies kept in subsequent 
iterations and a performance cutoff of 0.1%. Without CS-adduct formation, only 
17.13% of compounds in the combined database and 40.98% of compounds in 
the KEGG database can be identified from molecular formula alone. This 
represents the baseline performance against which different strategies can be 
compared. Furthermore, functional group information will be unable to resolve 
stereoisomers and thus the maximum performance of any strategy is the percent 
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of compounds in each database that have no stereoisomer which represents 
91.7% of the combined database and 90.6% of KEGG. 
 Stoichiometric CS-tagging consistently generated the best increases in 
percent unambiguously assignable compounds with the ideal strategy of 3 
functional groups improving assignment coverage from 17.13% to 30.35% in the 
combined database and from 40.98 to 61.63% in the KEGG database. Strategies 
with 15 functional groups achieved 36.67% in the combined database and 
69.13% in the KEGG database. Allowing for the detection of overlapping, 
subgraph or super functional groups only offers minimal improvement; less than 
1% for 3 functional groups and less than 2.5% for strategies of 15 functional 
groups.  
 Non-stoichiometric strategies unsurprisingly provide the worst 
improvements in assignment accuracy. The 3 functional group strategy under 
non-stoichiometric conditions enables 23.18% unique assignment in the 
combined database compared to 30.35% for stoichiometric. A similar decrease 
occurs in the KEGG database as well. For non-stoichiometric strategies detection 
of overlapping groups offers only marginal improvement as well. As with 
stoichiometric strategies a point of diminishing returns is reached after 10 
functional groups.  
 Neither stoichiometric nor non-stoichiometric CS-tagging is expected. 
Pseudostoichiometric CS-tagging likely best represents expected patterns of CS-
tagging. In general, pseudostoichiometric strategies perform slightly worse than 
stoichiometric strategies and much better than non-stoichiometric ones. The 
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optimal strategy of 3 groups allows for the unique assignment of 28.37% and 
59.32% of compounds in the combined and KEGG databases and increases to 
35.83% and 68.13% respectively with 15 groups. Again, overlap detection 
provides few improvements.  
 Strategies using only the super functional groups under stoichiometric, 
pseudostoichiometric, and non-stoichiometric conditions all performed poorly. 
During enumeration the algorithm terminated early in most cases due to the 
performance cutoff.  
 The most common functional groups in strategies with five or fewer 
functional groups are alkene, methyl, ketone, carboxylic acid, dialkyl ether and 
enol. The performance of these functional groups alone is shown in 
Supplemental Tables 6.2, 6.3 and 6.4 for stoichiometric, pseudostoichiometric 
and nonstoichiometric adduct formation for the KEGG and combined database. 
Reagents capable of derivatizing these functional groups in a detectable manner 
are optimal for disambiguating metabolite assignments and reagents already 
exist for most of these functional groups. No CS-tagging reagent exists for methyl 
groups nor can one be easily developed due to the groups lack of reactivity. This 
strongly suggests that direct infusion mass spectrometry combined with CS-




6.3.4 BASS Reliably Identifies KEGG Atom Types 
 Using the set of manually constructed and generated reference graphs for 
the KEGG atom types, KEGG atom types can be predicted. Recapitulating the 
KEGG atom types on all the KEGG entries resulted in a 97.5% agreement 
between the database annotated types and the predictions. Manual inspection of 
a subset of the entries where disagreement was observed revealed that the 
database atom types were inconsistent with their descriptions from the KEGG 
website. Three common errors were observed explaining these discrepancies: 
failure to detect a cycle in a compound, confusion between esters, carboxylic 
acids and their sulfur analogues, and inconsistent application of atom types to 
aromatic atoms. The agreement between the BASS-assigned atom types and the 






Figure 6.9: BASS-predicted KEGG Atom Types versus KEGG Atom Types 
BASS predicted KEGG atom types agree with the database assigned atom types 
for the majority of the atoms in KEGG database. Where disagreements are seen, 
they are the result of KEGG incorrectly applying their rules to the structures. 
Notably, many cyclic structures are missed by the KEGG entries and many 
atoms have annotations corresponding to other element types.  
 
6.3.5 Atom Coloring Identifies Possible NMR Equivalent Nuclei 
When the optional charge, stereochemistry and isotope fields are added to 
atom colors, the resulting colors are highly descriptive of the substructure 
centered at that atom. As a result, atom coloring is useful whenever comparisons 
between local structure are needed and this use case extends beyond 
CASS/BASS.  
One application is the need to identify potentially magnetically equivalent 
nuclei within a chemical structure. Nuclei located within the same chemical 
substructure are highly likely to be magnetically equivalent. For the case of 
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hydrogen and J-coupling the local structure out to three bonds (i.e. 
corresponding to the d2 color) of the nuclei describes its relevant substructure. 
Atoms with identical colors reside in the same chemical substructure and 
excluding effects from the 3D arraignment of the nuclei, are likely to represent a 
single spectral feature. For example, the hydrogens of the red methyl groups in 
Figure 6.10C will likely produce identical sets of 1H-NMR signals with the same 
relative intensity and splitting patterns. Thus, by coloring all nuclei in a molecule 
at d2 then finding sets of identically colored nuclei, a subset of nuclei with similar 
J-coupling patterns can be identified; however, additional work is needed to 
account for effects beyond 2D substructure similarity (e.g. this will not detect 
diastereotopic protons). This use of atom coloring has been incorporated into 






Figure 6.10: Possible NMR Equivalent Nuclei Predicted by Atom Coloring 
The d0-d2 colors of selected nuclei are shown in panel A. Each color contains 
charge information (green) and isotope information (red) if the nuclei is not the 
most abundant isotope of that element. Panel B shows groups of equivalent 
nuclei identified by atom coloring when one methyl carbon is labeled with 13C. 
Panel C shows the same result when that methyl group contains 12C. Not all 
identically colored atoms are equivalent due to effects that extend beyond simple 
substructure but atom coloring does make an efficient screening test to identify 
possible equivalent nuclei automatically.  
 
6.3.6 Application of Atom Coloring Based Structural Similarity Metrics 
 Additionally, atom coloring can provide a mechanism to estimate the 
structural similarity between a pair of compounds. First all atom colors out to a 
depth of N are generated for all atoms in the pair of compounds. Second, all 
atom colors at depth N are collected for all atoms in the compound to give a list 
of atom colors. Third, the Tanimoto coefficient between the list of colors in 
compound A and compound B are calculated(Chen and Reynolds, 2002). This 
returns a value between 0 and 1 that estimates overall structural similarity by 
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comparing the substructure similarity between two compounds. This structural 
similarity metric has been successfully applied for the construction of a reference 
metabolite interaction network in coronary artery disease  (Trainor et al., 2018).  
6.4 Discussion 
 Our new algorithms, CASS and its more capable version BASS, 
significantly outperform the Ullmann algorithm in finding subgraph isomorphisms 
in chemical structures. The stark difference in the performance of CASS/BASS 
compared to the Ullmann algorithm highlights that despite being the prototypical 
solution to the common subgraph isomorphism problem, its performance makes 
it unsuitable for solving this problem on all but trivial structures. Additionally, in 
the process of modernizing the Ullmann algorithm, a typographical mistake was 
found in the original publication.  
 Using our algorithm, a functional group annotated versions of KEGG and 
the HMDB were created that can be queried with information expected from FT-
MS CS-tagging. Storing these databases as SQLite provides several advantages 
such as portability, easy of query and improvements in database access speed. 
Furthermore, the custom mol file format created for functional group descriptions 
enables the description of complex substructures within a chemical context. 
Furthermore, these substructure descriptions can be created on the fly and 
searched for using CASS without any changes to CASS’s code.  
 Analyzing the functional group annotated databases revealed a high 
percentage of isomeric molecular formulas in both databases, highlighting the 
 207 
 
need for techniques such as CS-tagging for FT-MS. Additionally, a high 
percentage of stereoisomers (9%) were observed in both databases. These 
compounds are unresolvable using current CS-tagging and FT-MS methods and 
thus limit the maximum percentage of compounds that can be unambiguously 
assigned using these methods. However, stereospecific CS-reagents are not 
inconceivable – chiral resolving agents already exist for disambiguating 
enantiomers (Vincent and Vigh, 1998). Our analysis of CS-tagging strategies 
reveals that a set of only three or five reagents when multiplexed can 
substantially increase the ability to unambiguously assign metabolites provided 
their elemental molecular formulas are known accurately. Tools such as SMIRFE 
can provide these formula assignments. CS-tagging was substantially less 
effective in the HMDB than in KEGG largely due to the large number of isomeric 
lipids in the HMDB. Resolving isomers of lipids will require additional methods 
that identify more specific chemical substructures in this class of molecules.  
 The dramatic differences in the formula content of the HMDB and KEGG 
illustrate the potential biases of targeted FT-MS assignment. Only 24% of the 
total formulas between the HMDB and KEGG exist in both databases, implying 
that features that are not assignable by one database may be assignable by 
another. Additionally, the observation that some of the shared formulas are 
isomers in one database but not the other suggests that falsely unambiguous 
assignments can be generated if only one database is used for assignment. 
These findings not only strengthen the case for untargeted tools such as 
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SMIRFE but also that if targeted assignment is unavoidable, multiple databases 
should be used to prevent misassignment.  
 While originally designed only to accelerate stereochemistry calculations, 
the atom coloring methods found several additional applications outside of the 
original CASS algorithm. The ability to describe chemical substructures 
succinctly as an atom color string rather than as a graph, enables easy 
comparisons between different atom colors as a proxy for substructure 
comparisons. The ability to automatically identify potentially NMR equivalent 
nuclei will greatly improve the automaticity of NMR analysis tools while the ability 
to provide numerical estimates of structural similarity through substructure 
similarity has a variety of applications. The atom coloring structural priors that 
were generated for Bayesian graphical models could be applied to any modeling 
approach where a similarity score is needed for a pair of compounds.  
6.5 Conclusions 
 CASS and BASS represent a substantial improvement both 
computationally and in terms of their capabilities over the original Ullmann 
algorithm for identifying subgraph isomorphisms. Our algorithms were employed 
to identify and quantify instances of functional groups in every metabolite entry 
from the HMDB and KEGG as well as stereoisomeric entries in these databases. 
The results of this analysis were used to construct a functional group-annotated 
version of both databases as well as a combined HMDB and KEGG database. 
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 From this combined database it was determined that a large percentage of 
the metabolome represented by the database was isomeric and not 
unambiguously assignable from elemental formula alone. Using just 3 or 5 CS-
reagents in multiplex to partially determine the functional group composition of 
the compounds combined with accurate elemental molecular formula 
assignments significantly increases the percent of unambiguously assignable 
metabolites. Stereoisomers, which represent 9% of the metabolome, cannot be 
disambiguated using existing CS-reagents. The differences in the formula 
content between the HMDB and KEGG were dramatic, highlighting the need for 
untargeted tools that are not biased towards their databases for assignment of 
FT-MS spectra.  
 Finally, the atom coloring methodology developed to accelerate certain 
calculations in CASS and BASS has applications outside of this algorithm. The 
atom coloring techniques are useful for describing and comparing chemical 
substructures and have been used to identify NMR equivalent nuclei and to 





CHAPTER 7. CONCLUSION 
The untargeted assignment of FT-MS metabolomics datasets represents a 
significant unsolved problem in the metabolomics community. Existing 
assignment tools are largely targeted methods that rely upon databases of 
metabolites for assignment and are therefore ill-suited for discovering new 
metabolites. Additionally, the incompleteness of and inconsistency between 
databases can introduce significant assignment bias that can have significant 
effects on downstream data analysis. Existing untargeted assignment tools on 
the other hand are either not untargeted in a meaningful sense or rely upon 
heuristics and other rules that render them unusable in a stable-isotope tracing 
context. Furthermore, the presence of spectral artifacts and poor data quality in 
many FT-MS datasets make both assignment methods prone to misassignment 
and significant interpretative errors. Towards this end, a collection of tools was 
developed that address these data quality issues and the short comings of 
existing assignment tools.  
 The FT-MS spectral artifact detection tools identified a family of FT-MS 
artifacts that we named high peak density artifacts. These artifacts result in 
regions of spectra that have significantly higher peak density than the rest of the 
spectrum. The poor correspondence of peaks in these regions across multiple 
scans (peaks in these regions appear, disappear, and move around considerably 
in m/z between scans), the m/z difference patterns between these peaks, and the 
observation that the location of these regions depends both on sample 
 211 
 
composition and instrument and firmware versions all strongly support our claim 
that these features are artifactual. Spectral artifacts by themselves are 
undesirable, but not necessarily problematic, if they are not assigned; however, 
we observed that targeted assignment tools such as LipidSearch will assign 
these features. Because the location of these artifacts is sample-specific, these 
artifactual features allow for the classification of spectra into sample classes 
using machine learning models such as Random Forest. Ultimately classifiers 
that utilize these assigned artifactual features are both brittle and do not 
represent the real biochemical variance between the sample classes.  
 To eliminate these artifactual features, two methods were developed. The 
first of these was to remove regions of spectra that consistently contain these 
features across all spectra in the dataset. A cross-sample methodology for 
artifact removal was necessary for two reasons. First, our high-peak density 
artifact detection method was highly sensitive, but not very specific. Removing 
only regions of spectra with consistently identified artifacts minimizes the amount 
of unaffected spectra that is removed. Second, when artifactual regions of 
spectra are removed from each sample individually, this process will encode the 
presence of artifacts as the absence of peaks in parts of the spectra. In turn, this 
encoded information can trick the machine learning models in a similar to manner 
to the presence of the artifacts themselves. Thus, by removing consistent artifact 
regions across all samples, the specificity of our approach is effectively increased 
and the accidental encoding of spectra is prevented.  
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 The second method for eliminating these artifacts was the improved peak 
correspondence and peak characterization. Since artifactual peaks in fuzzy sites 
have low peak correspondence across scans, many of them can be eliminated 
using the peak correspondence algorithm (i.e. by detecting their poor 
correspondence). Peak correspondence and characterization also provide much 
better estimates of peak intensity by correcting for inconsistent injections and 
ionization efficiencies between scans. This has the notable effect of greatly 
reducing the variance in observed peak intensities at the aggregate peak list 
level. This approach does not result in absolute peak intensities that are 
comparable to one another, but it is necessary for comparisons of relative peak 
intensity between peaks – which was necessary for our SMIRFE assignment 
tool. Additionally, unlike other peak picking methods that only return an observed 
m/z and intensity for each detected peak, peak characterization provides 
statistical estimates of a peak’s m/z and intensity, along with the variances of 
those values across scans as well as in which scans a peak is present.  
 With many of the data quality problems in our FT-MS spectra resolved 
with peak correspondence and characterization, a novel algorithm for the 
untargeted assignment of FT-MS metabolomics datasets called SMIRFE was 
developed. SMIRFE does not use a database of known metabolites or even 
known compounds to generate assignments, rather SMIRFE searches a nearly 
exhaustively large EMF search space that represents all possible formulas within 
a defined region of theoretical chemical space. Other assignment tools typically 
query their databases with observed m/z values and a tolerance to generate 
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assignments for a peak, which is inherently error prone due to the lack of cross 
validating evidence supporting a returned assignment. SMIRFE uses m/z-based 
queries to generate possible assignments for peaks, but then compares the 
observed peak intensities between potential isotopologues of the same EMF to 
eliminate unlikely assignments and to assign statistical estimates of assignment 
quality. The relative intensity ratio between isotopologues can be predicted using 
the natural abundance probabilities of the isotopologues and these predictions 
can be calculated, taking the effects of isotopic labeling into consideration. As a 
result, SMIRFE can assign datasets from stable-isotope tracing experiments with 
no changes to the underlying algorithm. This methodology could be added to 
existing targeted tools based on metabolite databases to improve their 
assignment accuracy.  
 In our test case consisting of a mixture of isotopically labeled and 
unlabeled amino acids derivatized with ECF, SMIRFE was able to assign 18 of 
19 predicted amino acid derivatives. Manual examination of the spectra 
demonstrated that the unassigned derivative corresponding to cysteine was not 
present in the spectra for those samples, implying that SMIRFE assigned all the 
predicted amino acid derivatives present in each spectrum. From this set of 
assignments, the m/z accuracy of the peak lists generated by our peak 
characterization method was examined and found to be below the 1ppm error as 
advertised by the instrument vendor. However, the mass error pattern is not 
constant with respect to m/z and appears to change based on a peak’s proximity 
to one or more other intense peaks. As shown in our simulations, if mass 
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accuracy can be increased from 1ppm to 0.1ppm or even 0.01ppm, the number 
of possible assignments for each peak can be greatly reduced. Improved mass 
accuracy will be necessary for generating unambiguous assignments at high m/z. 
By correcting both the m/z dependent and the repulsion dependent mass error 
we observed, improved mass accuracy can be achieved.  
 As SMIRFE requires well characterized peaks with low mass error in order 
to generate less ambiguous assignments, experiments can be optimized to 
maximize their compatibility with the SMIRFE algorithm. Future experiments 
seeking to use SMIRFE should dedicate more acquisition time towards MS1, as 
MS2 data is not used currently in SMIRFE, and the number of scans acquired 
should be maximized. The optimal settings for microscan settings remain 
unknown. High dynamic range is desirable to observe the most isotopologues 
possible for each EMF, but only if the tradeoffs in mass and intensity accuracy 
that accompany higher dynamic range are minimal. Finally, when isotope 
labeling experiments are performed, unlabeled controls should be included in 
replicate for each population. 
 While these changes in experimental design can improve the accuracy of 
SMIRFE assigned IMFs and EMFs to observed spectral features, SMIRFE still 
suffers from one significant limitation – it does not assign metabolite structures to 
spectral features. Even if IMF and EMF assignments could be made with perfect 
accuracy, the prevalence of isomers for many metabolites implies that formula 
assignments will not map uniquely to metabolite structures. Fundamentally, this 
limitation arises from the inability of mass spectrometry alone to differentiate 
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isomers and if metabolite structure assignment is necessary, orthogonal 
information will be required.  
 The inability to assign metabolite structures to observed spectral features 
assigned by SMIRFE originally limited our ability to perform differential lipid 
analysis in our non-small cell lung cancer data set. Traditionally, lipid metabolite 
features are identified by querying databases of known lipids with observed m/z’s 
from experiments then inferring the class or category from the database. 
Obviously, this approach is not suitable for SMIRFE as it undermines much of the 
untargeted nature of the approach. To solve this problem, machine learning 
models were built to predict lipid category and class from assigned formulas 
directly. For all categories, these models achieved excellent accuracy and 
precision implying that for distributions of formulas similar to those observed in 
existing metabolite databases, trustworthy predictions of lipid category and to a 
lesser extent, lipid class, can be generated.  
Applying these models to large sets of formulas generated from a convex 
hull of HMDB formulas demonstrated that these models have difficulty generating 
trustworthy assignments for formulas that are significantly dissimilar from the 
training dataset. For example, formulas with multiple sulfur and phosphorus can 
classify but also are unlikely to exist. Similarly, large mass errors in spectra will 
result in incorrect assignments that still classify for much the same reason. Due 
to the large search space of SMIRFE almost any pair of peaks corresponding to 
a pair of isotopologues will be assigned to IMFs, but the assigned IMFs will only 
be limited to the correct IMFs when the mass error is relatively small. Eliminating 
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the extra untrustworthy assignments can be achieved through a combination of 
heuristics and cross-sample assignment correspondence. Incorrect formula 
assignments tend to correspond less well across samples than correct 
assignments, but inferring this pattern requires many samples. Improvements in 
peak characterization and / or instrumentation that result in improved peak 
intensity measurements will also reduce the inclusion of incorrect formula 
assignments.  
This sample correspondence method was successfully used in our lung 
cancer dataset (which contains ~180 samples) to filter out many inconsistent 
assigned features. Differential abundance analysis on lipid classified consistently 
assigned features revealed a subpopulation of NSCLC samples with substantially 
up-changed relative concentrations of sterol categorized features. These findings 
were consistent with previously reported observations in the scientific literature 
that have reported that NSCLC survival is improved in patients using statins, a 
class of drugs that inhibit the mevalonate pathway and interfere endogenous 
sterol production. To-date these findings have simply been observational. Statins 
have no clinically indicated use in cancer but due to the large number of patients 
prescribed statins for the treatment of high cholesterol or prophylactically in 
patients with a history or at risk for cardiovascular vascular disease, a significant 
number of lung cancer patients happen to be prescribed statins. While further 
testing is necessary to confirm our findings, if sterol upregulation is crucial to the 
development of a subpopulation of NSCLC, which currently lacks effective 
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treatments for late stage disease, statins provide a potential therapeutic option 
that should be explored.  
CS-tagging represents one method by which additional structural 
information could be obtained in direct infusion FT-MS experiments that is 
compatible with SMIRFE or other assignment methods. Through CS-tagging, the 
partial functional group composition of compounds can be determined and this 
information used to limit possible assignments to metabolite structures with those 
functional groups. The lack of a functional group annotated metabolite database 
however made leveraging the information that could be gained from CS-tagging 
for metabolite assignment effectively impossible. Towards this end, we 
developed algorithms that can identify substructures within chemical structures 
efficiently and used these algorithms to build a functional group annotated 
database of metabolites. Additionally, with these databases, the set of ideal 
functional groups to target for CS-tagging was identified. The mathematical 
formulation of the chemical substructure identification problem called the 
maximum common subgraph isomorphism problem is a widely encountered 
problem in graph theory and our algorithms provide best in class performance for 
this problem. Furthermore, the mathematical tools developed to tackle this 
problem have uses in a much wider context of chemoinformatics problems. The 
atom coloring algorithms in particular have applications in NMR and in the 
construction of metabolite interaction networks. Ultimately, these mathematical 
tools will be helpful in the construction of atom-resolved metabolic networks that 
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will allow the automated deduction of atom tracing through the metabolic 
network.  
In conclusion, these tools form a prototype FT-MS data analysis pipeline 
that is suitable for large scale metabolomics experiments utilizing stable-isotope 
tracing. Better quality peaklists with more reliable spectral features can be 
generated and then assigned in an untargeted manner. These formulas can be 
assigned to biologically meaningful metabolite categories and classes using 
machine learning and then used in differential abundance analyses to identify 




CHAPTER 8. FUTURE DIRECTIONS 
 In their current state, the tools described herein form a prototype FT-MS 
data analysis pipeline that could be used to power untargeted analyses of 
disease and non-disease metabolism. However, improvements in several key 
areas for each tool could dramatically improve the overall performance of this 
pipeline and expand the set of experiments to which it can be applied.  
8.1 Determining the Origin of Fuzzy Site Artifacts 
 Although our methods for handling spectral artifacts identify and eliminate 
fuzzy sites from FT-MS spectra, the source of the fuzzy site artifacts remain 
largely unknown. Our leading hypothesis for the cause of fuzzy site artifacts is 
radio frequency interference from the nanoelectrospray system. This would 
explain why the artifact locations are different between instruments (i.e., they 
have different ESI systems) and why the artifacts differ based on sample 
composition, as the electrospray system changes the pulses used for ionization 
depending on sample conditions. One approach to testing this hypothesis is to 
swap the electrospray systems on our two instruments and test if the artifact 
locations also “swap” on a solvent-only sample. If the fuzzy site locations appear 
to “swap”, this strongly suggests that the root cause of these artifacts is the 
electrospray system. If the fuzzy site locations remain the same, this suggests 
that the instruments themselves may be the cause. Additionally, since the 
appearance of these artifacts change with both microscan and resolution 
parameters on the instruments, these could be optimized to identify the settings 
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that minimize the severity of these artifacts. Although both peak characterization 
and artifact removal largely eliminate these artifacts, preventing these artifacts in 
the first place is desirable.  
8.2 Peak Characterization 
 Currently, peak characterization greatly improves the consistency of 
reported peak intensities and is a necessary step to assign peaklists using 
SMIRFE. However, the ability of SMIRFE to generate unambiguous assignments 
at high m/z is largely limited by the mass accuracy of the instrument. A 1ppm 
mass error, while small compared to other mass spectrometry techniques, 
translates into a large range of possible assignments at high m/z that cannot be 
disambiguated without substantial improvements in intensity accuracy or a 
modest improvement in mass accuracy. Peak characterization could potentially 
be modified to improve mass accuracy in one of two non-mutually exclusive 
ways.  
 First, if replicate spectra are collected across multiple instruments that 
have slightly different mass accuracy profiles, this information could be used to 
shift peaks toward their true m/z. For example, if instrument one has an 
increasing positive mass error across m/z and instrument two has an increasing 
negative mass error across m/z, a corresponded peak found in spectra from both 
instruments has a true m/z in between the two reported m/z’s from both 
instruments. Determining this mass error profile could be achieved using large 
amounts of replicate spectra and correspondence or with standards added to 
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each sample. Standards introduce potential artifacts but is the most 
straightforward way to determine the mass accuracy pattern on an instrument. 
 Alternatively, common contaminants such as plasticizers and keratin could 
be used as internal calibrants and used to calibrate a spectrum after acquisition. 
Some forms of chemical contamination are effectively impossible to eliminate 
and are likely to behave similarly in samples of similar composition. This 
approach could be used in conjunction with peak correspondence in lieu of 
traditional standards, but would require an iterative process of assigning spectra 
to identify contaminants and correcting based on assigned contaminant peaks 
before reassigning.  
 Additionally, if peak correspondence could be adapted to work with GC or 
LC-MS experiments, additional measurements of peak intensity could be 
obtained from the chromatographic peak areas. Noise and artifactual peaks 
could be eliminated by observing that they do not correspond to a 
chromatographic peak as well. This would have the additional benefit of opening 
up our methods to the broader metabolomics community who largely utilize GC 
or LC-MS experiments instead of direct infusion.  
8.3 Optimizing Experimental Designs for Peak Characterization and 
SMIRFE 
 Although improvements in peak characterization will ultimately provide 
more descriptive peaklists that will improve SMIRFE assignments, there is no 
substitute for better quality raw data. Currently, SMIRFE and the related tools 
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have only been applied to spectra that were acquired without the limitations of 
our methods in mind and thus the spectra we have worked with so far were 
collected using various numbers of scans, microscans, resolutions, etc. and the 
number of replicates in each experimental dataset has varied significantly. 
Quantifying the effects of changing each of these parameters with respect to 
assignment accuracy and cross-sample assignment correspondence provides a 
mechanism by which optimal values for these parameters can be determined.  
Therefore, a set of experiments should be performed to identify the ideal 
values of microscan and total ion target for a target spectrum acquisition time. 
Blood plasma lipid extracts would be an ideal candidate for these experiments 
given that it is biological in nature, reasonably complex and cheap. These 
spectra would be peak characterized and assigned with SMIRFE. The settings 
that produce the best e-values for validated assignments and produce the best 
intensity relative standard deviations (RSDs - standard deviation divided by 
mean) and smallest m/z errors represent the optimal settings. Validated 
assignments could be confirmed using CS-tagging.  If the settings that are 
optimal for intensity RSD are not optimal for m/z accuracy (or vice versa), a 
family of optimal settings could be identified and applied on a per-experiment 
basis. Additionally, the effect on cross-sample assignment correspondence could 
be investigated with a sufficiently large number of replicates.  
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8.4 Improving SMIRFE Improvements through Improved Scoring 
 The high mass error with respect to the mass resolution currently limits the 
statistical comparisons that SMIRFE can use to disambiguate possible 
assignments. If the mass error was relatively small compared to the mass 
resolution, the window of possible assignments could be tested by comparing the 
absolute mass difference between a peak’s m/z and a possible assignment’s m/z 
based on the resolution of the peak. Combined with existing tests on the relative 
intensity of peaks versus the expected ratio based on natural abundance 
probabilities, the field of possible assignments for a peak could be greatly 
reduced.  
 Scoring could also be improved by including a metric that compares how 
close an assigned formula resides to a known metabolite formula in EMF space. 
Formulas that are very similar to known metabolites will have better scores in this 
system, while formulas very different from known metabolites will have smaller 
scores. This would bias results towards formulas that are similar to known 
metabolites but could significantly disambiguate assignments. Furthermore, 
when sufficient evidence is present, the components of the score from m/z 
matching and intensity ratio matching could overcome this weighting to enable 
the assignment of novel metabolites when there is sufficient spectral evidence.  
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8.5 Investigating Lipid Profiles observed in NSCLC Samples 
 Our findings that sterols and glycerolipids were significantly up-changed in 
a sub-population of NSCLC implies that statins or other sterol altering drugs 
could have potential therapeutic effects in some NSCLC patients. However, it is 
not clear from which upstream mutations this metabolic phenotype results. 
Understanding the genetic drivers of these metabolic differences will be 
necessary to identify these patients clinically using genomics methods. 
Identifying these mutations will require genomic or transcriptomic data that could 
be acquired from additional patient samples. Of interest would be if the observed 
mutation patterns are mutually exclusive with other known mutation patterns in 
subtypes of NSCLC. This would suggest that the mutations that are responsible 
for this molecular phenotype are in fact drivers of NSCLC rather than just a 
byproduct of other upstream genomic changes. Enzymes and proteins in these 
pathways are potential drug targets if the upchanged sterols and glycerolipids are 
important for cancer development. 
 Additionally, our hypothesis that statins could be used therapeutically in 
this subtype of NSCLC can be tested experimentally. Patient tumors could be 
analyzed using the existing methodology to identify cancer samples with this 
molecular phenotype. These samples could then be cultured with and without 
various statins to observe if an effect is observed on the growth of the cancer 
cells derived from these tumors. However, differences between cell culture 
versus in vivo cancer could limit the accuracy of cell culture testing of statins with 
respect to clinical performance. 3D cell culture may be a potential remedy to 
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some of these discrepancies (Riedl et al., 2017). Alternatively, patient-derived 
xenograft mice models could be used, although these are likely to have other 
different limitations (Hidalgo et al., 2014). Additionally, using stable isotope 
tracing, changes of 13C incorporation into sterols would confirm if statin treatment 
influences sterol biosynthesis in the samples when cholesterol uptake from the 
diet is controlled. If an effect is observed with statin exposure on tumor growth 
discriminating between a cytotoxic or cytostatic effect will be necessary. These 
can be distinguished from one another using measures of cellular respiration 
(Cummings and Schnellmann, 2004), cell morphology (Bortner and Cidlowski, 
2001) (Zhang et al., 1999), or the presence of cellular components in the 
extracellular space.  
 A potential prophylactic role of statins could be investigated using 
chemically inducible lung cancer models in mice (Safari and Meuwissen, 2015). 
While the chemically inducible forms of lung cancer likely differ from the cancers 
present in human patients, if statin exposure prolongs survival in the mouse 
models significantly, this suggest a possible prophylactic role. While this is a long 
shot, if statins have a prophylactic role in at risk NSCLC patients (namely former 
smokers), the potential healthcare implications would be enormous.  
 One further aspect of the lipid profile differences to investigate is the 
possibility of upchanged sterol esters between cancer and non-cancer. Presence 
of sterol esters in an NSCLC tumor sample could be verified using NMR or 
tandem-MS. If sterol esterification is enhanced in NSCLC cancer cells, ACAT-1 
inhibitors could be tested using a similar design to that proposed for examining 
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the effects of statins. Determining from which cells in the tumor these sterol 
esters are produced, foam cells, cancer cells, or both, is challenging. One 
approach is to attempt to correlate the number of foam cells to sterol ester levels. 
No correlation or weak correlation suggests the major source is another cell type. 
Alternatively, inhibitors of foam cell differentiation could also be employed such 
as IL-33 (McLaren et al., 2010); however, these may have unexpected effects on 
the cancer cells as well.  
8.6 Aromaticity and Tautomer Detection for BASS 
 The improvements introduced in BASS enable the original CASS 
algorithm to handle chemical structures that contain resonant and aromatic 
bonds; however, the BASS methodology does not directly detect these features, 
rather they are inferred from KEGG atom type annotations that come from the 
database entries or added using BASS. A general approach for detecting 
resonance and aromaticity would eliminate the method’s dependency on KEGG 
atom types and provide more accurate predictions on chemical structures that 
contain substructures not described by KEGG atom types. Additionally, 
tautomeric structures are currently not handled correctly by BASS as there is no 
single graph that can represent a tautomer correctly. 
 A solution to all these problems is to create an algorithm that mimics the 
electron “pushing” that a chemist would perform on paper to identify resonant, 
aromatic and tautomeric structures. Valid structures that represent the movement 
of a pair of electrons would allow resonant bonds to be detected directly. 
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Aromaticity can be tested by checking each valid structure against Huckel’s 
rules. Tautomers could be generated if the rearrangement of hydrogens was 
considered. Metrics for the likelihood of hydrogen rearrangements would be 
necessary to prevent non-labile hydrogens from rearranging. Handling these 
edge cases will be necessary to handle the full range of chemical features 
present in biological compounds. 






APPENDIX 1. SAMPLE DESCRIPTIONS 
A1.1 Preparation of Solvent Blanks with and without Standards (Sample A) 
The solvent blank was composed of Isopropanol:Methanol:Chloroform 800 
μl:344 μl:200 μl. The solvent blank was mixed with 28 μl 1 M ammonium formate 
(final ~20 mM; Aldrich #516961), and without or with 70 μl 1:10 diluted Avanti 
SPLASH™ Lipidomix® Mass Spec Standard (cat# 330707) in MeOH. The 
solvent blank without or with lipid standards was loaded onto a 96-well 
polypropylene PCR plate (USA Scientific cat# 1402-9800) and 15 μl was injected 
into Fusion 1 by direct infusion through an Advion nanomate. Various resolution 
and microscan settings were tested in positive mode with 7 min acquisition, 
normal mass range between 150-1600 m/z, S-lens RF level 60%, AGC target 
1e5, maximum injection time 100 ms, and Easy-IC on. 
This sample was prepared by Dr. Qing Jun Wang at the University of 
Kentucky. Mass spectrometric analysis was performed by Dr. Wang using the 
Fusion instruments at the Center for Environmental and Systems Biochemistry 
under the direction of Drs. Teresa Fan, Andrew Lane and Richard Higashi.  
A1.2 Preparation of IC-MS standards from NSG Mice Liver (Sample B) 
 The NOD/SCID gamma (NSG) mouse colony was maintained by the 
Center for Environmental and Systems Biochemistry within Division of Laboratory 
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Animal Resources at the University of Kentucky. The initial breeding pairs were 
purchased from The Jackson Laboratory in Bar Harbor, ME. The mice were 
housed in a climate-controlled environment with a 1410 hours light / dark cycle 
and lights-on at 0600 hours. The mice had free access to food and water. The 
mice were feed a liquid diet base containing casein, L-cystine, soy oil, cellulose, 
mineral mix (AIN-93G-MX), calcium phosphate, vitamin mix (AIN-93-VX), choline 
bitartrate, tert-butylhydroquinone and xanthan gum purchased from Harlan 
Laboratories (Madison WI).  
Mice were euthanized by spinal dislocation and livers excised and flash 
frozen in liquid nitrogen within 5 minutes of euthanization. Frozen tissues were 
ground into powder under liquid nitrogen to <10 μm particles using a Spex 
freezer mill. Approximately 0.5 g of the powder was extracted with 50 ml 
acetonitrile:water (6:4, v/v). After centrifugation at 22 kg and 4°C for 20 min, the 
supernatant containing polar extracts was distributed into aliquots and lyophilized 
for long-term storage at -80 °C. 
Immediately before IC-FTMS analysis, the lyophilized powder was 
reconstituted with water and 10 μl was injected onto an ICS5000+ system 
(Dionex) interfaced to the FT-MS (Fusion 2). Data were acquired in negative 
mode at a resolving power of 500,000 (at m/z=200) over 52 min of 
chromatography. The mass range was set between m/z 80 and 700, maximum 
injection time was 100 ms with 1 microscan, AGC target was 2e5, S-lens RF 
level was 60%, and Easy-IC was turned on for internal mass calibration. The 
chromatograph was outfitted with a DionexIonPac AG11-HC-4μm RFIC&HPIC 
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guard (2x50mm) guard column upstream of a DionexIonPack AS11-HC-4μM 
RFIC HPIC (2x250mm) column (Sun et al., 2017). This analysis was selective for 
negatively charged ions only. 
These samples were prepared and analyzed by mass spectrometry by Dr. 
Qiushi Sun at the Center for Environmental and Systems Biochemistry at the 
University of Kentucky under the direction of Drs. Teresa Fan, Andrew Lane and 
Richard Higashi. 
A1.3 Preparation of Ethylchloroformate Solvent and Derived Amino Acids 
(Sample C) 
The ECF solvent blank was composed of acetonitrile:water 9:1 (v/v) with a 
concentration of 20 μM NaCl to convert positively charged ions into sodium 
adducts (Yang et al., 2017c). 
Unlabeled amino acid standards were purchased from Sigma Aldrich as a 
mixture of acidic and neutral amino acids and basic amino acids (A6407, A6282). 
The 15N-labeled amino acids mixture was purchased from Cambridge Isotope 
Laboratories (NLM-6695). Ethylchloroformate was also purchased from Sigma 
Aldrich.  
2 μL of 2.5 mM Sigma A6407 was added to 2 μL of 2.5mM Sigma A6282 
and 5 μL of mM unlabeled glutamine were combined to yield a sample containing 
unlabeled and labeled amino acids. In the hood, 100 μL of H2O/EtOH/Pyridine 
(6:3:1 by volume) was added to each sample and vortexed to let the sample 
dissolve. 5uL of ECF was then added to sample. The samples were then 
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vortexed for 30 seconds and then spun down. Under the hood, 100 μL of CHCl3 
(RT) were added and shaken vigorously at 3000rpm for 3 minutes with the 
Disruptor Genie. The samples were then centrifuged at 21100g on a Thermo 
Scientific Legend Micro 21R for 10 minutes 4C. The bottom CHCl3 layer was then 
transferred to a new glass vial and capped. 10 μL of 7M NaOH was added into 
the remaining aqueous phase to adjust the pH to 10. An additional 5 μL of ECF 
was then added and the samples centrifuged and extract again to ensure 
complete derivatization. The samples were then vortexed again and then diluted 
10x in 90% acetonitrile (in water) with 0.2 μM of tetraethylammonium and 2) μM 
NaCl in 0.5mL snap-cap tubes. These were then loaded onto 384-well plate that 
was pre-washed twice with ddH2O and 1x with acetonitrile for direct infusion 
FTMS.   
FTMS analysis was performed using a Tribrid Fusion Orbitrap interfaced 
with an Advion Triversa Nanomate. The Nanomate’s operating voltage was 
1.5kV and the head pressure was 0.5 psi. Spectra were acquired in positive 
mode. The maximum ion time for automatic gain control was set to 100ms, 5 
microscans were acquired per scan and total acquisition time was approximately 
5 minutes, resulting in approximately 100 total scans. Spectra were acquired for 
m/z’s in the 100 to 1000 range selected using quadrupole isolation.  
These samples were prepared and analyzed by mass spectrometry by 
Drs. Qing Jun Wang, and Dr. Ye Yang at the Center for Environmental and 
Systems Biochemistry at the University of Kentucky under the direction of Drs. 
Teresa Fan, Andrew Lane and Richard Higashi. 
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A1.4 Preparation of Paired Lipid Extracts from Suspected Human Non-Small 
Cell Lung Cancer and Non-Cancer Lung Tissue Samples (Sample D) 
Eighty-six patients with suspected resectable stage I or IIa primary non-
small cell lung cancer (NSCLC) and without diagnosed diabetes were recruited 
based on their surgical eligibility. The extent of resection was determined by the 
surgeon in accordance with clinical criteria. Many of the specimens were obtained 
from wedge resections which minimizes surgery time while the other specimens 
were acquired in less than 5 minutes after the pulmonary vein was clamped. Both 
techniques minimize ischemia in the resected tissues. Immediately after resection, 
the tumor was transected and section of cancerous tissue and surrounding non-
cancer tissue at least 5 cm away from the tumor were immediately flash frozen in 
liquid nitrogen and stored at <80°C. On-site pathologists confirmed the diagnosis 
and cancer-free margins on parallel tissue samples. All samples were collected 
under a University of Louisville approved Internal Review Board (IRB) protocol and 
written informed consent was obtained from all subjects prior to inclusion in the 
study (Sellers et al., 2015b).  
The frozen samples were pulverized under liquid nitrogen to <10 μm 
particles using a Spex freezer mill, and extracted using a modified Folch method 
as previously described (Ren et al., 2014). The lipid fraction was supplemented 
with 1 mM butylated hydroxytolune and then dried by vacuum centrifugation at 
room temperature. Samples for FT-MS analysis were redissolved 200-500 μl 
chloroform/methanol (2:1) supplemented with 1 mM butylated hydroxytolune. 
Reconsitituted lipids samples were diluted in in isopropanol/methanol/chloroform 
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4/2/1 (v/v/v) with 20 mM ammonium formate (95 μl of solvent for 5 μl of sample) 
before direct infusion. 
Ultrahigh resolution (UHR) mass spectrometry was performed on the paired 
samples using a Thermo Orbitrap Fusion interfaced to an Advion Nanomate 
nanoelectrospray source using the Advion “type A” chip, also from Advion, inc. 
(chip p/n HD_A_384).  The nanospray conditions on the Advion Nanomate were 
as follows: sample volume in wells in 96 well plate – 50 µl, sample volume taken 
up by tip for analysis – 15 µl, delivery time – 16 minutes, gas pressure – 0.4 psi, 
voltage applied – 1.5 kV, polarity – positive, pre-piercing depth – 10 mm. The 
Orbitrap Fusion Mass Spectrometer method duration was 15 minutes, and the MS 
conditions during the first 7 minutes were as follows: scan type – MS, detector type 
– Orbitrap, resolution – 450,000, lock mass with internal calibrant turned on, scan 
range (m/z) – 150-1600, S-Lens RF Level (%) – 60, AGC Target – 1e5, maximum 
injection time (ms) – 100, microscans – 10, data type – profile, polarity – positive. 
For the next 8 minutes, the conditions were as follows for the MS/MS analysis: MS 
properties: detector type – Orbitrap, resolution – 120,000, scan range (m/z) – 150-
1600, AGC Target – 2e5, maximum injection time (ms) – 100, microscans – 2, data 
type – profile, polarity – negative; monoisotopic precursor selection – applied, top 
500 most intense peaks evaluated with minimum intensity of 5e3 counts; data 
dependent MSn scan properties: MSn level – 2,  isolation mode – quadrupole, 
isolation window (m/z) – 1, activation type – HCD, HCD collision energy (%) – 25, 
collision gas – Nitrogen,  detector – Orbitrap, scan range mode – auto m/z normal, 
Orbitrap resolution – 120,000, first mass (m/z) – 120, maximum injection time (ms) 
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– 500, AGC target – 5e4,  data type – profile, polarity –  positive. The ion transfer 
tube temperature was 275oC.  (Yang et al., 2017b). 
These samples were collected and prepared under the direction of Dr. 
Andrew Lane, Dr. Teresa Fan, and Dr. Richard Higashi at the University of 
Kentucky and at the University of Louisville. Mass spectrometry was performed by 
Drs. Timothy Fahrenholz and Woo-Young Kang at the Center for Environmental 
and Systems Biochemistry at the University of Kentucky.  
A1.5 Preparation of Human Plasma Samples (Samples E) 
Mixed gender, unfiltered pooled lithium heparin treated plasma (Seralab 
Catalog# HMPLLIHP, Lot# BRH1049783) from healthy donors was extracted 
using previously published protocols (Acharjee et al., 2017). Briefly, 15 µl of 
plasma was extracted with 100 µl of ultra-pure H2O in a glass vial (2 ml). 250 µl 
of MeOH was added, and lipids were partitioned into 500 µl of methyl-tertiary-
butyl ether. Following centrifugation (13,000 rpm, 4°C, 4 min), a 20 µl aliquot of 
the organic layer was transferred to a 96-well glass coated plate (Thermo 
Fisher).  95 µl of a solution containing 7.5 mM ammonium acetate in 
Isopropanol:Methanol (2:1 v/v) was also added to the well.  Direct infusion high-
resolution mass spectrometry was performed using on a Q-Exactive+ Orbitrap 
(Thermo), equipped with a Triversa Nanomate (Advion).  The Nanomate infusion 
mandrel was used to pierce the seal of each well before analysis, after which, 
with a fresh tip, 5 μl of sample was aspirated, followed by a 1.5 μl air gap.  
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These samples were prepared and spectra were collected by Dr. Thomas 
Wilson and the High Resolution Metabolomics Laboratory at the Institute of 
Biological, Environmental and Rural Sciences at Aberystwyth University in the 




APPENDIX 2. COMMONLY USED ABBREVIATIONS / TERMINOLOGY 
 BASS – Biochemically Aware Substructure Search. An improvement over the 
CASS tool that is the focus of Chapter 6.  
 CASS – Chemically Aware Substructure Search. The chemical substructure 
search tool that is the focus of Chapter 6. 
 CHONPS – an acronym for Carbon, Hydrogen, Oxygen, Nitrogen, 
Phosphorus and Sulfur. These are the most common elements in molecules 
found in living systems. 
 EMF – Elemental Molecular Formula. An EMF is like a molecular formula in 
the traditional sense, it is what elements constitute the compound (e.g. 
C6H12O6 is the EMF of glucose). 
 EMF Clique - The set of all IMFs adducted to the same ion sharing the same 
EMF. For example, all labeled forms of 12C61H1216O6 adducted with sodium 
belong to the [Na+]-C6H12O6 clique. 
 EMF Subclique - The set of all IMFs adducted to the same ion with the same 
number and type of labeled isotopes sharing the same EMF. For example, all 
forms of 12C61H1216O6 adducted with sodium containing two 13C due to 
labeling belong to the m+13C2 [Na+]-C6H12O6 subclique. 
 EMF Superclique – The set of all IMFs sharing the same EMF. For example, 
all adducted and labeled forms of 12C61H1216O6 belong to the C6H12O6 
superclique. 
 IMF – Isotope-resolved Molecular Formula. An IMF is like a molecular formula 
but is isotope-resolved (e.g. 12C61H1216O6 is an IMF of glucose). 
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 m, m+13C1, m+15N1 – shorthand for describing isotopologues. Here m 
represents the lowest mass isotopologue for a given compound (or EMF). 
m+NEx represents an isotopologue where a X instances of the most abundant 
isotope of the element E has been replaced with the isotope NE. So for 
m+13C1 represents the isotopologue where one 12C has been replaced with 
one 13C. 
 NAP – Natural Abundance Probability. The NAP value for an IMF is a floating-
point number between 0 and 1 and represents the probability of observing 
that combination of isotopes at random assuming natural abundance. When 
the effects of labeling are not considered, these are referred to as absolute 
NAPs. When labeling is considered, it is a relative NAP as the isotope 
contribution from labeling is ignored. 
 SMIRFE – Small Molecule Isotope Resolved Formula Enumerator. The 
untargeted assignment tool that assigns FT-MS spectra without a database of 
expected metabolites that is the focus of Chapter 4.  
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